

Supporting Information for

Original artical

Extensive expanding the chemical diversity of fusidane-type antibiotics using a stochastic combinational strategy

Xiaojun Song^{a,†}, Jianming Lv^{b,†}, Zhiqin Cao^b, Huiyun Huang^b, Guodong Chen^b, Takayoshi Awakawa^c, Dan Hu^{b,*}, Hao Gao^{a,b,*}, Ikuro Abe^{c,*}, Xinsheng Yao^{a,b,*}

^a*College of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, China*

^b*Institute of Traditional Chinese Medicine and Natural Products, College of Pharmacy/Guangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research, Jinan University, Guangzhou 510632, China*

^c*Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo 113-0033, Japan*

†These authors made equal contributions to this work.

*Corresponding authors. Tel./fax: +86 20 8522 1559.

E-mail addresses: tyaoxs@jnu.edu.cn (Xinsheng Yao), abei@mol.f.u-tokyo.ac.jp (Ikuro Abe), tghao@jnu.edu.cn (Hao Gao), thudan@jnu.edu.cn (Dan Hu).

Received 23 September 2020; received in revised form 11 November 2020; accepted 4 December 2020

Table of contents

Supporting Methods	6
Supporting Figures	21
Figure S1 HPLC analysis of metabolites from <i>A. oryzae</i> transformants.....	21
Figure S2 Fusidane-type antibiotics produced via the stochastic combinational strategy.....	24
Figure S3 HRESIMS and NMR spectra of 5	27
Figure S4 HRESIMS and NMR spectra of 6	31
Figure S5 HRESIMS and NMR spectra of 9	34
Figure S6 HRESIMS and NMR spectra of 10	37
Figure S7 HRESIMS and NMR spectra of 11	40
Figure S8 HRESIMS and NMR spectra of 12	43
Figure S9 HRESIMS and NMR spectra of 13	46
Figure S10 HRESIMS and NMR spectra of 14	49
Figure S11 HRESIMS and NMR spectra of 15	52
Figure S12 HRESIMS and NMR spectra of 17	55
Figure S13 HRESIMS and NMR spectra of 18	58

Figure S14 HRESIMS and NMR spectra of 19	61
Figure S15 HRESIMS and NMR spectra of 20	64
Figure S16 HRESIMS and NMR spectra of 21	67
Figure S17 HRESIMS and NMR spectra of 22	70
Figure S18 HRESIMS and NMR spectra of 23	73
Figure S19 HRESIMS and NMR spectra of 24	76
Figure S20 HRESIMS and NMR spectra of 25	79
Figure S21 HRESIMS and NMR spectra of 26	82
Figure S22 HRESIMS and NMR spectra of 29	85
Figure S23 HRESIMS and NMR spectra of 30	88
Figure S24 HRESIMS and NMR spectra of 31	91
Figure S25 HRESIMS and NMR spectra of 32	94
Figure S26 HRESIMS and NMR spectra of 33	97
Figure S27 HRESIMS and NMR spectra of 34	100
Figure S28 HRESIMS and NMR spectra of 35	103
Figure S29 HRESIMS and NMR spectra of 36	106
Figure S30 HRESIMS and NMR spectra of 37	109
Figure S31 HRESIMS and NMR spectra of 38	112
Figure S32 HRESIMS and NMR spectra of 39	115
Figure S33 HRESIMS and NMR spectra of 40	118
Figure S34 HRESIMS and NMR spectra of 41	121
Figure S35 HRESIMS and NMR spectra of 42	124
Figure S36 HRESIMS and NMR spectra of 43	127
Figure S37 HRESIMS and NMR spectra of 44	130
Figure S38 HRESIMS and NMR spectra of 45	133
Figure S39 HRESIMS and NMR spectra of 46	136
Figure S40 HRESIMS and NMR spectra of 47	139
Figure S41 HRESIMS and NMR spectra of 48	142
Figure S42 HRESIMS and NMR spectra of 49	145
Figure S43 HRESIMS and NMR spectra of 50	148
Figure S44 HRESIMS and NMR spectra of 51	151
Figure S45 HRESIMS and NMR spectra of 52	154
Figure S46 HRESIMS and NMR spectra of 55	157
Figure S47 HRESIMS and NMR spectra of 56	160
Figure S48 HRESIMS and NMR spectra of 57	163
Figure S49 HRESIMS and NMR spectra of 58	166
Figure S50 HRESIMS and NMR spectra of 59	169
Figure S51 HRESIMS and NMR spectra of 60	172
Figure S52 HRESIMS and NMR spectra of 61	175
Figure S53 HRESIMS and NMR spectra of 62	178
Figure S54 HRESIMS and NMR spectra of 63	182
Figure S55 HRESIMS and NMR spectra of 64	185
Figure S56 HRESIMS and NMR spectra of 65	188
Figure S57 HRESIMS and NMR spectra of 66	191

Figure S58 HRESIMS and NMR spectra of 67	194
Figure S59 HRESIMS and NMR spectra of 68	197
Figure S60 HRESIMS and NMR spectra of 69	200
Figure S61 HRESIMS and NMR spectra of 81	203
Figure S62 Linear correlation between calculated ^{13}C NMR chemical shift values of 34-A/34-B and experimental values of 34	204
Figure S63 Linear correlation between calculated ^{13}C NMR chemical shift values of 35-A/35-B and experimental values of 35	205
Figure S64 Linear correlation between calculated ^{13}C NMR chemical shift values of 38-A/38-B and experimental values of 38	206
Figure S65 Linear correlation between calculated ^{13}C NMR chemical shift values of 42-A/42-B and experimental values of 42	207
Figure S66 HPLC analysis for spontaneous 1,4-addition of 37 in Tri-HCl buffer.....	208
Figure S67 Previously isolated fusidane-type antibiotics during the biosynthetic study of helvolic acid, fusidic acid and cephalosporin P ₁	209
Figure S68 Comparison of anti- <i>S. aureus</i> 209P activity of fusidane-type antibiotics featured with 3-keto and 3 β -OH.	210
Figure S69 Comparison of anti- <i>S. aureus</i> 209P activity of fusidane-type antibiotics featured with 3-keto and 3 α -OH.	211
Figure S70 The effect of the C1/C2 double bond on anti- <i>S. aureus</i> 209P activity.....	212
Figure S71 The detrimental effect of mono-oxidation at C6 or C7 on anti- <i>S. aureus</i> 209P activity.....	213
Figure S72 The effect of dual-oxidation at C6 and C7 on anti- <i>S. aureus</i> 209P activity.....	214
Figure S73 The effect of C11 α -hydroxylation on anti- <i>S. aureus</i> 209P activity.....	215
Figure S74 The effect of acetylation of 6-OH on anti- <i>S. aureus</i> 209P activity.	216
Figure S75 C1 α -hydroxylation has the negative effect on anti- <i>S. aureus</i> 209P activity.	217
Figure S76 Analysis of the impurity peak in the feeding experiment using CO6 as the host.	218
Supporting Tables	219
Table S1 Eight post-tailoring genes from <i>hel</i> , <i>fus</i> and <i>cep</i> clusters.....	219
Table S2 All gene combinations and the obtained products.....	220
Table S3 NMR data for 5 (^1H for 400 MHz and ^{13}C for 100 MHz in CDCl ₃).	221
Table S4 NMR data for 6 (^1H for 600 MHz and ^{13}C for 150 MHz in CDCl ₃).	222
Table S5 NMR data for 9 (^1H for 600 MHz and ^{13}C for 150 MHz in CDCl ₃).	223
Table S6 NMR data for 10 (^1H for 600 MHz and ^{13}C for 150 MHz in CDCl ₃).	224
Table S7 NMR data for 11 (^1H for 400 MHz and ^{13}C for 100 MHz in CDCl ₃).	225
Table S8 NMR data for 12 (^1H for 400 MHz and ^{13}C for 100 MHz in CDCl ₃).	226
Table S9 NMR data for 13 (^1H for 600 MHz and ^{13}C for 150 MHz in CDCl ₃).	227
Table S10 NMR data for 14 (^1H for 400 MHz and ^{13}C for 100 MHz in CDCl ₃).	228
Table S11 NMR data for 15 (^1H for 400 MHz and ^{13}C for 100 MHz in CDCl ₃).	229
Table S12 NMR data for 17 (^1H for 600 MHz and ^{13}C for 150 MHz in CDCl ₃).	230
Table S13 NMR data for 18 (^1H for 600 MHz and ^{13}C for 150 MHz in CD ₃ OD).	231
Table S14 NMR data for 19 (^1H for 600 MHz and ^{13}C for 150 MHz in CD ₃ OD).	232
Table S15 NMR data for 20 (^1H for 600 MHz and ^{13}C for 150 MHz in CD ₃ OD).	233

Table S16 NMR data for 21 (¹ H for 600 MHz and ¹³ C for 150 MHz in CDCl ₃)	234
Table S17 NMR data for 22 (¹ H for 600 MHz and ¹³ C for 150 MHz in CDCl ₃)	235
Table S18 NMR data for 23 (¹ H for 400 MHz and ¹³ C for 100 MHz in CDCl ₃)	236
Table S19 NMR data for 24 (¹ H for 600 MHz and ¹³ C for 150 MHz in CDCl ₃)	237
Table S20 NMR data for 25 (¹ H for 600 MHz and ¹³ C for 150 MHz in CDCl ₃)	238
Table S21 NMR data for 26 (¹ H for 400 MHz and ¹³ C for 100 MHz in CDCl ₃)	239
Table S22 NMR data for 29 (¹ H for 600 MHz and ¹³ C for 150 MHz in CDCl ₃)	240
Table S23 NMR data for 30 (¹ H for 600 MHz and ¹³ C for 150 MHz in CDCl ₃)	241
Table S24 NMR data for 31 (¹ H for 600 MHz and ¹³ C for 150 MHz in CDCl ₃)	242
Table S25 NMR data for 32 (¹ H for 600 MHz and ¹³ C for 150 MHz in CDCl ₃)	243
Table S26 NMR data for 33 (¹ H for 600 MHz and ¹³ C for 150 MHz in CDCl ₃)	244
Table S27 NMR data for 34 (¹ H for 600 MHz and ¹³ C for 150 MHz in CDCl ₃)	245
Table S28 NMR data for 35 (¹ H for 600 MHz and ¹³ C for 150 MHz in CD ₃ OD)	246
Table S29 NMR data for 36 (¹ H for 600 MHz and ¹³ C for 150 MHz in CD ₃ OD)	247
Table S30 NMR data for 37 (¹ H for 600 MHz and ¹³ C for 150 MHz in CD ₃ OD)	248
Table S31 NMR data for 38 (¹ H for 400 MHz and ¹³ C for 100 MHz in CD ₃ OD)	249
Table S32 NMR data for 39 (¹ H for 600 MHz and ¹³ C for 150 MHz in CD ₃ OD)	250
Table S33 NMR data for 40 (¹ H for 400 MHz and ¹³ C for 100 MHz in CD ₃ OD)	251
Table S34 NMR data for 41 (¹ H for 400 MHz and ¹³ C for 100 MHz in CD ₃ OD)	252
Table S35 NMR data for 42 (¹ H for 600 MHz and ¹³ C for 150 MHz in CD ₃ OD)	253
Table S36 NMR data for 43 (¹ H for 600 MHz and ¹³ C for 150 MHz in CD ₃ OD)	254
Table S37 NMR data for 44 (¹ H for 600 MHz and ¹³ C for 150 MHz in CDCl ₃)	255
Table S38 NMR data for 45 (¹ H for 600 MHz and ¹³ C for 150 MHz in CDCl ₃)	256
Table S39 NMR data for 46 (¹ H for 600 MHz and ¹³ C for 150 MHz in CDCl ₃)	257
Table S40 NMR data for 47 (¹ H for 600 MHz and ¹³ C for 150 MHz in CD ₃ OD)	258
Table S41 NMR data for 48 (¹ H for 600 MHz and ¹³ C for 150 MHz in CD ₃ OD)	259
Table S42 NMR data for 49 (¹ H for 600 MHz and ¹³ C for 150 MHz in CD ₃ OD)	260
Table S43 NMR data for 50 (¹ H for 400 MHz and ¹³ C for 100 MHz in CD ₃ OD)	261
Table S44 NMR data for 51 (¹ H for 400 MHz and ¹³ C for 100 MHz in CDCl ₃)	262
Table S45 NMR data for 52 (¹ H for 400 MHz and ¹³ C for 100 MHz in CD ₃ OD)	263
Table S46 NMR data for 55 (¹ H for 600 MHz and ¹³ C for 150 MHz in CD ₃ OD)	264
Table S47 NMR data for 56 (¹ H for 600 MHz and ¹³ C for 150 MHz in CD ₃ OD)	265
Table S48 NMR data for 57 (¹ H for 600 MHz and ¹³ C for 150 MHz in CD ₃ OD)	266
Table S49 NMR data for 58 (¹ H for 400 MHz and ¹³ C for 100 MHz in CD ₃ OD)	267
Table S50 NMR data for 59 (¹ H for 400 MHz and ¹³ C for 100 MHz in CD ₃ OD)	268
Table S51 NMR data for 60 (¹ H for 600 MHz and ¹³ C for 150 MHz in CDCl ₃)	269
Table S52 NMR data for 61 (¹ H for 400 MHz and ¹³ C for 100 MHz in CDCl ₃)	270
Table S53 NMR data for 62 (¹ H for 600 MHz and ¹³ C for 150 MHz in CD ₃ OD)	271
Table S54 NMR data for 63 (¹ H for 600 MHz and ¹³ C for 150 MHz in pyridine- <i>d</i> ₅)	272
Table S55 NMR data for 64 (¹ H for 600 MHz and ¹³ C for 150 MHz in CD ₃ OD)	273
Table S56 NMR data for 65 (¹ H for 600 MHz and ¹³ C for 150 MHz in CD ₃ OD)	274
Table S57 NMR data for 66 (¹ H for 600 MHz and ¹³ C for 150 MHz in CD ₃ OD)	275
Table S58 NMR data for 67 (¹ H for 400 MHz and ¹³ C for 100 MHz in acetone- <i>d</i> ₆)	276
Table S59 NMR data for 68 (¹ H for 400 MHz and ¹³ C for 100 MHz in CD ₃ OD)	277

Table S60 NMR data for 69 (¹ H for 600 MHz and ¹³ C for 150 MHz in CD ₃ OD).	278
Table S61 NMR data for 81 (¹ H for 600 MHz and ¹³ C for 150 MHz in CDCl ₃).	279
Table S62 The Boltzmann distribution for two possible structures (34-A and 34-B) of 34 . ..	280
Table S63 The Boltzmann distribution for two possible structures (35-A and 35-B) of 35 . ..	280
Table S64 The Boltzmann distribution for two possible structures (38-A and 38-B) of 38 . ..	281
Table S65 The Boltzmann distribution for two possible structures (42-A and 42-B) of 42 . ..	281
Table S66 Comparison of the chemical shifts of compounds 38 and 40	282
Table S67 R square (R ²) of the linear correlations, mean absolute error (MAE) values and DP4+ probabilities of 34-A/34-B and 42-A/42-B of 34 and 42 , respectively.....	283
Table S68 R square (R ²) of the linear correlations, mean absolute error (MAE) values and DP4+ probabilities of 35-A/35-B and 38-A/38-B of 35 and 38 , respectively.....	284
Table S69 Comparison of the coupling constants of compounds containing C1-C2 double bond and C3-hydroxyl group.	285
Table S71 Plasmids used in the study.....	286
Table S72 Strains used in the study.....	287

Supporting Methods

Detailed purification procedure of compounds

Purification of 5

The culture medium extract (1.0 g) from the 5 L culture of AOS1 was subjected to ODS column chromatography on MPLC and eluted stepwise using MeOH–H₂O gradient (35:65, 80:20 and 100:0, v/v). Fraction 2 was further purified by reverse-phase semi-preparative HPLC (70% CH₃CN–H₂O containing 0.1% formic acid, 3 mL/min) to yield **5** (43.5 mg).

Purification of 6

The culture medium extract (0.31 g) from the 2 L culture of AOS2 was subjected to ODS column chromatography on MPLC and eluted stepwise using MeOH–H₂O gradient (35:65, 80:20 and 100:0, v/v). Fraction 2 was further purified by reverse-phase semi-preparative HPLC (80% CH₃CN–H₂O containing 0.1% formic acid, 3 mL/min) to yield **6** (4.3 mg).

Purification of 9–11

The culture medium extract (0.41 g) from the 2 L culture of AOS3 was subjected to ODS column chromatography on MPLC and eluted stepwise using MeOH–H₂O gradient (35:65, 70:30 and 100:0, v/v). Fraction 2 was further purified by reverse-phase semi-preparative HPLC (90% CH₃CN–H₂O containing 0.1% formic acid, 3 mL/min) to yield **9** (2.1 mg), **10** (1.2 mg) and **11** (5.0 mg).

Purification of 12–15

The culture medium extract (0.6 g) from the 3.5 L culture of AOS4 was subjected to ODS column chromatography on MPLC and eluted stepwise using MeOH–H₂O gradient (35:65, 60:40 and 100:0, v/v). Fraction 2 was further purified by reverse-phase semi-preparative HPLC (55% CH₃CN–H₂O containing 0.1% formic acid, 3 mL/min) to yield **12** (27.5 mg), **13** (3.6 mg), **14** (8.1 mg) and **15** (15.3 mg).

Purification of 17–22

The culture medium extract (1.03 g) from the 5 L culture of AOS5 was subjected to ODS column chromatography on MPLC and eluted stepwise using MeOH–H₂O gradient (30:70, 60:40 and 100:0, v/v). Fraction 2 was further purified by reverse-phase semi-preparative HPLC (45% CH₃CN–H₂O containing 0.1% formic acid, 3 mL/min) to yield **17** (28.0 mg), **18** (17 mg), **19** (7.0 mg), **20** (98.0 mg), **21** (20.0 mg) and **22** (10.0 mg).

Purification of 23–25

The culture medium extract (0.52 g) from the 2.5 L culture of AOS6 was subjected to ODS column chromatography on MPLC and eluted stepwise using MeOH–H₂O gradient (35:75, 70:30 and 100:0, v/v). Fraction 2 was further purified by reverse-phase semi-preparative

HPLC (70% CH₃CN–H₂O containing 0.1% formic acid, 3 mL/min) to yield **23** (47.0 mg), **24** (4.0 mg) and **25** (1.5 mg).

Purification of 26

The culture medium extract (0.8 g) from the 3 L culture of AOS7 was subjected to ODS column chromatography on MPLC and eluted stepwise using MeOH–H₂O gradient (35:65, 70:30 and 100:0, v/v). Fraction 2 was further purified by reverse-phase semi-preparative HPLC (70% CH₃CN–H₂O containing 0.1% formic acid, 3 mL/min) to yield **26** (47.0 mg).

Purification of 29

The culture medium extract (0.55 g) from the 3 L culture of AOS8 was subjected to ODS column chromatography on MPLC and eluted stepwise using MeOH–H₂O gradient (40:60, 70:30 and 100:0, v/v). Fraction 2 was further purified by reverse-phase semi-preparative HPLC (70% CH₃CN–H₂O containing 0.1% formic acid, 3 mL/min) to yield **29** (14.0 mg).

Purification of 30–34

The culture medium extract (0.67 g) from 4 L culture of AOS9 was subjected to ODS column chromatography on MPLC and eluted stepwise using MeOH–H₂O gradient (40:60, 70:30 and 100:0, v/v). Fraction 2 was further purified by reverse-phase semi-preparative HPLC (80% MeOH–H₂O containing 0.1% formic acid, 3 mL/min) to yield **30** (1.8 mg), **31** (12.0 mg), **32** (2.0 mg), **33** (5.0 mg) and **34** (6.4 mg).

Purification of 35–40

The culture medium extract (1.05 g) from the 5 L culture of AOS10 was subjected to ODS column chromatography on MPLC and eluted stepwise using MeOH–H₂O gradient (40:60, 60:40, 70:30 and 100:0, v/v). Fractions 2 and 3 were further purified by reverse-phase semi-preparative HPLC (42% CH₃CN–H₂O containing 0.1% formic acid, 3 mL/min) to yield **35** (3.1 mg), **36** (7.7 mg), **37** (7.0 mg), **38** (3.0 mg), **39** (1.4 mg) and **40** (25.0 mg).

Purification of 41–43

The culture medium extract (0.83 g) from the 4 L culture of AOS11 was subjected to ODS column chromatography on MPLC and eluted stepwise using MeOH–H₂O gradient (35:65, 50:50, 70:30 and 100:0, v/v). Fraction 3 was further purified by reverse-phase semi-preparative HPLC (60% CH₃CN–H₂O containing 0.1% formic acid, 3 mL/min) to yield **41** (2.0 mg), **42** (1.1 mg) and **43** (3.0 mg).

Purification of 44–46

The culture medium extract (0.93 g) from 4 L culture of AOS12 was subjected to ODS column chromatography on MPLC and eluted stepwise using MeOH–H₂O gradient (35:65, 55:45, 70:30 and 100:0, v/v). Fraction 3 was further purified by reverse-phase

semi-preparative HPLC (60% CH₃CN–H₂O containing 0.1% formic acid, 3 mL/min) to yield **44** (3.0 mg), **45** (1.1 mg) and **46** (5.0 mg).

Purification of 47–49

The culture medium extract (0.82 g) from the 3.5 L culture of AOS13 was subjected to ODS column chromatography on MPLC and eluted stepwise using MeOH–H₂O gradient (35:65, 70:30 and 100:0, v/v). Fraction 2 was further purified by reverse-phase semi-preparative HPLC (37% CH₃CN–H₂O containing 0.1% formic acid, 3 mL/min) to yield **47** (12.0 mg), **48** (38.0 mg) and **49** (11.0 mg).

Purification of 50–52

The culture medium extract (0.91 g) from the 5 L culture of AOS14 was subjected to ODS column chromatography on MPLC and eluted stepwise using MeOH–H₂O gradient (45:55, 55:45, 65:35, 75:25 and 100:0, v/v). Fractions 3 and 4 were further purified by reverse-phase semi-preparative HPLC (42% CH₃CN–H₂O containing 0.1% formic acid, 3 mL/min) to yield **50** (6.3 mg), **51** (10.4 mg) and **52** (3.5 mg).

Purification of 55–57

The culture medium extract (0.88 g) from the 5 L culture of AOS15 was subjected to ODS column chromatography on MPLC and eluted stepwise using MeOH–H₂O gradient (40:60, 60:40, 70:30 and 100:0, v/v). Fraction 3 was further purified by reverse-phase semi-preparative HPLC (40% CH₃CN–H₂O containing 0.1% formic acid, 3 mL/min) to yield **55** (15.3 mg), **56** (13.0 mg) and **57** (6.3 mg).

Purification of 58 and 59

The culture medium extract (0.83 g) from the 5 L culture of AOS16 was subjected to ODS column chromatography on MPLC and eluted stepwise using MeOH–H₂O gradient (50:50, 60:40, 70:30 and 100:0, v/v). Fractions 2 and 3 were further purified by reverse-phase semi-preparative HPLC (50% CH₃CN–H₂O containing 0.1% formic acid, 3 mL/min) to yield **58** (33.5 mg) and **59** (7.5 mg).

Purification of 60

The culture medium extract (1.0 g) from the 5 L culture of AOS17 was subjected to ODS column chromatography on MPLC and eluted stepwise using MeOH–H₂O gradient (50:50, 70:30 and 100:0, v/v). Fraction 2 was further purified by reverse-phase semi-preparative HPLC (60% CH₃CN–H₂O containing 0.1% formic acid, 3 mL/min) to yield **60** (80.0 mg).

Purification of 61

The culture medium extract (1.1 g) from the 5 L culture of AOS18 was subjected to ODS column chromatography on MPLC and eluted stepwise using MeOH–H₂O gradient (35:65,

50:50, 70:30 and 100:0, v/v). Fraction 3 was further purified by reverse-phase semi-preparative HPLC (75% CH₃CN–H₂O containing 0.1% formic acid, 3 mL/min) to yield **61** (35.0 mg).

Purification of 37, 38 and 62

The culture medium extract (1.04 g) from the 4 L culture of AOS19 was subjected to ODS column chromatography on MPLC and eluted stepwise using MeOH–H₂O gradient (35:65, 50:50, 60:40, 70:30 and 100:0, v/v). Fraction 3 was further purified by reverse-phase semi-preparative HPLC (40% CH₃CN–H₂O containing 0.1% formic acid, 3 mL/min) to yield **37** (7.0 mg), **38** (3.0 mg) and **62** (1.2 mg).

Purification of 63

The culture medium extract (1.04 g) from the 4 L culture of AOS20 was subjected to ODS column chromatography on MPLC and eluted stepwise using MeOH–H₂O gradient (50:50, 60:40, 70:30, 80:20 and 100:0, v/v). Fraction 4 was further purified by reverse-phase semi-preparative HPLC (60% CH₃CN–H₂O containing 0.1% formic acid, 3 mL/min) to yield **63** (6.0 mg).

Purification of 64–66

The culture medium extract (1.2 g) from the 10 L culture of AOS23 was subjected to ODS column chromatography on MPLC and eluted stepwise using MeOH–H₂O gradient (50:50, 60:40, 70:30 and 100:0, v/v). Fraction 3 was further purified by reverse-phase semi-preparative HPLC (60% CH₃CN–H₂O containing 0.1% formic acid, 3 mL/min) to yield **64** (3.4 mg), **65** (3.8 mg) and **66** (10.0 mg).

Purification of 67

The culture medium extract (0.89 g) from the 5 L culture of AOS24 was subjected to ODS column chromatography on MPLC and eluted stepwise using MeOH–H₂O gradient (50:50, 70:30 and 100:0, v/v). Fraction 2 was further purified by reverse-phase semi-preparative HPLC (45% CH₃CN–H₂O containing 0.1% formic acid, 3 mL/min) to yield **67** (10.0 mg).

Purification of 68 and 69

The culture medium extract (1.03 g) from 5 L culture of AOS26 was subjected to MPLC on ODS column chromatography and eluted stepwise using MeOH–H₂O gradient (50:50, 70:30 and 100:0, v/v). Fraction 2 was further purified by reverse-phase semi-preparative HPLC (45% CH₃CN–H₂O containing 0.1% formic acid, 3 mL/min) to yield **68** (10.0 mg) and **69** (1.2 mg).

Structural characterization

Compound **5**: white powder; $[\alpha]_D^{27} +7.80$ (*c* 5.67, CH₃OH); UV (CH₃OH) λ_{max} (log ε) 206 nm (4.09); IR (KBr) ν_{max} 3437, 2971, 2949, 2871, 1716, 1666, 1440, 1374, 1254, 1019 cm⁻¹;

HRESIMS (positive) m/z 513.3212 [M + H]⁺ (Calcd. for C₃₁H₄₅O₆, 513.3216), see Fig. S3A; NMR spectra, see Fig. S3B–H; NMR data, see Table S3; **5** is identified as 16 β -acetoxy-11 α -hydroxy-29-norprotosta-1,17(20)Z,24-trien-3-one-21-oic acid.

Compound **6**: white powder; $[\alpha]_D^{22}$ +54.9 (c 0.59, CH₃OH); UV (CH₃OH) λ_{\max} (log ε) 204 nm (3.78); IR (KBr) ν_{\max} 3370, 3026, 2970, 2923, 2866, 1711, 1453, 1379, 1265, 1106 cm⁻¹. HRESIMS (positive) m/z 439.3209 [M + H – CH₃COOH]⁺ (Calcd. for C₂₉H₄₃O₃, 439.3212), see Fig. S4A; NMR spectra, see Fig. S4B–H; NMR data, see Table S4; **6** is identified as 16 β -acetoxy-3 α -hydroxy-29-norprotosta-1,17(20)Z,24-trien-21-oic acid.

Compound **9**: white powder, $[\alpha]_D^{26}$ +56.3 (c 0.77, CH₂Cl₂); UV (CH₃OH) λ_{\max} (log ε) 205 nm (4.32); IR (KBr) ν_{\max} 3503, 2955, 2921, 2852, 1716, 1672, 1554, 1542, 1456, 1374, 1252, 1030 cm⁻¹; HRESIMS (positive) m/z 551.2975 [M + Na]⁺ (Calcd. for C₃₁H₄₄O₇Na, 551.2985), see Fig. S5A; NMR spectra, see Fig. S5B–H; NMR data, see Table S5; **9** is identified as 16 β -acetoxy-6 α ,7 β -dihydroxy-29-norprotosta-1,17(20)Z,24-trien-3-one-21-oic acid.

Compound **10**: white powder; $[\alpha]_D^{26}$ +42.6 (c 0.47, CH₃OH); UV (CH₃OH) λ_{\max} (log ε) 204 nm (3.75); IR (KBr) ν_{\max} 3446, 2921, 2853, 1719, 1671, 1454, 1375, 1250, 1028 cm⁻¹; HRESIMS (positive) m/z 513.3224 [M + H]⁺ (Calcd. for C₃₁H₄₅O₆, 513.3216), see Fig. S6A; NMR spectra, see Fig. S6B–H; NMR data, see Table S6; **10** is identified as 16 β -acetoxy-6 α -hydroxy-29-norprotosta-1,17(20)Z,24-trien-3-one-21-oic acid.

Compound **11**: white powder; $[\alpha]_D^{26}$ +31.0 (c 0.98, CH₃OH); UV (CH₃OH) λ_{\max} (log ε) 204 nm (4.44); IR (KBr) ν_{\max} 3423, 2973, 2938, 2876, 1715, 1669, 1453, 1376, 1254, 1141, 1028 cm⁻¹; HRESIMS (positive) m/z 513.3211 [M + H]⁺ (Calcd. for C₃₁H₄₅O₆, 513.3216), see Fig. S7A; NMR spectra, see Fig. S7B–H; NMR data, see Table S7; **11** is identified as 16 β -acetoxy-7 β -hydroxy-29-norprotosta-1,17(20)Z,24-trien-3-one-21-oic acid.

Compound **12**: white powder; $[\alpha]_D^{22}$ +56.3 (c 1.82, CH₃OH); UV (CH₃OH) λ_{\max} (log ε) 205 nm (3.89); IR (KBr) ν_{\max} 3484, 2968, 2941, 2886, 1711, 1454, 1379, 1263, 1182, 1153, 1106, 1031 cm⁻¹; HRESIMS (positive) m/z 569.3099 [M + Na]⁺ (Calcd. for C₃₁H₄₆O₈Na, 569.3090), see Fig. S8A; NMR spectra, see Fig. S8B–H; NMR data, see Table S8; **12** is identified as 16 β -acetoxy-6 α ,7 β ,11 α -trihydroxy-29-norprotosta-17(20)Z,24-dien-3-one-21-oic acid.

Compound **13**: white powder; $[\alpha]_D^{23}$ +15.7 (c 0.54, CH₃OH); UV (CH₃OH) λ_{\max} (log ε) 204 nm (3.91); IR (KBr) ν_{\max} 3450, 2940, 2876, 1714, 1551, 1447, 1378, 1263, 1184, 1151, 1026 cm⁻¹; HRESIMS (positive) m/z 555.3290 [M + Na]⁺ (Calcd. for C₃₁H₄₈O₇Na, 555.3298), see Fig. S9A; NMR spectra, see Fig. S9B–H; NMR data, see Table S9; **13** is identified as

16β -acetoxy- $3\beta,7\beta,11\alpha$ -trihydroxy-29-norprotosta-17(20)Z,24-dien-21-oic acid.

Compound **14**: white powder; $[\alpha]_D^{23} +48.6$ (*c* 0.37, CH₃OH); UV (CH₃OH) λ_{\max} (log ε) 205 nm (3.97); IR (KBr) ν_{\max} 3441, 2970, 2939, 2883, 1703, 1649, 1383, 1261, 1019 cm⁻¹; HRESIMS (positive) *m/z* 553.3136 [M + Na]⁺ (Calcd. for C₃₁H₄₆O₇Na, 553.3141), see Fig. S10A; NMR spectra, see Fig. S10B–H; NMR data, see Table S10; **14** is identified as 16β -acetoxy- $6\alpha,11\alpha$ -dihydroxy-29-norprotosta-17(20)Z,24-dien-3-one-21-oic acid.

Compound **15**: white powder; $[\alpha]_D^{23} +22.4$ (*c* 0.62, CH₃OH); UV (CH₃OH) λ_{\max} (log ε) 204 nm (3.88); IR (KBr) ν_{\max} 3500, 2966, 2941, 2880, 1703, 1557, 1452, 1378, 1262, 1194, 1150, 1105, 1031 cm⁻¹; HRESIMS (positive) *m/z* 553.3130 [M + Na]⁺ (Calcd. for C₃₁H₄₆O₇Na, 553.3141), see Fig. S11A; NMR spectra, see Fig. S11B–H; NMR data, see Table S11; **15** is identified as 16β -acetoxy- $7\beta,11\alpha$ -dihydroxy-29-norprotosta-17(20)Z,24-dien-3-one-21-oic acid.

Compound **17**: white powder; $[\alpha]_D^{24} -38.5$ (*c* 0.55, CH₃OH); UV (CH₃OH) λ_{\max} (log ε) 204 nm (3.90); IR (KBr) ν_{\max} 3444, 2980, 2936, 2871, 1712, 1650, 1454, 1440, 1377, 1263, 1182, 1153, 1101, 1033 cm⁻¹; HRESIMS (positive) *m/z* 569.3085 [M + Na]⁺ (Calcd. for C₃₁H₄₆O₈Na, 569.3090), see Fig. S12A; NMR spectra, see Fig. S12B–H; NMR data, see Table S12; **17** is identified as 16β -acetoxy- $3\beta,6\beta,11\alpha$ -trihydroxy-29-norprotosta-17(20)Z,24-dien-7-one-21-oic acid.

Compound **18**: white powder; $[\alpha]_D^{25} -10.4$ (*c* 5.08, CH₃OH); UV (CH₃OH) λ_{\max} (log ε) 204 nm (3.99); IR (KBr) ν_{\max} 3451, 2961, 2934, 2869, 1716, 1444, 1377, 1264, 1175, 1137, 1062, 1038 cm⁻¹; HRESIMS (positive) *m/z* 555.3280 [M + Na]⁺ (Calcd. for C₃₁H₄₈O₇Na, 555.3298), see Fig. S13A; NMR spectra, see Fig. S13B–H; NMR data, see Table S13; **18** is identified as 16β -acetoxy- $3\beta,7\alpha,11\alpha$ -trihydroxy-29-norprotosta-17(20)Z,24-dien-21-oic acid.

Compound **19**: white powder; $[\alpha]_D^{22} -24.3$ (*c* 0.45, CH₃OH); UV (CH₃OH) λ_{\max} (log ε) 204 nm (3.86); IR (KBr) ν_{\max} 3439, 2952, 2930, 2871, 1707, 1557, 1438, 1425, 1378, 1266, 1188, 1144, 1078, 1054, 1022 cm⁻¹; HRESIMS (positive) *m/z* 553.3141 [M + Na]⁺ (Calcd. for C₃₁H₄₆O₇Na, 553.3141), see Fig. S14A; NMR spectra, see Fig. S14B–H; NMR data, see Table S14; **19** is identified as 16β -acetoxy- $3\beta,11\alpha$ -dihydroxy-29-norprotosta-17(20)Z,24-dien-7-one-21-oic acid.

Compound **20**: white powder; $[\alpha]_D^{22} -29.1$ (*c* 0.40, CH₃OH); UV (CH₃OH) λ_{\max} (log ε) 205 nm (3.96); IR (KBr) ν_{\max} 3472, 2973, 1697, 1457, 1375, 1263, 1185, 1048, 1107, 1069, 1035 cm⁻¹; HRESIMS (positive) *m/z* 567.2930 [M + Na]⁺ (Calcd. for C₃₁H₄₄O₈Na, 567.2934), see Fig. S15A; NMR spectra, see Fig. S15B–H; NMR data, see Table S15; **20** is identified as

16β -acetoxy- $6\beta,11\alpha$ -dihydroxy-29-norprotosta-17(20)Z,24-dien-3,7-dione-21-oic acid.

Compound **21**: white powder; $[\alpha]_D^{22} -12.0$ (*c* 1.37, CH₃OH); UV (CH₃OH) λ_{\max} (log ε) 206 nm (3.80); IR (KBr) ν_{\max} 3502, 2969, 2938, 2886, 1703, 1444, 1378, 1260, 1177, 1147, 1066, 1036, 1010 cm⁻¹; HRESIMS (positive) *m/z* 553.3130 [M + Na]⁺, (Calcd. for C₃₁H₄₆O₇Na, 553.3141), see Fig. S16A; NMR spectra, see Fig. S16B–H; NMR data, see Table S16; **21** is identified as 16β -acetoxy- $7\alpha,11\alpha$ -dihydroxy-29-norprotosta-17(20)Z,24-dien-3-one-21-oic acid.

Compound **22**: white powder; $[\alpha]_D^{28} -20.7$ (*c* 5.08, CH₃OH); UV (CH₃OH) λ_{\max} (log ε) 207 nm (3.93); IR (KBr) ν_{\max} 3464, 2972, 1708, 1455, 1378, 1258, 1196, 1147, 1071, 1038 cm⁻¹; HRESIMS (positive) *m/z* 551.2984 [M + Na]⁺, (Calcd. for C₃₁H₄₄O₇Na, 551.2985), see Fig. S17A; NMR spectra, see Fig. S17B–H; NMR data, see Table S17; **22** is identified as 16β -acetoxy- 11α -hydroxy-29-norprotosta-17(20)Z,24-dien-3,7-dione-21-oic acid.

Compound **23**: white powder; $[\alpha]_D^{24} -50.5$ (*c* 0.60, CH₃OH); UV (CH₃OH) λ_{\max} (log ε) 205 nm (3.83); IR (KBr) ν_{\max} 3445, 2975, 2938, 2874, 1714, 1467, 1376, 1259, 1158, 1074, 1030, 1000 cm⁻¹; HRESIMS (positive) *m/z* 553.3129 [M + Na]⁺ (Calcd. for C₃₁H₄₆O₇Na, 553.3141), see Fig. S18A; NMR spectra, see Fig. S18B–H; NMR data, see Table S18; **23** is identified as 16β -acetoxy- $3\alpha,6\beta$ -dihydroxy-29-norprotosta-17(20)Z,24-dien-7-one-21-oic acid.

Compound **24**: white powder; $[\alpha]_D^{26} -26.5$ (*c* 0.17, CH₂Cl₂); UV (CH₃OH) λ_{\max} (log ε) 204 nm (4.52); IR (KBr) ν_{\max} 3121, 2951, 2870, 1713, 1447, 1399, 1265, 1140 cm⁻¹; HRESIMS (positive) *m/z* 539.3366 [M + Na]⁺, (Calcd. for C₃₁H₄₈O₆Na, 539.3349), see Fig. S19A; NMR spectra, see Fig. S19B–H; NMR data, see Table S19; **24** is identified as 16β -acetoxy- $3\alpha,7\alpha$ -dihydroxy-29-norprotosta-17(20)Z,24-dien-21-oic acid.

Compound **25**: white powder; $[\alpha]_D^{26} -30.8$ (*c* 0.50, CH₂Cl₂); UV (CH₃OH) λ_{\max} (log ε) 204 nm (3.75); IR (KBr) ν_{\max} 3404, 2980, 2963, 2934, 2872, 1741, 1700, 1678, 1443, 1376, 1245, 1177, 1145, 1028 cm⁻¹; HRESIMS (positive) *m/z* 537.3196 [M + Na]⁺, (Calcd. for C₃₁H₄₆O₆Na, 537.3192), see Fig. S20A; NMR spectra, see Fig. S20B–H; NMR data, see Table S20; **25** is identified as 16β -acetoxy- 3α -hydroxy-29-norprotosta-17(20)Z,24-dien-7-one-21-oic acid.

Compound **26**: white powder; $[\alpha]_D^{26} -47.1$ (*c* 1.25, CH₃OH); UV (CH₃OH) λ_{\max} (log ε) 204 nm (3.97), 232 nm (3.99); IR (KBr) ν_{\max} 3447, 2971, 2928, 2855, 1712, 1666, 1456, 1377, 1257, 1034 cm⁻¹; HRESIMS (positive) *m/z* 543.2949 [M + H]⁺ (Calcd. for C₃₁H₄₃O₈, 543.2958), see Fig. S21A; NMR spectra, see Fig. S21B–H; NMR data, see Table S21; **26** is identified as 16β -acetoxy- $6\beta,11\alpha$ -dihydroxy-29-norprotosta-1,17(20)Z,24-trien-3,7-dione-21-oic acid.

Compound **29**: white powder; $[\alpha]_D^{26} -96.0$ (*c* 0.32, CH₃OH); UV (CH₃OH) λ_{\max} (log ε) 204 nm (4.13); IR (KBr) ν_{\max} 3550, 3024, 2970, 2955, 2929, 2897, 2871, 1723, 1457, 1376, 1254, 1175, 1152, 1109, 1087, 1059, 1033 cm⁻¹; HRESIMS (positive) *m/z* 497.3270 [M + H - H₂O]⁺ (Calcd. for C₃₁H₄₅O₅, 497.3267), see Fig. S22A; NMR spectra, see Fig. S22B-H; NMR data, see Table S22; **29** is identified as 16 β -acetoxy-3 α ,11 α -dihydroxy-29-norprotosta-1,17(20)Z,24-trien-21-oic acid.

Compound **30**: white powder; $[\alpha]_D^{26} -117.7$ (*c* 0.23, CH₂Cl₂); UV (CH₃OH) λ_{\max} (log ε) 204 nm (3.88); IR (KBr) ν_{\max} 3417, 2959, 2931, 2876, 1712, 1453, 1377, 1258, 1205, 1142, 1035 cm⁻¹; HRESIMS (positive) *m/z* 551.2980 [M + Na]⁺ (Calcd. for C₃₁H₄₄O₇Na, 551.2985), see Fig. S23A; NMR spectra, see Fig. S23B-H; NMR data, see Table S23; **30** is identified as 16 β -acetoxy-3 α ,6 β -dihydroxy-29-norprotosta-1,17(20)Z,24-trien-7-one-21-oic acid.

Compound **31**: white powder; HRESIMS (positive) *m/z* 513.3204 [M + H]⁺ (Calcd. for C₃₁H₄₅O₆, 513.3216), see Fig. S24A; NMR spectra, see Fig. S24 B-H; NMR data, see Table S24; **31** is identified as 16 β -acetoxy-7 α -hydroxy-29-norprotosta-1,17(20)Z,24-trien-3-one-21-oic acid (Maunakeanolic acid A).

Compound **32**: white powder; $[\alpha]_D^{26} -36.9$ (*c* 0.42, CH₃OH); UV (CH₃OH) λ_{\max} (log ε) 204 nm (3.95); IR (KBr) ν_{\max} 3443, 2965, 2932, 2867, 1718, 1451, 1376, 1261, 1036 cm⁻¹; HRESIMS (positive) *m/z* 537.3209 [M + Na]⁺ (Calcd. for C₃₁H₄₆O₆Na, 537.3192), see Fig. S25A; NMR spectra, see Fig. S25B-H; NMR data, see Table S25; **32** is identified as 16 β -acetoxy-3 α ,7 α -dihydroxy-29-norprotosta-1,17(20)Z,24-trien-21-oic acid.

Compound **33**: white powder; $[\alpha]_D^{26} +39.2$ (*c* 0.53, CH₃OH); UV (CH₃OH) λ_{\max} (log ε) 204 nm (4.11), 231 nm (4.14); IR (KBr) ν_{\max} 3423, 2976, 2929, 2870, 1731, 1704, 1669, 1445, 1400, 1380, 1244, 1190, 1143, 1030 cm⁻¹; HRESIMS (positive) *m/z* 533.2862 [M + Na]⁺ (Calcd. for C₃₁H₄₂O₆Na, 533.2879), see Fig. S26A; NMR spectra, see Fig. S26B-H; NMR data, see Table S26; **33** is identified as 16 β -acetoxy-29-norprotosta-1,17(20)Z,24-trien-3,7-dione-21-oic acid.

Compound **34**: white powder; $[\alpha]_D^{26} -100.1$ (*c* 0.13, CH₃OH); UV (CH₃OH) λ_{\max} (log ε) 204 nm (3.90); IR (KBr) ν_{\max} 3396, 2972, 2929, 2870, 1742, 1703, 1454, 1374, 1257, 1146, 1028 cm⁻¹; HRESIMS (positive) *m/z* 535.3053 [M + Na]⁺ (Calcd. for C₃₁H₄₄O₆Na, 535.3036), see Fig. S27A; NMR spectra, see Fig. S27B-H; NMR data, see Table S27; **34** is identified as 16 β -acetoxy-3 α -hydroxy-29-norprotosta-1,17(20)Z,24-trien-7-one-21-oic acid.

Compound **35**: white powder; $[\alpha]_D^{29} +121.7$ (*c* 1.0, CH₃OH); UV (CH₃OH) λ_{\max} (log ε) 205 nm

(4.50); IR (KBr) ν_{max} 3353, 2967, 2932, 2873, 1714, 1542, 1456, 1433, 1382, 1267, 1077, 1033, 1017 cm^{-1} ; HRESIMS (positive) m/z 545.3113 [$\text{M} + \text{H} - \text{H}_2\text{O}$]⁺, (Calcd. for C₃₁H₄₅O₈, 545.3114), see Fig. S28A; NMR spectra, see Fig. S28B–H; NMR data, see Table S28; **35** is identified as

16 β -acetoxy-1 α ,6 α ,7 β ,11 α -tetrahydroxy-29-norprotosta-17(20)Z,24-dien-3-one-21-oic acid.

Compound **36**: white powder; $[\alpha]_D^{29} +29.6$ (c 0.7, CH₃OH); UV (CH₃OH) λ_{max} (log ε) 196 nm (4.88); IR (KBr) ν_{max} 3398, 2969, 2935, 2873, 1713, 1663, 1554, 1442, 1381, 1266, 1028 cm^{-1} ; HRESIMS (positive) m/z 529.3177 [$\text{M} + \text{H}$]⁺ (Calcd. for C₃₁H₄₅O₇, 529.3165), see Fig. S29A; NMR spectra, see Fig. S29B–H; NMR data, see Table S29; **36** is identified as 16 β -acetoxy-6 α ,11 α -dihydroxy-29-norprotosta-1,17(20)Z,24-trien-3-one-21-oic acid.

Compound **37**: white powder; $[\alpha]_D^{29} +30.4$ (c 2.57, CH₃OH); UV (CH₃OH) λ_{max} (log ε) 210 nm (4.02), 227 nm (4.01); IR (KBr) ν_{max} 2967, 2929, 2870, 1715, 1666, 1438, 1376, 1036, 1007; HRESIMS (positive) m/z 529.3165 [$\text{M} + \text{H}$]⁺ (Calcd. for C₃₁H₄₅O₇, 529.3165), see Fig. S30A; NMR spectra, see Fig. S30B–H; NMR data, see Table S30; **37** is identified as 16 β -acetoxy-7 α ,11 α -dihydroxy-29-norprotosta-1,17(20)Z,24-trien-3-one-21-oic acid.

Compound **38**: white powder; $[\alpha]_D^{29} +75.2$ (c 0.93, CH₃OH); UV (CH₃OH) λ_{max} (log ε) 205 nm (3.96); IR (KBr) ν_{max} 3442, 2962, 2929, 2870, 1712, 1546, 1440, 1381, 1265, 1038, 1007; HRESIMS (positive) m/z 469.2958 [$\text{M} + \text{H} - \text{H}_2\text{O} - \text{CH}_3\text{COOH}$]⁺ (Calcd. for C₂₉H₄₁O₅, 469.2954), see Fig. S31A; NMR spectra, see Fig. S31B–H; NMR data, see Table S31; **38** is identified as

16 β -acetoxy-1 α ,7 α ,11 α -trihydroxy-29-norprotosta-17(20)Z,24-dien-3-one-21-oic acid.

Compound **39**: white powder; $[\alpha]_D^{29} -53.4$ (c 0.47, CH₃OH); UV (CH₃OH) λ_{max} (log ε) 204 nm (4.35), 231 nm (4.21); IR (KBr) ν_{max} 3299, 2972, 2919, 2851, 1714, 1671, 1542, 1457, 1436, 1419, 1384, 1264, 1035 cm^{-1} ; HRESIMS (positive) m/z 467.2789 [$\text{M} + \text{H} - \text{CH}_3\text{COOH}$]⁺ (Calcd. for C₂₉H₃₉O₅, 467.2797), see Fig. S32A; NMR spectra, see Fig. S32B–H; NMR data, see Table S32; **39** is identified as

16 β -acetoxy-11 α -hydroxy-29-norprotosta-1,17(20)Z,24-trien-3,7-dione-21-oic acid.

Compound **40**: white powder; $[\alpha]_D^{29} +13.1$ (c 1.7, CH₃OH); UV (CH₃OH) λ_{max} (log ε) 206 nm (3.83); IR (KBr) ν_{max} 3485, 2968, 2932, 2870, 1713, 1455, 1379, 1260, 1165, 1029 cm^{-1} ; HRESIMS (positive) m/z 469.2954 [$\text{M} + \text{H} - \text{H}_2\text{O} - \text{CH}_3\text{COOH}$]⁺ (Calcd. for C₂₉H₄₁O₅, 469.2954), see Fig. S33A; NMR spectra, see Fig. S33B–H; NMR data, see Table S33; **40** is identified as

16 β -acetoxy-1 α ,7 β ,11 α -trihydroxy-29-norprotosta-17(20)Z,24-dien-3-one-21-oic acid.

Compound **41**: white powder; $[\alpha]_D^{29} -7.9$ (*c* 1.13, CH₃OH); UV (CH₃OH) λ_{\max} (log ε) 203 nm (4.05); IR (KBr) ν_{\max} 2918, 2874, 2848, 1715, 1596, 1543, 1454, 1383, 1359, 1272, 1032 cm⁻¹; HRESIMS (positive) *m/z* 553.3124 [M + Na]⁺ (Calcd. for C₃₁H₄₆O₇Na, 553.3141), see Fig. S34A; NMR spectra, see Fig. S34B–H; NMR data, see Table S34; **41** is identified as 16 β -acetoxy-3 α ,6 α ,7 β -trihydroxy-29-norprotosta-1,17(20)Z,24-trien-21-oic acid.

Compound **42**: white powder; $[\alpha]_D^{27} -26.1$ (*c* 0.67, CH₃OH); UV (CH₃OH) λ_{\max} (log ε) 203 nm (4.17); IR (KBr) ν_{\max} 3439, 2952, 2933, 2871, 1714, 1649, 1442, 1377, 1268, 1021 cm⁻¹; HRESIMS (positive) *m/z* 495.3103 [M + H – H₂O]⁺ (Calcd. for C₃₁H₄₃O₅, 495.3110), see Fig. S35A; NMR spectra, see Fig. S35B–H; NMR data, see Table S35; **42** is identified as 16 β -acetoxy-3 α -hydroxy-29-norprotosta-1,17(20)Z,24-trien-6-one-21-oic acid.

Compound **43**: white powder; $[\alpha]_D^{29} -8.2$ (*c* 1.67, CH₃OH); UV (CH₃OH) λ_{\max} (log ε) 203 nm (5.05); IR (KBr) ν_{\max} 3515, 2942, 2870, 1713, 1450, 1379, 1269, 1026 cm⁻¹; HRESIMS (positive) *m/z* 537.3190 [M + Na]⁺ (Calcd. for C₃₁H₄₆O₆Na, 537.3192), see Fig. S36A; NMR spectra, see Fig. S36B–H; NMR data, see Table S36; **43** is identified as 16 β -acetoxy-3 α ,7 β -dihydroxy-29-norprotosta-1,17(20)Z,24-trien-21-oic acid.

Compound **44**: white powder; $[\alpha]_D^{26} +9.3$ (*c* 1.23, CH₃OH); UV (CH₃OH) λ_{\max} (log ε) 206 nm (4.10), 231 nm (4.13); IR (KBr) ν_{\max} 3449, 2963, 2933, 2877, 1731, 1675, 1564, 1455, 1376, 1251, 1034 cm⁻¹; HRESIMS (positive) *m/z* 593.3098 [M + Na]⁺ (Calcd. for C₃₃H₄₆O₈Na, 593.3090), see Fig. S37A; NMR spectra, see Fig. S37B–H; NMR data, see Table S37; **44** is identified as 6 α ,16 β -diacetoxy-7 β -hydroxy-29-norprotosta-1,17(20)Z,24-trien-3-one-21-oic acid.

Compound **45**: white powder; $[\alpha]_D^{26} +19.9$ (*c* 7.3, CH₃OH); UV (CH₃OH) λ_{\max} (log ε) 204 nm (4.03), 230 nm (3.99); IR (KBr) ν_{\max} 3463.5, 2959, 2932, 2876, 1730, 1676, 1454, 1375, 1249, 1141, 1029 cm⁻¹; HRESIMS (positive) *m/z* 593.3080 [M + Na]⁺ (Calcd. for C₃₃H₄₆O₈Na, 593.3090), see Fig. S38A; NMR spectra, see Fig. S38B–H; NMR data, see Table S38; **45** is identified as 7 β ,16 β -diacetoxy-6 α -hydroxy-29-norprotosta-1,17(20)Z,24-trien-3-one-21-oic acid.

Compound **46**: white powder; $[\alpha]_D^{26} +35.1$ (*c* 0.87, CH₃OH); UV (CH₃OH) λ_{\max} (log ε) 204 nm (4.31), 229 nm (4.20); IR (KBr) ν_{\max} 3418, 2959, 2934, 2870, 1731, 1676, 1454, 1245, 1029 cm⁻¹; HRESIMS (positive) *m/z* 577.3149 [M + Na]⁺ (Calcd. for C₃₃H₄₆O₇Na, 577.3141), see Fig. S39A; NMR spectra, see Fig. S39B–H; NMR data, see Table S39; **46** is identified as 7 β ,16 β -diacetoxy-29-norprotosta-1,17(20)Z,24-trien-3-one-21-oic acid.

Compound **47**: white powder; $[\alpha]_D^{21} +19.3$ (*c* 0.44, CH₃OH); UV (CH₃OH) λ_{\max} (log ε) 204 nm

(4.08); IR (KBr) ν_{max} 2961, 2934, 2877, 1716, 1653, 1635, 1558, 1454, 1377, 1266, 1179, 1147, 1024 cm^{-1} ; HRESIMS (positive) m/z 571.3237 [$\text{M} + \text{Na}$]⁺ (Calcd. for C₃₁H₄₈O₈Na, 571.3247), see Fig. S40A; NMR spectra, see Fig. S40B–H; NMR data, see Table S40; **47** is identified as

16 β -acetoxy-3 α ,6 α ,7 β ,11 α -tetrahydroxy-29-norprotosta-17(20)Z,24-dien-21-oic acid.

Compound **48**: white powder; $[\alpha]_D^{21} +10.3$ (c 0.28, CH₃OH); UV (CH₃OH) λ_{max} (log ε) 204 nm (3.94); IR (KBr) ν_{max} 3454, 2971, 2935, 2879, 1718, 1446, 1380, 1260, 1145, 1060, 1022 cm^{-1} ; HRESIMS (positive) m/z 533.3484 [$\text{M} + \text{H}$]⁺ (Calcd. for C₃₁H₄₉O₇, 533.3478), see Fig. S41A; NMR spectra, see Fig. S41B–H; NMR data, see Table S41; **48** is identified as 16 β -acetoxy-3 α ,6 α ,11 α -trihydroxy-29-norprotosta-17(20)Z,24-dien-21-oic acid.

Compound **49**: white powder, $[\alpha]_D^{21} 14.7$ (c 0.19, CH₃OH); UV (CH₃OH) λ_{max} (log ε) 204 (3.54); IR (KBr) ν_{max} 3446, 2952, 2929, 2874, 1716, 1654, 1558, 1541, 1457, 1377, 1267, 1144, 1105, 1025, 973 cm^{-1} ; HRESIMS (positive) m/z 533.3497 [$\text{M} + \text{H}$]⁺ (Calcd. for C₃₁H₄₉O₇, 533.3478), see Fig. S42A; NMR spectra, see Fig. S42B–H; NMR data, see Table S42,

49 is identified as

16 β -Acetoxy-3 α ,7 β ,11 α -trihydroxy-29-norprotosta-17(20)Z,24-dien-21-oic acid.

Compound **50**: white powder; $[\alpha]_D^{21} +20.9$ (c 0.63, CH₂Cl₂); UV (CH₃OH) λ_{max} (log ε) 204 nm (4.09); IR (KBr) ν_{max} 3501, 2968, 2938, 2886, 1715, 1453, 1376, 1256, 1146, 1107, 1032 cm^{-1} ; HRESIMS (positive) m/z 611.3185 [$\text{M} + \text{Na}$]⁺ (Calcd. for C₃₃H₄₈O₉Na, 611.3196), see Fig. S43A; NMR spectra, see Fig. S43B–H; NMR data, see Table S43; **50** is identified as 7 β ,16 β -diacetoxy-6 α ,11 α -dihydroxy-29-norprotosta-17(20)Z,24-dien-3-one-21-oic acid.

Compound **51**: white powder; $[\alpha]_D^{21} +65.2$ (c 0.45, CH₃OH); UV (CH₃OH) λ_{max} (log ε) 205 nm (4.27); IR (KBr) ν_{max} 3484, 2969, 2943, 2886, 1713, 1456, 1440, 1377, 1257, 1032 cm^{-1} ; HRESIMS (positive) m/z 611.3174 [$\text{M} + \text{Na}$]⁺ (Calcd. for C₃₃H₄₈O₉Na, 611.3196), see Fig. S44A; NMR spectra, see Fig. S44B–H; NMR data, see Table S44; **51** is identified as 6 α ,16 β -diacetoxy-7 β ,11 α -dihydroxy-29-norprotosta-17(20)Z,24-dien-3-one-21-oic acid.

Compound **52**: white powder; $[\alpha]_D^{21} +40.6$ (c 0.42, CH₃OH); UV (CH₃OH) λ_{max} (log ε) 201 nm (3.99); IR (KBr) ν_{max} 3525, 2957, 2938, 2883, 1715, 1457, 1377, 1253, 1142, 1028 cm^{-1} ; HRESIMS (positive) m/z 595.3248 [$\text{M} + \text{Na}$]⁺ (Calcd. for C₃₃H₄₈O₈Na, 595.3247), see Fig. S45A; NMR spectra, see Fig. S45B–H; NMR data, see Table S45; **52** is identified as 6 α ,16 β -diacetoxy-11 α -hydroxy-29-norprotosta-17(20)Z,24-dien-3-one-21-oic acid.

Compound **55**: white powder; HRESIMS (positive) m/z 569.3071 [$\text{M} + \text{Na}$]⁺ (Calcd. for C₃₁H₄₆O₈Na, 569.3090), see Fig. S46A; NMR spectra, see Fig. S46B–H; NMR data, see

Table S46; **55** is identified as 16β -acetyloxy- $3\alpha,6\beta,11\alpha$ -trihydroxy-29-norprotosta-17(20)Z,24-dien-7-one-21-oic acid (CAS Registry Number: 779980-64-2).

Compound **56**: white powder; HRESIMS (positive) m/z 533.3490 [$M + H$]⁺ (Calcd. for C₃₁H₄₉O₇, 533.3478), see Fig. S47A; NMR spectra, see Fig. S47B–H; NMR data, see Table S47; **56** is identified as 16β -acetyloxy- $3\alpha,7\alpha,11\alpha$ -trihydroxy-29-norprotosta-17(20)Z,24-dien-21-oic acid (CAS Registry Number: 35805-38-0).

Compound **57**: white powder; HRESIMS (positive) m/z 531.3325 [$M + H$]⁺ (Calcd. for C₃₁H₄₇O₇, 531.3322), see Fig. S48A; NMR spectra, see Fig. S48B–H; NMR data, see Table S48; **57** is identified as 16β -acetyloxy- $3\alpha,11\alpha$ -dihydroxy-29-norprotosta-17(20)Z,24-dien-7-one-21-oic acid (CAS Registry Number: 764590-42-3).

Compound **58**: white powder; $[\alpha]_D^{26} -66.3$ (*c* 2.67, CH₃OH); UV (CH₃OH) λ_{max} (log ε) 204 nm (3.65); IR (KBr) ν_{max} 3445, 2950, 2930, 2870, 1718, 1652, 1455, 1442, 1375, 1261, 1233, 1154, 1032 cm⁻¹; HRESIMS (positive) m/z 609.3043 [$M + Na$]⁺ (Calcd. for C₃₃H₄₆O₉Na, 609.3040), see Fig. S49A; NMR spectra, see Fig. S49B–H; NMR data, see Table S49; **58** is identified as $6\beta,16\beta$ -diacetyloxy- 11α -hydroxy-29-norprotosta-17(20)Z,24-dien-3,7-dione-21-oic acid.

Compound **59**: white powder, $[\alpha]_D^{26} -85.6$ (*c* 0.92, CH₃OH); UV (CH₃OH) λ_{max} (log ε) 204 nm (4.07); IR (KBr) ν_{max} 3502, 2975, 2935, 2864, 1746, 1713, 1459, 1438, 1375, 1224, 1150, 1060, 1028 cm⁻¹; HRESIMS (positive) m/z 611.3185 [$M + Na$]⁺ (Calcd. for C₃₃H₄₈O₉Na, 611.3196), see Fig. S50A; NMR spectra, see Fig. S50B–H; NMR data, see Table S50; **59** is identified as $6\beta,16\beta$ -diacetyloxy- $3\beta,11\alpha$ -dihydroxy-29-norprotosta-17(20)Z,24-dien-7-one-21-oic acid.

Compound **60**: white powder; $[\alpha]_D^{25} -74.7$ (*c* 1.33, CH₃OH); UV (CH₃OH) λ_{max} (log ε) 204 nm (3.95); IR (KBr) ν_{max} 3395, 2952, 2924, 2852, 1750, 1716, 1652, 1458, 1376, 1255, 1226, 1021 cm⁻¹; HRESIMS (positive) m/z 595.3240 [$M + Na$]⁺ (Calcd. for C₃₃H₄₈O₈Na, 595.3247), see Fig. S51A; NMR spectra, see Fig. S51B–H; NMR data, see Table S51; **60** is identified as $6\beta,16\beta$ -diacetyloxy- 3α -hydroxy-29-norprotosta-17(20)Z,24-dien-7-one-21-oic acid.

Compound **61**: white powder; $[\alpha]_D^{27} -89.0$ (*c* 2.33, CH₃OH); UV (CH₃OH) λ_{max} (log ε) 204 nm (4.07), 231 nm (4.08); IR (KBr) ν_{max} 3546, 3468, 2977, 2941, 2883, 1752, 1725, 1699, 1663, 1457, 1374, 1252, 1214, 1033 cm⁻¹; HRESIMS (positive) m/z 585.3038 [$M + H$]⁺ (Calcd. for

$C_{33}H_{45}O_9$, 585.3064), see Fig. S52A; NMR spectra, see Fig. S52B–H; NMR data, see Table S52;

61 is identified as

$6\beta,16\beta$ -diacetyloxy- 11α -hydroxy-29-norprotosta-1,17(20)Z,24-trien-3,7-dione-21-oic acid.

Compound **62**: white powder; $[\alpha]_D^{25} -41.3$ (c 0.40, CH_3OH); UV (CH_3OH) λ_{max} ($\log \varepsilon$) 201 nm (3.98); IR (KBr) ν_{max} 3315, 2964, 2929, 2879, 1711, 1593, 1456, 1433, 1382, 1266, 1034 cm^{-1} ; HRESIMS (positive) m/z 567.2936 [$M + Na$]⁺ (Calcd. for $C_{31}H_{44}O_8Na$, 567.2934), see Fig. S53A; NMR spectra, see Fig. S53B–H; NMR data, see Table S53; **62** is identified as 16β -acetyloxy- $3\alpha,6\beta,11\alpha$ -trihydroxy-29-norprotosta-1,17(20)Z,24-trien-7-one-21-oic acid.

Compound **63**: white powder; $[\alpha]_D^{21} -148.3$ (c 0.47, CH_3OH); UV (CH_3OH) λ_{max} ($\log \varepsilon$) 203 nm (4.06); IR (KBr) ν_{max} 32970, 2925, 2882, 1751, 1712, 1454, 1374, 1226, 1036 cm^{-1} ; HRESIMS (positive) m/z 571.3270 [$M + H$]⁺ (Calcd. for $C_{33}H_{47}O_8$, 571.3271), see Fig. S54A; NMR spectra, see Figs. S54B–K and S61; NMR data, see Table S54; **63** is identified as $6\beta,16\beta$ -diacetyloxy- 3α -hydroxy-29-norprotosta-1,17(20)Z,24-trien-7-one-21-oic acid.

Compound **64**: white powder; $[\alpha]_D^{21} -21.7$ (c 1.27, CH_3OH); UV (CH_3OH) λ_{max} ($\log \varepsilon$) 203 nm (4.00); IR (KBr) ν_{max} 3419, 2962, 2932, 2873, 1721, 1652, 1438, 1377, 1256, 1026 cm^{-1} ; HRESIMS (positive) m/z 513.3210 [$M + H - CH_3COOH$]⁺ (Calcd. for $C_{31}H_{45}O_6$, 513.3216), see Fig. S55A; NMR spectra, see Fig. S55B–H; NMR data, see Table S55; **64** is identified as $7\beta,16\beta$ -diacetyloxy- $3\alpha,6\alpha$ -dihydroxy-29-norprotosta-1,17(20)Z,24-trien-21-oic acid.

Compound **65**: white powder; $[\alpha]_D^{27} +18.0$ (c 2.13, CH_3OH); UV (CH_3OH) λ_{max} ($\log \varepsilon$) 203 nm (4.08); IR (KBr) ν_{max} 3412, 2960, 2939, 2871, 1731, 1652, 1439, 1375, 1251, 1019 cm^{-1} ; HRESIMS (positive) m/z 579.3308 [$M + Na$]⁺ (Calcd. for $C_{33}H_{48}O_7Na$, 579.3298), see Fig. S56A; NMR spectra, see Fig. S56B–H; NMR data, see Table S56; **65** is identified as $6\alpha,16\beta$ -diacetyloxy- 3α -hydroxy-29-norprotosta-1,17(20)Z,24-trien-21-oic acid.

Compound **66**: white powder; $[\alpha]_D^{21} +41.2$ (c 1.13, CH_3OH); UV (CH_3OH) λ_{max} ($\log \varepsilon$) 205 nm (4.07), 231 nm (4.12); IR (KBr) ν_{max} 3444, 2977, 2936, 2873, 1734, 1674, 1439, 1375, 1250, 1025 cm^{-1} ; HRESIMS (positive) m/z 555.3330 [$M + H$]⁺ (Calcd. for $C_{33}H_{47}O_7$, 555.3322), see Fig. S57A; NMR spectra, see Fig. S57B–H; NMR data, see Table S57; **66** is identified as $6\alpha,16\beta$ -diacetyloxy-29-norprotosta-1,17(20)Z,24-trien-3-one-3-one-21-oic acid.

Compound **67**: white powder; $[\alpha]_D^{29} +27.6$ (c 3.8, CH_3OH); UV (CH_3OH) λ_{max} ($\log \varepsilon$) 206 nm (4.10); IR (KBr) ν_{max} 3485, 2952, 2936, 2885, 1719, 1441, 1378, 1261, 1141, 1025 cm^{-1} ; HRESIMS (positive) m/z 597.3405 [$M + Na$]⁺ (Calcd. for $C_{33}H_{50}O_8Na$, 597.3403), see Fig. S58A; NMR spectra, see Fig. S58B–H; NMR data, see Table S58; **67** is identified as $6\alpha,16\beta$ -diacetyloxy- $3\alpha,11\alpha$ -dihydroxy-29-norprotosta-17(20)Z,24-dien-21-oic acid.

Compound **68**: white powder; $[\alpha]_D^{26} -92.9$ (*c* 0.38, CH₃OH); UV (CH₃OH) λ_{\max} (log ε) 204 nm (4.02); IR (KBr) ν_{\max} 3482, 2958, 2935, 2883, 1719, 1440, 1376, 1230, 1144, 1066, 1023 cm⁻¹; HRESIMS (positive) *m/z* 611.3179 [M + Na]⁺ (Calcd. for C₃₃H₄₈O₉Na, 611.3196), see Fig. S59A; NMR spectra, see Fig. S59B–H; NMR data, see Table S59; **68** is identified as 6 β ,16 β -diacetyloxy-3 α ,11 α -dihydroxy-29-norprotosta-17(20)Z,24-dien-7-one-21-oic acid.

Compound **69**: white powder; $[\alpha]_D^{26} -58.0$ (*c* 0.8, CH₃OH); UV (CH₃OH) λ_{\max} (log ε) 203 nm (4.08); IR (KBr) ν_{\max} 3413, 2960, 2929, 2879, 1717, 1648, 1436, 1383, 1263, 1232, 1057, 1019 cm⁻¹; HRESIMS (positive) *m/z* 609.3029 [M + Na]⁺ (Calcd. for C₃₃H₄₆O₉Na, 609.3040), see Fig. S60A; NMR spectra, see Fig. S60B–H; NMR data, see Table S60; **69** is identified as 6 β ,16 β -diacetyloxy-3 α ,11 α -dihydroxy-29-norprotosta-1,17(20)Z,24-trien-7-one-21-oic acid.

Compound **81**: white powder; $[\alpha]_D^{28} +63.0$ (*c* 4.3, CH₃OH); UV (CH₃OH) λ_{\max} (log ε) 204 nm (4.10); IR (KBr) ν_{\max} 3451.0, 3023, 2959, 2933, 2870, 1717, 1648, 1591, 1443, 1374, 1261, 1029, 1006 cm⁻¹; HRESIMS (positive) *m/z* 521.3245 [M + Na]⁺ (Calcd. for C₃₁H₄₆O₅Na, 521.3243), see Fig. S61A; NMR spectra, see Fig. S61B–H; NMR data, see Table S61; **81** is identified as 16 β -acetyloxy-3 β -hydroxy-29-norprotosta-1,17(20)Z,24-trien-21-oic acid.

*Absolute configuration determination of **35**, **38** and **40***

As the relative configuration of C-1 of **35**, **38** and **40** cannot be determined *via* ROESY analysis, quantum chemical calculation of NMR shifts was employed. The flexible side chain of fusidane-type antibiotics can lead to more conformations, which has less impact on NMR shifts. Therefore, **35** was simplified as

(1S*,4S*,5S*,6R*,7R*,8S*,9S*,10S*,11R*,13R*,14S*,16S*)-**35-A** and (1R*,4S*,5S*,6R*,7R*,8S*,9S*,10S*,11R*,13R*,14S*,16S*)-**35-B** (Fig. S63). The molecules of **35-A** and **35-B** were converted into SIMILES codes before their initial 3D structure were generated with CORINA version 3.4. Conformer databases were generated in CONFLEX version 7.0 using the MMFF94s force-field, with an energy window for acceptable conformers (ewindow) of 5 kcal/mol above the ground state, a maximum number of conformations per molecule (maxconfs) of 100, and an RMSD cutoff (rmsd) of 0.5 Å. Then each conformer of the acceptable conformers was optimized with the HF/6-31G(d) method in Gaussian09. Further optimization at the B3LYP/6-31G(d) level determined the dihedral angles. The optimized conformers (Table S63) were used for ¹³C NMR shifts calculation, which was performed with Gaussian09 (mPW1PW91/6-31+G(d,p)). The solvent effect was taken into account by the polarizable-conductor calculation model (PCM, CD₃OD as the solvent). Computed chemical shifts were scaled empirically according to $\delta_{\text{corr.}} = \delta_{\text{calcd.}} \times \text{slope}$

+ intercept, where $\delta_{\text{calcd.}}$ is the calculated chemical shift, and slope and intercept are the slope and intercept resulting from a regression calculation on a plot of $\delta_{\text{calcd.}}$ against $\delta_{\text{exptl.}}^1$. The comparison was judged by R square (R^2) analysis, mean absolute error (MAE) and DP4+ probability² (Table S68). Finally, the relative configuration of **35** was determined as $1S^*, 4S^*, 5S^*, 6R^*, 7R^*, 8S^*, 9S^*, 10S^*, 11R^*, 13R^*, 14S^*, 16S^*$, and the absolute configuration was assigned as $1S, 4S, 5S, 6R, 7R, 8S, 9S, 10S, 11R, 13R, 14S, 16S$. Likewise, the optimized conformers (Table S64) were used for ^{13}C NMR shifts calculation, which was performed with Gaussian09 (mPW1PW91/6-311+G(d,p)) for **38**. The absolute configuration of **38** was assigned as $1S, 4S, 5S, 7R, 8S, 9S, 10S, 11R, 13R, 14S, 16S$ (Fig. S64, Tables S64 and S68). On the basis of comparision of ^{13}C chemical shifts between **38** and **40** (Table S66), the relative configuration of **40** was determined, and the absolute configuration of **40** was assigned as $1S, 4S, 5S, 7S, 8S, 9S, 10S, 11R, 13R, 14S, 16S$.

*Absolute configuration determination of **6**, **29**, **30**, **32**, **34**, **41–43**, **63–65** and **69***

For compounds **6**, **29**, **30**, **32**, **34**, **41–43**, **63–65** and **69**, the relative configuration of C-3 cannot be determined *via* NOESY or coupling constants analysis. Therefore, we planned to perform chemical derivatization to obtain analogues bearing 3α -OH/the C1–C2 double bond and 3β -OH/the C1–C2 double bond. We added **7** (10.0 mg) to a stirred solution of NaBH₄ (5.0 mg) in Et₂O (10 mL) in an ice and water bath. Then the mixture was stirred in the dark at room temperature for 24 h. The solvent was removed under reduced pressure, and the residue was further purified by semi-preparative HPLC with isocratic elution of 80% CH₃CN–H₂O to give **6** (0.5 mg) and **81** (4.1 mg). According to ROESY analysis, the relative configuration of **81** was determined as $3S^*, 4S^*, 5S^*, 8S^*, 9S^*, 10S^*, 13R^*, 14S^*, 16S^*$, and the absolute configuration of **81** was assigned as $3S, 4S, 5S, 8S, 9S, 10S, 13R, 14S, 16S$. Therefore, the absolute configuration of **6**, the epimer of **81** at C-3, was assigned as $3R, 4S, 5S, 8S, 9S, 10S, 13R, 14S, 16S$. And based on the coupling constants ($^3J_{\text{H-3, H-4}} = 4.4$ Hz for 3α -OH, and $^3J_{\text{H-3, H-4}} = 7.9$ Hz for 3β -OH), we determined that 3-OH in compounds **29**, **30**, **32**, **34**, **41–43**, **63–65** and **69** was α -oriented (Table. S69). Additionally, we also performed quantum chemical calculation of NMR shifts for **34** (CD₃OD as the solvent) and **42** (CDCl₃ as the solvent)^{1,2}, and the optimized conformers (Tables S62 and S65) were used for ^{13}C NMR shifts calculation, which was performed with Gaussian09 (mPW1PW91/6-31+G(d,p)). The results indicated that 3-OH in **34** and **42** was indeed α -oriented (Figs. S62 and S65, Table S67).

Supporting Figures





Figure S1 HPLC analysis of metabolites from *A. oryzae* transformants.

(A) *A. oryzae* NSAR1; (B) *A. oryzae* harboring *helA*, *helB1*, *helB2*, *helC*, *helB4* and *held2* (AOS0); (C) AOS0 harboring *helE* and *fusB1* (AOS1); (D) AOS0 harboring *helE* and *fusC1* (AOS2); (E) AOS0 harboring *helE* and *cepB4* (AOS3); (F) AOS0 harboring *fusB1* and *cepB4* (AOS4); (G) AOS0 harboring *helB3* and *fusB1* (AOS5); (H) AOS0 harboring *helB3* and *fusC1* (AOS6); (I) AOS0 harboring *helE*, *fusB1* and *helB3* (AOS7); (J) AOS0 harboring *helE*, *fusB1*

and *fusC1* (AOS8); (K) AOS0 harboring *helE*, *fusC1* and *helB3* (AOS9); (L) AOS0 harboring *helE*, *fusB1* and *cepB4* (AOS10); (M) AOS0 harboring *helE*, *fusC1* and *cepB4* (AOS11); (N) AOS0 harboring *helE*, *cepB4* and *cepD2* (AOS12); (O) AOS0 harboring *fusB1*, *cepB4* and *fusC1* (AOS13); (P) AOS0 harboring *fusB1*, *cepB4* and *cepD2* (AOS14); (Q) AOS0 harboring *helB3*, *fusB1* and *fusC1* (AOS15); (R) AOS0 harboring *helB3*, *fusB1* and *helD1* (AOS16); (S) AOS0 harboring *helB3*, *fusC1* and *helD1* (AOS17); (T) AOS0 harboring *helE*, *fusB1*, *helB3* and *helD1* (AOS18); (U) AOS0 harboring *helE*, *fusB1*, *helB3* and *fusC1* (AOS19); (V) AOS0 harboring *helE*, *fusC1*, *helB3* and *helD1* (AOS20); (W) AOS0 harboring *helE*, *fusB1*, *cepB4* and *fusC1* (AOS21); (X) AOS0 harboring *helE*, *fusB1*, *cepB4* and *cepD2* (AOS22); (Y) AOS0 harboring *helE*, *cepB4*, *cepD2* and *fusC1* (AOS23); (Z) AOS0 harboring *fusB1*, *fusC1*, *cepB4* and *cepD2* (AOS24); (AA) AOS0 harboring *fusB1*, *fusC1*, *helB3* and *helD1* (AOS25). (AB) AOS0 harboring *helE*, *fusB1*, *fusC1*, *helB3* and *helD1* (AOS26); (AC) AOS0 harboring *helE*, *fusB1*, *fusC1*, *cepB4* and *cepD2* (AOS27).








Figure S2 Fusidane-type antibiotics produced *via* the stochastic combinational strategy.

New compounds are marked in red. And compounds **7**, **8**, **16**, **27**, **28**, **53** and **54** were identified by comparison with standards or mass spectrometry analysis.


A




B




C




D




E



F



G



H






Figure S3 HRESIMS and NMR spectra of **5**.

(A) HRESIMS spectrum; (B) ^1H NMR spectrum in CDCl_3 at 400 MHz; (C) ^{13}C NMR spectrum in CDCl_3 at 100 MHz; (D) DEPT 135 spectrum in CDCl_3 at 100 MHz; (E) ^1H - ^1H COSY spectrum in CDCl_3 at 400 MHz; (F) HSQC spectrum in CDCl_3 at 400 MHz; (G) HMBC spectrum in CDCl_3 at 400 MHz; (H) ROESY spectrum in CDCl_3 at 400 MHz.


A




B




C




D




E




F



G



H



I






Figure S4 HRESIMS and NMR spectra of **6**.

(A) HRESIMS spectrum; (B) ^1H NMR spectrum in CDCl_3 at 600 MHz; (C) ^{13}C NMR spectrum in CDCl_3 at 150 MHz; (D) DEPT 135 spectrum in CDCl_3 at 150 MHz; (E) ^1H - ^1H COSY spectrum in CDCl_3 at 600 MHz; (F) HSQC spectrum in CDCl_3 at 600 MHz; (G) HMBC spectrum in CDCl_3 at 600 MHz; (H) NOESY spectrum in CDCl_3 at 600 MHz; (I) ^1H NMR spectrum of **6** obtained *via* chemical derivatization in CDCl_3 at 600 MHz.


A




B




C




D



E



F







Figure S5 HRESIMS and NMR spectra of **9**.

(A) HRESIMS spectrum; (B) ^1H NMR spectrum in CDCl_3 at 600 MHz; (C) ^{13}C NMR spectrum in CDCl_3 at 150 MHz; (D) DEPT 135 spectrum in CDCl_3 at 150 MHz; (E) ^1H - ^1H COSY spectrum in CDCl_3 at 600 MHz; (F) HSQC spectrum in CDCl_3 at 600 MHz; (G) HMBC spectrum in CDCl_3 at 600 MHz; (H) NOESY spectrum in CDCl_3 at 600 MHz.

Monoisotopic Mass, Even Electron Ions

248 formula(e) evaluated with 1 results within limits (up to 50 closest results for each mass)


Elements Used:

C: 0-500 H: 0-1000 O: 0-200 Na: 0-1

54


20190107_59 219 (1.773)

1: TOF MS ES+
9.85e+004




Mass	Calc. Mass	mDa	PPM	DBE	i-FIT	Norm	Conf (%)	Formula
513.3224	513.3216	0.8	1.6	9.5	143.4	n/a	n/a	C31 H45 O6


B




C




D




E



F



G



H






Figure S6 HRESIMS and NMR spectra of **10**.

(A) HRESIMS spectrum; (B) ^1H NMR spectrum in CDCl_3 at 600 MHz; (C) ^{13}C NMR spectrum in CDCl_3 at 150 MHz; (D) DEPT 135 spectrum in CDCl_3 at 150 MHz; (E) ^1H - ^1H COSY spectrum in CDCl_3 at 600 MHz; (F) HSQC spectrum in CDCl_3 at 600 MHz; (G) HMBC spectrum in CDCl_3 at 600 MHz; (H) NOESY spectrum in CDCl_3 at 600 MHz.


A




B




C




D




E



F



G



H







Figure S7 HRESIMS and NMR spectra of **11**.

(A) HRESIMS spectrum; (B) ^1H NMR spectrum in CDCl_3 at 400 MHz; (C) ^{13}C NMR spectrum in CDCl_3 at 100 MHz; (D) DEPT 135 spectrum in CDCl_3 at 100 MHz; (E) ^1H - ^1H COSY spectrum in CDCl_3 at 400 MHz; (F) HSQC spectrum in CDCl_3 at 400 MHz; (G) HMBC spectrum in CDCl_3 at 400 MHz; (H) ROESY spectrum in CDCl_3 at 400 MHz.


A




B




D




E



F



G



H






Figure S8 HRESIMS and NMR spectra of **12**.

(A) HRESIMS spectrum; (B) ^1H NMR spectrum in CDCl_3 at 400 MHz; (C) ^{13}C NMR spectrum in CDCl_3 at 100 MHz; (D) DEPT 135 spectrum in CDCl_3 at 100 MHz; (E) ^1H - ^1H COSY spectrum in CDCl_3 at 400 MHz; (F) HSQC spectrum in CDCl_3 at 400 MHz; (G) HMBC spectrum in CDCl_3 at 400 MHz; (H) ROESY spectrum in CDCl_3 at 400 MHz.


A




B




C




D




E



F



G



H






Figure S9 HRESIMS and NMR spectra of **13**.

(A) HRESIMS spectrum; (B) ^1H NMR spectrum in CDCl_3 at 600 MHz; (C) ^{13}C NMR spectrum in CDCl_3 at 150 MHz; (D) DEPT 135 spectrum in CDCl_3 at 150 MHz; (E) ^1H - ^1H COSY spectrum in CDCl_3 at 600 MHz; (F) HSQC spectrum in CDCl_3 at 600 MHz; (G) HMBC spectrum in CDCl_3 at 600 MHz; (H) NOESY spectrum in CDCl_3 at 600 MHz.


A




B




C




D




E



F



G



H






Figure S10 HRESIMS and NMR spectra of **14**.

(A) HRESIMS spectrum; (B) ^1H NMR spectrum in CDCl_3 at 400 MHz; (C) ^{13}C NMR spectrum in CDCl_3 at 100 MHz; (D) DEPT 135 spectrum in CDCl_3 at 100 MHz; (E) ^1H - ^1H COSY spectrum in CDCl_3 at 400 MHz; (F) HSQC spectrum in CDCl_3 at 400 MHz; (G) HMBC spectrum in CDCl_3 at 400 MHz; (H) ROESY spectrum in CDCl_3 at 400 MHz.


A




B




C




D




E



F



G



H






Figure S11 HRESIMS and NMR spectra of **15**.

(A) HRESIMS spectrum; (B) ^1H NMR spectrum in CDCl_3 at 400 MHz; (C) ^{13}C NMR spectrum in CDCl_3 at 100 MHz; (D) DEPT 135 spectrum in CDCl_3 at 100 MHz; (E) ^1H - ^1H COSY spectrum in CDCl_3 at 400 MHz; (F) HSQC spectrum in CDCl_3 at 400 MHz; (G) HMBC spectrum in CDCl_3 at 400 MHz; (H) ROESY spectrum in CDCl_3 at 400 MHz.


A




B




C




D




E



F



G



H






Figure S12 HRESIMS and NMR spectra of 17.

(A) HRESIMS spectrum; (B) ^1H NMR spectrum in CDCl_3 at 600 MHz; (C) ^{13}C NMR spectrum in CDCl_3 at 150 MHz; (D) DEPT 135 spectrum in CDCl_3 at 150 MHz; (E) ^1H - ^1H COSY spectrum in CDCl_3 at 600 MHz; (F) HSQC spectrum in CDCl_3 at 600 MHz; (G) HMBC spectrum in CDCl_3 at 600 MHz; (H) ROESY spectrum in CDCl_3 at 400 MHz.


A




B




C




D




E



F



G



H






Figure S13 HRESIMS and NMR spectra of **18**.

(A) HRESIMS spectrum; (B) ^1H NMR spectrum in CD_3OD at 600 MHz; (C) ^{13}C NMR spectrum in CD_3OD at 150 MHz; (D) DEPT 135 spectrum in CD_3OD at 150 MHz; (E) ^1H - ^1H COSY spectrum in CD_3OD at 600 MHz; (F) HSQC spectrum in CD_3OD at 600 MHz; (G) HMBC spectrum in CD_3OD at 600 MHz; (H) NOESY spectrum in CD_3OD at 600 MHz.


A




B




D




E



F



G



H






Figure S14 HRESIMS and NMR spectra of **19**.

(A) HRESIMS spectrum; (B) ^1H NMR spectrum in CD_3OD at 600 MHz; (C) ^{13}C NMR spectrum in CD_3OD at 150 MHz; (D) DEPT 135 spectrum in CD_3OD at 150 MHz; (E) ^1H - ^1H COSY spectrum in CD_3OD at 600 MHz; (F) HSQC spectrum in CD_3OD at 600 MHz; (G) HMBC spectrum in CD_3OD at 600 MHz; (H) NOESY spectrum in CD_3OD at 600 MHz.


A




B




C




D




E



F



G



H





Figure S15 HRESIMS and NMR spectra of **20**.


(A) HRESIMS spectrum; (B) ^1H NMR spectrum in CD_3OD at 600 MHz; (C) ^{13}C NMR spectrum in CD_3OD at 150 MHz; (D) DEPT 135 spectrum in CD_3OD at 150 MHz; (E) ^1H - ^1H COSY spectrum in CD_3OD at 600 MHz; (F) HSQC spectrum in CD_3OD at 600 MHz; (G) HMBC spectrum in CD_3OD at 600 MHz; (H) NOESY spectrum in CD_3OD at 600 MHz.

A


Monoisotopic Mass, Even Electron Ions
285 formula(e) evaluated with 2 results within limits (up to 50 closest results for each mass)
Elements Used:
C: 0-500 H: 0-1000 O: 0-200 Na: 0-1
46
20190107_51 208 (1.679)




B




C




D




E



F



G



H




Figure S16 HRESIMS and NMR spectra of **21**.

(A) HRESIMS spectrum; (B) ^1H NMR spectrum in CDCl_3 at 600 MHz; (C) ^{13}C NMR spectrum in CDCl_3 at 150 MHz; (D) DEPT 135 spectrum in CDCl_3 at 150 MHz; (E) ^1H - ^1H COSY spectrum in CDCl_3 at 600 MHz; (F) HSQC spectrum in CDCl_3 at 600 MHz; (G) HMBC spectrum in CDCl_3 at 600 MHz; (H) NOESY spectrum in CDCl_3 at 600 MHz.

A

Monoisotopic Mass, Even Electron Ions

295 formula(e) evaluated with 2 results within limits (up to 50 closest results for each mass)


Elements Used:

C: 0-500 H: 0-1000 O: 0-200 Na: 0-1


47

20190107_52 220 (1.780)


1: TOF MS ES+
2.77e+004




B




C




D




E



F



G



H






Figure S17 HRESIMS and NMR spectra of **22**.

(A) HRESIMS spectrum; (B) ^1H NMR spectrum in CDCl_3 at 600 MHz; (C) ^{13}C NMR spectrum in CDCl_3 at 150 MHz; (D) DEPT 135 spectrum in CDCl_3 at 150 MHz; (E) ^1H - ^1H COSY spectrum in CDCl_3 at 400 MHz; (F) HSQC spectrum in CDCl_3 at 400 MHz; (G) HMBC spectrum in CDCl_3 at 400 MHz; (H) ROESY spectrum in CDCl_3 at 400 MHz.


A




B




C




D




E



F



G



H






Figure S18 HRESIMS and NMR spectra of **23**.

(A) HRESIMS spectrum; (B) ^1H NMR spectrum in CDCl_3 at 400 MHz; (C) ^{13}C NMR spectrum in CDCl_3 at 100 MHz; (D) DEPT 135 spectrum in CDCl_3 at 100 MHz; (E) ^1H - ^1H COSY spectrum in CDCl_3 at 400 MHz; (F) HSQC spectrum in CDCl_3 at 400 MHz; (G) HMBC spectrum in CDCl_3 at 400 MHz; (H) ROESY spectrum in CDCl_3 at 400 MHz.


A




B




C




D




E



F



G



H






Figure S19 HRESIMS and NMR spectra of **24**.

(A) HRESIMS spectrum; (B) ^1H NMR spectrum in CDCl_3 at 600 MHz; (C) ^{13}C NMR spectrum in CDCl_3 at 150 MHz; (D) DEPT 135 spectrum in CDCl_3 at 150 MHz; (E) ^1H - ^1H COSY spectrum in CDCl_3 at 600 MHz; (F) HSQC spectrum in CDCl_3 at 600 MHz; (G) HMBC spectrum in CDCl_3 at 600 MHz; (H) ROESY spectrum in CDCl_3 at 600 MHz.


A




B




C




D




E



F



G



H





Figure S20 HRESIMS and NMR spectra of **25**.


(A) HRESIMS spectrum; (B) ^1H NMR spectrum in CDCl_3 at 600 MHz; (C) ^{13}C NMR spectrum in CDCl_3 at 150 MHz; (D) DEPT 135 spectrum in CDCl_3 at 150 MHz; (E) ^1H - ^1H COSY spectrum in CDCl_3 at 600 MHz; (F) HSQC spectrum in CDCl_3 at 600 MHz; (G) HMBC spectrum in CDCl_3 at 600 MHz; (H) NOESY spectrum in CDCl_3 at 600 MHz.

A


Monoisotopic Mass, Even Electron Ions
286 formula(e) evaluated with 2 results within limits (up to 50 closest results for each mass)
Elements Used:
C: 0-500 H: 0-1000 O: 0-200 Na: 0-1
EB1-B3-2
20180423-39 195 (1.582)




B




C




D




E



F



G



H










Figure S21 HRESIMS and NMR spectra of **26**.

(A) HRESIMS spectrum; (B) ^1H NMR spectrum in CDCl_3 at 400 MHz; (C) ^{13}C NMR spectrum in CDCl_3 at 100 MHz; (D) DEPT 135 spectrum in CDCl_3 at 100 MHz; (E) ^1H - ^1H COSY spectrum in CDCl_3 at 400 MHz; (F) HSQC spectrum in CDCl_3 at 400 MHz; (G) HMBC spectrum in CDCl_3 at 400 MHz; (H) ROESY spectrum in CDCl_3 at 400 MHz.

A**B**

D**E****F**

G



H






Figure S22 HRESIMS and NMR spectra of **29**.

(A) HRESIMS spectrum; (B) ^1H NMR spectrum in CDCl_3 at 600 MHz; (C) ^{13}C NMR spectrum in CDCl_3 at 150 MHz; (D) DEPT 135 spectrum in CDCl_3 at 150 MHz; (E) ^1H - ^1H COSY spectrum in CDCl_3 at 600 MHz; (F) HSQC spectrum in CDCl_3 at 600 MHz; (G) HMBC spectrum in CDCl_3 at 600 MHz; (H) ROESY spectrum in CDCl_3 at 600 MHz.


A




B




C




D




E



F



G



H






Figure S23 HRESIMS and NMR spectra of **30**.

(A) HRESIMS spectrum; (B) ^1H NMR spectrum in CDCl_3 at 600 MHz; (C) ^{13}C NMR spectrum in CDCl_3 at 150 MHz; (D) DEPT 135 spectrum in CDCl_3 at 150 MHz; (E) ^1H - ^1H COSY spectrum in CDCl_3 at 600 MHz; (F) HSQC spectrum in CDCl_3 at 600 MHz; (G) HMBC spectrum in CDCl_3 at 600 MHz; (H) NOESY spectrum in CDCl_3 at 600 MHz.


A




B




C




D




E



F



G



H






Figure S24 HRESIMS and NMR spectra of **31**.

(A) HRESIMS spectrum; (B) ^1H NMR spectrum in CDCl_3 at 600 MHz; (C) ^{13}C NMR spectrum in CDCl_3 at 150 MHz; (D) DEPT 135 spectrum in CDCl_3 at 150 MHz; (E) ^1H - ^1H COSY spectrum in CDCl_3 at 600 MHz; (F) HSQC spectrum in CDCl_3 at 600 MHz; (G) HMBC spectrum in CDCl_3 at 600 MHz; (H) NOESY spectrum in CDCl_3 at 600 MHz.


A




B




C




D




E



F



G



H






Figure S25 HRESIMS and NMR spectra of **32**.

(A) HRESIMS spectrum; (B) ^1H NMR spectrum in CDCl_3 at 600 MHz; (C) ^{13}C NMR spectrum in CDCl_3 at 150 MHz; (D) DEPT 135 spectrum in CDCl_3 at 150 MHz; (E) ^1H - ^1H COSY spectrum in CDCl_3 at 600 MHz; (F) HSQC spectrum in CDCl_3 at 600 MHz; (G) HMBC spectrum in CDCl_3 at 600 MHz; (H) NOESY spectrum in CDCl_3 at 600 MHz.


A




B




D




E



F



G



H






Figure S26 HRESIMS and NMR spectra of **33**.

(A) HRESIMS spectrum; (B) ^1H NMR spectrum in CDCl_3 at 600 MHz; (C) ^{13}C NMR spectrum in CDCl_3 at 150 MHz; (D) DEPT 135 spectrum in CDCl_3 at 150 MHz; (E) ^1H - ^1H COSY spectrum in CDCl_3 at 600 MHz; (F) HSQC spectrum in CDCl_3 at 600 MHz; (G) HMBC spectrum in CDCl_3 at 600 MHz; (H) NOESY spectrum in CDCl_3 at 600 MHz.


A




B




C




D




E



F



G



H





Figure S27 HRESIMS and NMR spectra of **34**.


(A) HRESIMS spectrum; (B) ^1H NMR spectrum in CDCl_3 at 600 MHz; (C) ^{13}C NMR spectrum in CDCl_3 at 150 MHz; (D) DEPT 135 spectrum in CDCl_3 at 150 MHz; (E) ^1H - ^1H COSY spectrum in CDCl_3 at 600 MHz; (F) HSQC spectrum in CDCl_3 at 600 MHz; (G) HMBC spectrum in CDCl_3 at 600 MHz; (H) ROESY spectrum in CDCl_3 at 600 MHz.

A


Monoisotopic Mass, Even Electron Ions
277 formula(e) evaluated with 2 results within limits (up to 50 closest results for each mass)
Elements Used:
C: 0-500 H: 0-1000 O: 0-200 Na: 0-1
E81-B4-70-1
20190527_12_193 (1,556)




B




C




D




E



F



G



H






Figure S28 HRESIMS and NMR spectra of **35**.

(A) HRESIMS spectrum; (B) ^1H NMR spectrum in CD_3OD at 600 MHz; (C) ^{13}C NMR spectrum in CD_3OD at 150 MHz; (D) DEPT 135 spectrum in CD_3OD at 150 MHz; (E) ^1H - ^1H COSY spectrum in CD_3OD at 600 MHz; (F) HSQC spectrum in CD_3OD at 600 MHz; (G) HMBC spectrum in CD_3OD at 600 MHz; (H) ROESY spectrum in CD_3OD at 600 MHz.


A




B




C




D




E



F



G



H





Figure S29 HRESIMS and NMR spectra of **36**.


(A) HRESIMS spectrum; (B) ^1H NMR spectrum in CD_3OD at 600 MHz; (C) ^{13}C NMR spectrum in CD_3OD at 150 MHz; (D) DEPT 135 spectrum in CD_3OD at 150 MHz; (E) ^1H - ^1H COSY spectrum in CD_3OD at 600 MHz; (F) HSQC spectrum in CD_3OD at 600 MHz; (G) HMBC spectrum in CD_3OD at 600 MHz; (H) ROESY spectrum in CD_3OD at 600 MHz.

A


Monoisotopic Mass, Even Electron Ions
263 formula(e) evaluated with 2 results within limits (up to 50 closest results for each mass)
Elements Used:
C: 0-500 H: 0-1000 O: 0-200 Na: 0-1
EB1C1-B3-B0-4
20190923024 193 (1.556)




B




C




D



E



F



G






Figure S30 HRESIMS and NMR spectra of **37**.

(A) HRESIMS spectrum; (B) ¹H NMR spectrum in CD₃OD at 600 MHz; (C) ¹³C NMR spectrum in CD₃OD at 150 MHz; (D) DEPT 135 spectrum in CD₃OD at 150 MHz; (E) ¹H-¹H COSY spectrum in CD₃OD at 600 MHz; (F) HSQC spectrum in CD₃OD at 600 MHz; (G) HMBC spectrum in CD₃OD at 600 MHz; (H) ROESY spectrum in CD₃OD at 600 MHz.


A




B




C




D



E



F



G






Figure S31 HRESIMS and NMR spectra of **38**.

(A) HRESIMS spectrum; (B) ^1H NMR spectrum in CD_3OD at 400 MHz; (C) ^{13}C NMR spectrum in CD_3OD at 100 MHz; (D) DEPT 135 spectrum in CD_3OD at 100 MHz; (E) ^1H - ^1H COSY spectrum in CD_3OD at 400 MHz; (F) HSQC spectrum in CD_3OD at 400 MHz; (G) HMBC spectrum in CD_3OD at 400 MHz; (H) ROESY spectrum in CD_3OD at 400 MHz.


A




B




C




D




E



F



G



H




Figure S32 HRESIMS and NMR spectra of **39**.

(A) HRESIMS spectrum; (B) ^1H NMR spectrum in CD_3OD at 600 MHz; (C) ^{13}C NMR spectrum in CD_3OD at 150 MHz; (D) DEPT 135 spectrum in CD_3OD at 150 MHz; (E) ^1H - ^1H COSY spectrum in CD_3OD at 600 MHz; (F) HSQC spectrum in CD_3OD at 600 MHz; (G) HMBC spectrum in CD_3OD at 600 MHz; (H) ROESY spectrum in CD_3OD at 600 MHz.

A

Monoisotopic Mass, Even Electron Ions


212 formula(e) evaluated with 1 results within limits (up to 50 closest results for each mass)

Elements Used:

C:

59
20190107_62309 (1,687)


1: TOF MS ES+
1.20e+005




Minimum: -1.5
Maximum: 5.0 5.0 50.0

Mass	Calc. Mass	mDa	PPM	DBE	i-FIT	Norm	Conf (%)	Formula
469.2954	469.2954	0.0	0.0	9.5	295.2	n/a	n/a	C29 H41 O5


B




C




D




E



F



G



H






Figure S33 HRESIMS and NMR spectra of **40**.

(A) HRESIMS spectrum; (B) ^1H NMR spectrum in CD_3OD at 400 MHz; (C) ^{13}C NMR spectrum in CD_3OD at 100 MHz; (D) DEPT 135 spectrum in CD_3OD at 100 MHz; (E) ^1H - ^1H COSY spectrum in CD_3OD at 400 MHz; (F) HSQC spectrum in CD_3OD at 400 MHz; (G) HMBC spectrum in CD_3OD at 400 MHz; (H) ROESY spectrum in CD_3OD at 400 MHz.


A




B




C




D




E



F



G



H




Figure S34 HRESIMS and NMR spectra of **41**.

(A) HRESIMS spectrum; (B) ^1H NMR spectrum in CD_3OD at 400 MHz; (C) ^{13}C NMR spectrum in CD_3OD at 100 MHz; (D) DEPT 135 spectrum in CD_3OD at 100 MHz; (E) ^1H - ^1H COSY spectrum in CD_3OD at 400 MHz; (F) HSQC spectrum in CD_3OD at 400 MHz; (G) HMBC spectrum in CD_3OD at 400 MHz; (H) ROESY spectrum in CD_3OD at 400 MHz.

A

Monoisotopic Mass, Even Electron Ions

243 formula(e) evaluated with 2 results within limits (up to 50 closest results for each mass)


Elements Used:

C: 0-200 H: 0-1000 O: 0-200 Na: 0-1


EB4C1-80-3

20190923036 229 (1.848)


1: TOF MS ES+
5.83e+004




B




C




D




E



F



G



H






Figure S35 HRESIMS and NMR spectra of 42.

(A) HRESIMS spectrum; (B) ¹H NMR spectrum in CD₃OD at 600 MHz; (C) ¹³C NMR spectrum in CD₃OD at 150 MHz; (D) DEPT 135 spectrum in CD₃OD at 150 MHz; (E) ¹H–¹H COSY spectrum in CD₃OD at 600 MHz; (F) HSQC spectrum in CD₃OD at 600 MHz; (G) HMBC spectrum in CD₃OD at 600 MHz; (H) ROESY spectrum in CD₃OD at 600 MHz.


A




B




C




D




E



F



G



H






Figure S36 HRESIMS and NMR spectra of **43**.

(A) HRESIMS spectrum; (B) ^1H NMR spectrum in CD_3OD at 600 MHz; (C) ^{13}C NMR spectrum in CD_3OD at 150 MHz; (D) DEPT 135 spectrum in CD_3OD at 150 MHz; (E) ^1H - ^1H COSY spectrum in CD_3OD at 600 MHz; (F) HSQC spectrum in CD_3OD at 600 MHz; (G) HMBC spectrum in CD_3OD at 600 MHz; (H) ROESY spectrum in CD_3OD at 600 MHz.


A




B




C




D




E



F



G



H






Figure S37 HRESIMS and NMR spectra of **44**.

(A) HRESIMS spectrum; (B) ^1H NMR spectrum in CDCl_3 at 600 MHz; (C) ^{13}C NMR spectrum in CDCl_3 at 150 MHz; (D) DEPT 135 spectrum in CDCl_3 at 150 MHz; (E) ^1H - ^1H COSY spectrum in CDCl_3 at 600 MHz; (F) HSQC spectrum in CDCl_3 at 600 MHz; (G) HMBC spectrum in CDCl_3 at 600 MHz; (H) NOESY spectrum in CDCl_3 at 600 MHz.


A




B




C




D




E



F



G



H






Figure S38 HRESIMS and NMR spectra of **45**.

(A) HRESIMS spectrum; (B) ^1H NMR spectrum in CDCl_3 at 600 MHz; (C) ^{13}C NMR spectrum in CDCl_3 at 150 MHz; (D) DEPT 135 spectrum in CDCl_3 at 150 MHz; (E) ^1H - ^1H COSY spectrum in CDCl_3 at 600 MHz; (F) HSQC spectrum in CDCl_3 at 600 MHz; (G) HMBC spectrum in CDCl_3 at 600 MHz; (H) ROESY spectrum in CDCl_3 at 600 MHz.


A




B




C




D



E



F



G






Figure S39 HRESIMS and NMR spectra of **46**.

(A) HRESIMS spectrum; (B) ^1H NMR spectrum in CDCl_3 at 600 MHz; (C) ^{13}C NMR spectrum in CDCl_3 at 150 MHz; (D) DEPT 135 spectrum in CDCl_3 at 150 MHz; (E) ^1H - ^1H COSY spectrum in CDCl_3 at 600 MHz; (F) HSQC spectrum in CDCl_3 at 600 MHz; (G) HMBC spectrum in CDCl_3 at 600 MHz; (H) NOESY spectrum in CDCl_3 at 600 MHz.


A




B




C




D




E



F



G



H






Figure S40 HRESIMS and NMR spectra of **47**.

(A) HRESIMS spectrum; (B) ^1H NMR spectrum in CD_3OD at 600 MHz; (C) ^{13}C NMR spectrum in CD_3OD at 150 MHz; (D) DEPT 135 spectrum in CD_3OD at 150 MHz; (E) ^1H - ^1H COSY spectrum in CD_3OD at 600 MHz; (F) HSQC spectrum in CD_3OD at 600 MHz; (G) HMBC spectrum in CD_3OD at 600 MHz; (H) ROESY spectrum in CD_3OD at 600 MHz.


A




B




C




D




E



F



G



H











Figure S41 HRESIMS and NMR spectra of **48**.

(A) HRESIMS spectrum; (B) ^1H NMR spectrum in CDCl_3 at 600 MHz; (C) ^{13}C NMR spectrum in CDCl_3 at 150 MHz; (D) DEPT 135 spectrum in CDCl_3 at 150 MHz; (E) ^1H - ^1H COSY spectrum in CDCl_3 at 600 MHz; (F) HSQC spectrum in CDCl_3 at 600 MHz; (G) HMBC spectrum in CDCl_3 at 600 MHz; (H) ROESY spectrum in CDCl_3 at 600 MHz.

A**B****C**

D**E****F**

G



H




Figure S42 HRESIMS and NMR spectra of **49**.

(A) HRESIMS spectrum; (B) ^1H NMR spectrum in CD_3OD at 600 MHz; (C) ^{13}C NMR spectrum in CD_3OD at 150 MHz; (D) DEPT 135 spectrum in CD_3OD at 150 MHz; (E) ^1H - ^1H COSY spectrum in CD_3OD at 600 MHz; (F) HSQC spectrum in CD_3OD at 600 MHz; (G) HMBC spectrum in CD_3OD at 600 MHz; (H) ROESY spectrum in CD_3OD at 600 MHz.


A

Monoisotopic Mass, Even Electron Ions
353 formula(e) evaluated with 2 results within limits (up to 50 closest results for each mass)
Elements Used:

Elements used:
C: 0-500 H: 0-1000 O: 0-200 Na: 0-1
42

20190107_47 209 (1.687)


1: TOF MS ES+
3.34e+004




Minimum: -1.5
Maximum: 5.0 5.0 50.0

Mass	Calc. Mass	mDa	PPM	DBE	i-FIT	Norm	Conf (%)	Formula
611.3185	611.3196	-1.1	-1.8	9.5	37.8	0.172	84.19	C ₃₃ H ₄₈ O ₉ Na
	611.3161	2.4	3.9	21.5	39.4	1.845	15.81	C ₄₂ H ₄₃ O ₉


B




C




D




E



F



G



H






Figure S43 HRESIMS and NMR spectra of **50**.

(A) HRESIMS spectrum; (B) ^1H NMR spectrum in CD_3OD at 400 MHz; (C) ^{13}C NMR spectrum in CD_3OD at 100 MHz; (D) DEPT 135 spectrum in CD_3OD at 100 MHz; (E) ^1H - ^1H COSY spectrum in CD_3OD at 400 MHz; (F) HSQC spectrum in CD_3OD at 400 MHz; (G) HMBC spectrum in CD_3OD at 400 MHz; (H) ROESY spectrum in CD_3OD at 400 MHz.


A




B




C




D




E



F



G



H






Figure S44 HRESIMS and NMR spectra of **51**.

(A) HRESIMS spectrum; (B) ^1H NMR spectrum in CDCl_3 at 400 MHz; (C) ^{13}C NMR spectrum in CDCl_3 at 100 MHz; (D) DEPT 135 spectrum in CDCl_3 at 100 MHz; (E) ^1H - ^1H COSY spectrum in CDCl_3 at 400 MHz; (F) HSQC spectrum in CDCl_3 at 400 MHz; (G) HMBC spectrum in CDCl_3 at 400 MHz; (H) ROESY spectrum in CDCl_3 at 400 MHz.


A




B




C




D




E



F



G



H





Figure S45 HRESIMS and NMR spectra of **52**.

(A) HRESIMS spectrum; (B) ^1H NMR spectrum in CD_3OD at 400 MHz; (C) ^{13}C NMR spectrum in CD_3OD at 100 MHz; (D) DEPT 135 spectrum in CD_3OD at 100 MHz; (E) ^1H - ^1H COSY spectrum in CD_3OD at 400 MHz; (F) HSQC spectrum in CD_3OD at 400 MHz; (G) HMBC spectrum in CD_3OD at 400 MHz; (H) ROESY spectrum in CD_3OD at 600 MHz.


A

Monoisotopic Mass, Even Electron Ions
300 formula(e) evaluated with 2 results within limits (up to 50 closest results for each mass)
Elements Used:
C: 0-500 H: 0-1000 O: 0-200 Na: 0-1
37
20190107_41 188 (1.518)




Minimum:	-1.5							
Maximum:	5.0	5.0	50.0					
Mass	Calc. Mass	mDa	PPM	DBE	i-FIT	Norm	Conf (%)	Formula
569.3071	569.3056	1.5	2.6	20.5	76.8	3.337	3.55	C40 H41 O3
	569.3090	-1.9	-3.3	8.5	73.5	0.036	96.45	C31 H46 O8 Na


B




C




D




E



F



G



H




Figure S46 HRESIMS and NMR spectra of **55**.

(A) HRESIMS spectrum; (B) ^1H NMR spectrum in CD_3OD at 600 MHz; (C) ^{13}C NMR spectrum in CD_3OD at 150 MHz; (D) DEPT 135 spectrum in CD_3OD at 150 MHz; (E) ^1H - ^1H COSY spectrum in CD_3OD at 600 MHz; (F) HSQC spectrum in CD_3OD at 600 MHz; (G) HMBC spectrum in CD_3OD at 600 MHz; (H) ROESY spectrum in CD_3OD at 600 MHz.

A

Monoisotopic Mass, Even Electron Ions

267 formula(e) evaluated with 1 results within limits (up to 50 closest results for each mass)


Elements Used:

C: 0-500 H: 0-1000 O: 0-200 Na: 0-1


B3B1-C1-2-4

2018091047 200 (1.619)


1: TOF MS ES+
7.02e+005




B




C




D




E



F



G



H






Figure S47 HRESIMS and NMR spectra of **56**.

(A) HRESIMS spectrum; (B) ¹H NMR spectrum in CD₃OD at 600 MHz; (C) ¹³C NMR spectrum in CD₃OD at 150 MHz; (D) DEPT 135 spectrum in CD₃OD at 150 MHz; (E) ¹H–¹H COSY spectrum in CD₃OD at 600 MHz; (F) HSQC spectrum in CD₃OD at 600 MHz; (G) HMBC spectrum in CD₃OD at 600 MHz; (H) ROESY spectrum in CD₃OD at 600 MHz.


A




B




C




D




E



F



G



H






Figure S48 HRESIMS and NMR spectra of **57**.

(A) HRESIMS spectrum; (B) ¹H NMR spectrum in CD₃OD at 600 MHz; (C) ¹³C NMR spectrum in CD₃OD at 150 MHz; (D) DEPT 135 spectrum in CD₃OD at 150 MHz; (E) ¹H-¹H COSY spectrum in CD₃OD at 600 MHz; (F) HSQC spectrum in CD₃OD at 600 MHz; (G) HMBC spectrum in CD₃OD at 600 MHz; (H) ROESY spectrum in CD₃OD at 600 MHz.


A




B




C




D




E



F



G



H





Figure S49 HRESIMS and NMR spectra of **58**.


(A) HRESIMS spectrum; (B) ^1H NMR spectrum in CD_3OD at 400 MHz; (C) ^{13}C NMR spectrum in CD_3OD at 100 MHz; (D) DEPT 135 spectrum in CD_3OD at 100 MHz; (E) ^1H - ^1H COSY spectrum in CD_3OD at 400 MHz; (F) HSQC spectrum in CD_3OD at 400 MHz; (G) HMBC spectrum in CD_3OD at 400 MHz; (H) ROESY spectrum in CD_3OD at 400 MHz.

A


Monoisotopic Mass, Even Electron Ions
353 formula(e) evaluated with 2 results within limits (up to 50 closest results for each mass)
Elements Used:
C: 0-500 H: 0-1000 O: 0-200 Na: 0-1




B




C




D




E



F



G



H






Figure S50 HRESIMS and NMR spectra of **59**.

(A) HRESIMS spectrum; (B) ^1H NMR spectrum in CD_3OD at 400 MHz; (C) ^{13}C NMR spectrum in CD_3OD at 100 MHz; (D) DEPT 135 spectrum in CD_3OD at 100 MHz; (E) ^1H - ^1H COSY spectrum in CD_3OD at 400 MHz; (F) HSQC spectrum in CD_3OD at 400 MHz; (G) HMBC spectrum in CD_3OD at 400 MHz; (H) ROESY spectrum in CD_3OD at 400 MHz.


A




B




C




D




E



F



G



H




Figure S51 HRESIMS and NMR spectra of **60**.

(A) HRESIMS spectrum; (B) ^1H NMR spectrum in CDCl_3 at 600 MHz; (C) ^{13}C NMR spectrum in CDCl_3 at 150 MHz; (D) DEPT 135 spectrum in CDCl_3 at 150 MHz; (E) ^1H - ^1H COSY spectrum in CDCl_3 at 600 MHz; (F) HSQC spectrum in CDCl_3 at 600 MHz; (G) HMBC spectrum in CDCl_3 at 600 MHz; (H) ROESY spectrum in CDCl_3 at 600 MHz.

A

Monoisotopic Mass, Even Electron Ions

315 formula(e) evaluated with 2 results within limits (up to 50 closest results for each mass)


Elements Used:

C: 0-500 H: 0-1000 O: 0-200 Na: 0-1


EB1-B3D1-5

20180423-45 207 (1.672)


1: TOF MS ES+
1.01e+005




B




C




D




E



F



G



H





Figure S52 HRESIMS and NMR spectra of **61**.


(A) HRESIMS spectrum; (B) ^1H NMR spectrum in CDCl_3 at 400 MHz; (C) ^{13}C NMR spectrum in CDCl_3 at 100 MHz; (D) DEPT 135 spectrum in CDCl_3 at 100 MHz; (E) ^1H - ^1H COSY spectrum in CDCl_3 at 400 MHz; (F) HSQC spectrum in CDCl_3 at 400 MHz; (G) HMBC spectrum in CDCl_3 at 400 MHz; (H) ROESY spectrum in CDCl_3 at 400 MHz.

A


Monoisotopic Mass, Even Electron Ions
310 formula(e) evaluated with 2 results within limits (up to 50 closest results for each mass)
Elements Used:
C: 0-500 H: 0-1000 O: 0-200 Na: 0-1
EB1C1-B3-80-3
20190923026 185 (1.496)




B




C




D




E



F



G



H






Figure S53 HRESIMS and NMR spectra of **62**.

(A) HRESIMS spectrum; (B) ^1H NMR spectrum in CD_3OD at 600 MHz; (C) ^{13}C NMR spectrum in CD_3OD at 150 MHz; (D) DEPT 135 spectrum in CD_3OD at 150 MHz; (E) ^1H - ^1H COSY spectrum in CD_3OD at 600 MHz; (F) HSQC spectrum in CD_3OD at 600 MHz; (G) HMBC spectrum in CD_3OD at 600 MHz; (H) ROESY spectrum in CD_3OD at 600 MHz.


A




B




C




D




E




F




G



H



I







Figure S54 HRESIMS and NMR spectra of **63**.

(A) HRESIMS spectrum; (B) ^1H NMR spectrum in pyridine-*d*₅ at 600 MHz; (C) ^{13}C NMR spectrum in pyridine-*d*₅ at 150 MHz; (D) DEPT 135 spectrum in pyridine-*d*₅ at 150 MHz; (E) ^1H - ^1H COSY spectrum in pyridine-*d*₅ at 600 MHz; (F) HSQC spectrum in pyridine-*d*₅ at 600 MHz; (G) HMBC spectrum in pyridine-*d*₅ at 600 MHz; (H) ROESY spectrum in pyridine-*d*₅ at 600 MHz; (I) ^1H NMR spectrum in CD₃OD at 400 MHz; (J) ^{13}C NMR spectrum in CD₃OD at 100 MHz; (K) DEPT 135 spectrum in CD₃OD at 100 MHz.

A

Monoisotopic Mass, Even Electron Ions


248 formula(e) evaluated with 2 results within limits (up to 50 closest results for each mass)

Elements Used:


C: 0-500 H: 0-1000 O: 0-200 Na: 0-1

EB4D2C1-80-7


20191118045 228 (1.840)

1: TOF MS ES+
1.02e+005


B




C




D




E



F



G



H





Figure S55 HRESIMS and NMR spectra of **64**.


(A) HRESIMS spectrum; (B) ^1H NMR spectrum in CD_3OD at 600 MHz; (C) ^{13}C NMR spectrum in CD_3OD at 150 MHz; (D) DEPT 135 spectrum in CD_3OD at 150 MHz; (E) ^1H - ^1H COSY spectrum in CD_3OD at 600 MHz; (F) HSQC spectrum in CD_3OD at 600 MHz; (G) HMBC spectrum in CD_3OD at 600 MHz; (H) ROESY spectrum in CD_3OD at 600 MHz.

A


Monoisotopic Mass, Even Electron Ions
321 formula(e) evaluated with 2 results within limits (up to 50 closest results for each mass)
Elements Used:
C: 0-500 H: 0-1000 O: 0-200 Na: 0-1
FBAC1D2-B0-L8




B




C




D




E



F



G



H






Figure S56 HRESIMS and NMR spectra of **65**.

(A) HRESIMS spectrum; (B) ^1H NMR spectrum in CD_3OD at 600 MHz; (C) ^{13}C NMR spectrum in CD_3OD at 150 MHz; (D) DEPT 135 spectrum in CD_3OD at 150 MHz; (E) ^1H - ^1H COSY spectrum in CD_3OD at 600 MHz; (F) HSQC spectrum in CD_3OD at 600 MHz; (G) HMBC spectrum in CD_3OD at 600 MHz; (H) ROESY spectrum in CD_3OD at 600 MHz.


A




B




C




D




E



F



G



H






Figure S57 HRESIMS and NMR spectra of **66**.

(A) HRESIMS spectrum; (B) ^1H NMR spectrum in CD_3OD at 600 MHz; (C) ^{13}C NMR spectrum in CD_3OD at 150 MHz; (D) DEPT 135 spectrum in CD_3OD at 150 MHz; (E) ^1H - ^1H COSY spectrum in CD_3OD at 600 MHz; (F) HSQC spectrum in CD_3OD at 600 MHz; (G) HMBC spectrum in CD_3OD at 600 MHz; (H) ROESY spectrum in CD_3OD at 600 MHz.


A




B




C




D




E



F



G



H






Figure S58 HRESIMS and NMR spectra of **67**.

(A) HRESIMS spectrum; (B) ^1H NMR spectrum in acetone- d_6 at 400 MHz; (C) ^{13}C NMR spectrum in acetone- d_6 at 100 MHz; (D) DEPT 135 spectrum in acetone- d_6 at 100 MHz; (E) ^1H - ^1H COSY spectrum in acetone- d_6 at 400 MHz; (F) HSQC spectrum in acetone- d_6 at 400 MHz; (G) HMBC spectrum in acetone- d_6 at 400 MHz; (H) ROESY spectrum in acetone- d_6 at 400 MHz.


A




B




C




D




E



F



G



H






Figure S59 HRESIMS and NMR spectra of **68**.

(A) HRESIMS spectrum; (B) ^1H NMR spectrum in CD_3OD at 400 MHz; (C) ^{13}C NMR spectrum in CD_3OD at 100 MHz; (D) DEPT 135 spectrum in CD_3OD at 100 MHz; (E) ^1H - ^1H COSY spectrum in CD_3OD at 400 MHz; (F) HSQC spectrum in CD_3OD at 400 MHz; (G) HMBC spectrum in CD_3OD at 400 MHz; (H) ROESY spectrum in CD_3OD at 400 MHz.


A




B




C




D




E



F



G



H




Figure S60 HRESIMS and NMR spectra of **69**.

(A) HRESIMS spectrum; (B) ^1H NMR spectrum in CD_3OD at 600 MHz; (C) ^{13}C NMR spectrum in CD_3OD at 150 MHz; (D) DEPT 135 spectrum in CD_3OD at 150 MHz; (E) ^1H - ^1H COSY spectrum in CD_3OD at 600 MHz; (F) HSQC spectrum in CD_3OD at 600 MHz; (G) HMBC spectrum in CD_3OD at 600 MHz; (H) ROESY spectrum in CD_3OD at 600 MHz.

A

Monoisotopic Mass, Even Electron Ions

256 formula(e) evaluated with 2 results within limits (up to 50 closest results for each mass)


Elements Used:

C: 0-200 H: 0-1000 O: 0-200 Na: 0-1


AFU-20-3

2020081731 226 (1.825)


1: TOF MS ES+
1.26e+005




B




C




D




E



F



G



H




Figure S61 HRESIMS and NMR spectra of **81**.

(A) HRESIMS spectrum; (B) ^1H NMR spectrum in CDCl_3 at 600 MHz; (C) ^{13}C NMR spectrum in CDCl_3 at 150 MHz; (D) DEPT 135 spectrum in CDCl_3 at 150 MHz; (E) ^1H - ^1H COSY spectrum in CDCl_3 at 600 MHz; (F) HSQC spectrum in CDCl_3 at 600 MHz; (G) HMBC spectrum in CDCl_3 at 600 MHz; (H) ROESY spectrum in CDCl_3 at 600 MHz.







Figure S62 Linear correlation between calculated ^{13}C NMR chemical shift values of **34-A/34-B** and experimental values of **34**.

Based on the R^2 values, the relative configuration of **34** is assigned as $3R^*, 4S^*, 5S^*, 8S^*, S^*, 10S^*, 13R^*, 14S^*, 16S^*$.




Figure S63 Linear correlation between calculated ^{13}C NMR chemical shift values of 35-A/35-B and experimental values of 35.

Based on the R^2 values, the relative configuration of 35 is assigned as 1S*,4S*,5S*,6R*,7R*,8S*,9S*,10S*,11R*,13R*,14S*,16S*.





Figure S64 Linear correlation between calculated ^{13}C NMR chemical shift values of 38-A/38-B and experimental values of **38**.

Based on the R^2 values, the relative configuration of **38** is assigned as $1S^*, 4S^*, 5S^*, 7R^*, 8S^*, 9S^*, 10S^*, 11R^*, 13R^*, 14S^*, 16S^*$.





Figure S65 Linear correlation between calculated ^{13}C NMR chemical shift values of **42-A/42-B** and experimental values of **42**.

Based on the R^2 values, the relative configuration of **42** is assigned as $3R^*, 4S^*, 5S^*, 8S^*, 9S^*, 10R^*, 13R^*, 14S^*, 16S^*$.




Figure S66 HPLC analysis for spontaneous 1,4-addition of **37** in Tri-HCl buffer.

(A) **37** incubated in 1 mol/L Tris-HCl buffer (pH 8.0); (B) **37** incubated in 1 mol/L Tris-HCl buffer (pH 7.0); (C) **37** incubated in 1 mol/L Tris-HCl buffer (pH 5.0); (D) Compound **37**.




Figure S67 Previously isolated fusidane-type antibiotics during the biosynthetic study of helvolic acid, fusidic acid and cephalosporin P₁.




Figure S68 Comparison of anti-*S. aureus* 209P activity of fusidane-type antibiotics featured with 3-keto and 3 β -OH.




Figure S69 Comparison of anti-*S. aureus* 209P activity of fusidane-type antibiotics featured with 3-keto and 3 α -OH.

(A) For most fusidane-type antibiotics, 3 α -OH has the positive effect on the activity; (B) For a few fusidane-type antibiotics, 3 α -OH has the negative effect on the activity.




Figure S70 The effect of the C1/C2 double bond on anti-*S. aureus* 209P activity.

(A) For most fusidane-type antibiotics, the C1/C2 double bond has the negative effect; (B) For a few fusidane-type antibiotics, the C1/C2 double bond has the positive effect.







Figure S71 The detrimental effect of mono-oxidation at C6 or C7 on anti-*S. aureus* 209P activity.

A**B****Figure S72** The effect of dual-oxidation at C6 and C7 on anti-*S. aureus* 209P activity.

(A) For most fusidane-type antibiotics, the dual-oxidation at C6 and C7 has the negative effect; (B) For a few fusidane-type antibiotics, the dual-oxidation at C6 and C7 has the positive effect.




Figure S73 The effect of C11 α -hydroxylation on anti-*S. aureus* 209P activity.

(A) For a few fusidane-type antibiotics, C11 α -hydroxylation has the positive effect; (B) For most fusidane-type antibiotics, C11 α -hydroxylation has the negative effect.




Figure S74 The effect of acetylation of 6-OH on anti-*S. aureus* 209P activity.

(A) Acetylation of 6 β -OH has the negative effect; (B) Acetylation of 6 α -OH has the positive effect.






Figure S75 C1 α -hydroxylation has the negative effect on anti-*S. aureus* 209P activity.

A



B



C




Figure S76 Analysis of the impurity peak in the feeding experiment using CO6 as the host.

(A) The HPLC profile of CO6 incubated with **37**; (B) The positive mass spectrum of the impurity peak labelled with asterisk; (C) The negative mass spectrum of the impurity peak labelled with asterisk.


Supporting Tables

Table S1 Eight post-tailoring genes from *hel*, *fus* and *cep* clusters.

Tailoring gene	Annotated enzyme function
<i>helE</i>	3-Ketosteroid- Δ^1 -dehydrogenase
<i>helB3</i>	Cytochrome P450 monooxygenase
<i>helD1</i>	Acetyl transferase
<i>fusB1</i>	Cytochrome P450 monooxygenase
<i>fusC1</i>	Short chain dehydrogenase/reductase
<i>cepB4</i>	Cytochrome P450 monooxygenase
<i>cepC2</i>	Short chain dehydrogenase/reductase
<i>cepD2</i>	Acetyl transferase


Table S2 All gene combinations and the obtained products.

Gene combination	Transformant	Product
Two-gene combination		
<i>helE + fusB1</i>	AOS1	5
<i>helE + fusC1</i>	AOS2	6, 7, 8
<i>helE + cepB4</i>	AOS3	7, 9, 10, 11
<i>fusB1 + cepB4</i>	AOS4	12, 13, 14, 15, 16
<i>fusB1 + helB3</i>	AOS5	17, 18, 19, 20, 21, 22
<i>fusC1 + helB3</i>	AOS6	23, 24, 25
Three-gene combination		
<i>helE + fusB1 + helB3</i>	AOS7	26, 27, 28
<i>helE + fusB1 + fusC1</i>	AOS8	2, 5, 29
<i>helE + fusC1 + helB3</i>	AOS9	24, 25, 27, 30, 31, 32, 33, 34
<i>helE + fusB1 + cepB4</i>	AOS10	9, 11, 35, 36, 37, 38, 39, 40
<i>helE + fusC1 + cepB4</i>	AOS11	9, 11, 41, 42, 43
<i>helE + cepB4 + cepD2</i>	AOS12	7, 11, 44, 45, 46
<i>fusB1 + cepB4 + fusC1</i>	AOS13	15, 47, 48, 49
<i>fusB1 + cepB4 + cepD2</i>	AOS14	50, 51, 52, 53, 54
<i>fusB1 + helB3 + fusC1</i>	AOS15	17, 23, 55, 56, 57
<i>fusB1 + helB3 + helD1</i>	AOS16	18, 19, 21, 58, 59
<i>fusC1 + helB3 + helD1</i>	AOS17	23, 25, 60
Four-gene combination		
<i>helE + fusB1 + helB3 + helD1</i>	AOS18	1, 26, 27, 61
<i>helE + fusB1 + helB3 + fusC1</i>	AOS19	5, 26, 27, 37, 38, 62
<i>helE + fusC1 + helB3 + helD1</i>	AOS20	24, 25, 27, 30, 31, 33, 63
<i>helE + cepC1 + fusB1 + cepB4</i>	AOS21	16, 75
<i>helE + fusB1 + cepB4 + cepD2</i>	AOS22	5, 44, 53
<i>helE + fusC1 + cepB4 + cepD2</i>	AOS23	64, 65, 66
<i>fusB1 + fusC1 + cepB4 + cepD2</i>	AOS24	3, 15, 46, 67
<i>fusB1 + fusC1 + helB3 + helD1</i>	AOS25	56, 68
Five-gene combination		
<i>helE + fusB1 + fusC1 + helB3 + helD1</i>	AOS26	23, 60, 68, 69
<i>helE + fusB1 + fusC1 + cepB4 + cepD2</i>	AOS27	5, 9, 29

Table S3 NMR data for **5** (¹H for 400 MHz and ¹³C for 100 MHz in CDCl₃).**5**

Position	δ_c , type	δ_H (<i>J</i> in Hz) ^a	¹ H- ¹ H COSY	HMBC	ROESY
1	160.4, CH	7.66, d (10.3)	2	3, 5, 9, 10	11
2	126.6, CH	5.85, d (10.3)	1	4, 10	
3	202.2, C				
4	43.4, CH	2.35	5, 28		19
5	42.8, CH	2.41	4, 6a, 6b	4	28, 30
6	21.0, CH ₂	a: 1.76 b: 1.33	5, 6b, 7a, 7b		
7	31.8, CH ₂	a: 1.77 b: 1.24	6a, 6b, 7b		
8	38.8, C		6a, 6b, 7a		
9	49.2, CH	1.70, br s	11	1, 10, 11, 19, 30	18, 19
10	39.1, C				
11	67.5, CH	4.50, br s	9, 12a, 12b	9, 10, 13	1, 19
12	35.5, CH ₂	a: 2.37 b: 2.00	11, 12b, 13	11, 14	
13	44.0, CH	3.04, br d (11.5)	12a, 12b	12, 14, 17, 18, 20	15a, 16, 30
14	48.7, C				
15	39.1, CH ₂	a: 2.17 b: 1.33	15b, 16	14, 18	13
16	74.3, CH	5.89, br d (8.5)	15a, 15b	14, 17, 20, 16-COCH ₃	13
17	150.3, C				
18	17.8, CH ₃	0.94, s		8, 13, 14, 15	9
19	26.7, CH ₃	1.21, s		1, 5, 9, 10	4, 9, 11
20	130.0, C				
21	174.5, C				
22	28.8, CH ₂	2.45	23a, 23b	17, 20, 21, 23, 24	24
23	28.3, CH ₂	a: 2.17 b: 2.08	22, 23b, 24	24, 25	
24	122.8, CH	5.09, br t (7.0)	23a, 23b, 26, 27	22, 23, 26, 27	22, 26
25	132.8, C				
26	25.7, CH ₃	1.67, br s	24	24, 25, 27	24
27	17.8, CH ₃	1.59, br s	24	24, 25, 26	
28	12.5, CH ₃	1.12, d (6.6)	4	3, 4, 5	5
30	23.5, CH ₃	1.28, s		7, 8, 9, 14	5, 13
16-COCH ₃	170.5, C				
16-COCH ₃	20.5, CH ₃	1.96, s		16-COCH ₃	


^aThe indiscernible signals from overlap or the complex multiplicity are reported without designating multiplicity.

Table S4 NMR data for **6** (¹H for 600 MHz and ¹³C for 150 MHz in CDCl₃).**6**

Position	δ_c , type	δ_h (J in Hz) ^a	¹ H- ¹ H COSY	HMBC	NOESY	δ_h (J in Hz) ^b
1	141.1, CH	6.15, d (9.8)	2	3, 5, 9, 10	11a, 19	6.15, d (10.0)
2	126.9, CH	5.61, br d (9.8)	1, 3	3, 4, 10		5.62, dd (10.0, 4.3)
3	68.8, CH	3.94, br s	2, 4	1, 2, 5	28	3.94, t (4.4)
4	33.1, CH	1.95	3, 5, 28	5, 10, 28	19	1.97
5	38.3, CH	1.83, br t (11.9)	4, 6a, 6b	1, 3, 4, 10, 19	28, 30	1.83, td (11.6, 1.9)
6	19.1, CH ₂	a: 1.60 b: 1.11	5, 6b, 7a, 7b	5, 10 4, 5, 7, 10	28	a: 1.61 b: 1.12
7	33.5, CH ₂	a: 1.91 b: 1.24	6a, 6b, 7b 6a, 6b, 7a	5, 6, 14, 30 6, 8, 9, 30		a: 1.92 b: 1.25
8	38.6, C					
9	44.2, CH	1.55, br d (13.3)	11a, 11b	1, 10, 11, 19, 30	18, 19	1.56, dd (12.9, 3.1)
10	38.3, C					
11	24.8, CH ₂	a: 1.72 b: 1.35	9, 11b, 12a, 12b 9, 11a, 12a, 12b	10 9	1, 19 30	a: 1.73 b: 1.36
12	26.2, CH ₂	a: 2.28, br d (11.1) b: 1.68	11a, 11b, 12b, 13 11a, 11b, 12a, 13	9, 14 11, 13		a: 2.29 b: 1.69
13	49.0, CH	2.54	12a, 12b	12, 14, 17, 18	30	2.55
14	48.5, C					
15	39.2, CH ₂	a: 2.04 b: 1.30	15b, 16 15a, 16	8, 14, 18 13, 14, 16, 17, 18		a: 2.05 b: 1.30
16	74.2, CH	5.84, br d (7.6)	15a, 15b	14, 17, 20, 16-COCH ₃		5.84, br d (8.3)
17	150.4, C					
18	18.3, CH ₃	0.94, s		8, 13, 14, 15	9	0.95, s
19	26.2, CH ₃	0.94, s		1, 5, 9, 10	1, 4, 9, 11a	0.95, s
20	129.6, C					
21	173.8, C					
22	28.6, CH ₂	a: 2.51 b: 2.43	22b, 23a, 23b 22a, 23a, 23b	17, 20, 21, 23, 24 17, 20, 21, 23, 24	24	a: 2.53 b: 2.44
23	28.3, CH ₂	a: 2.12 b: 2.06	22a, 22b, 23b, 24 22a, 22b, 23a, 24	20, 22, 24, 25 20, 22, 24, 25		a: 2.13 b: 2.07
24	123.0, CH	5.09, br s	23a, 23b, 26, 27	23, 26, 27	22a, 22b, 26	5.11, t (7.1)
25	132.6, C					
26	25.7, CH ₃	1.68, br s	24	24, 25, 27	24	1.68, br s
27	17.7, CH ₃	1.59, br s	24	24, 25, 26		1.61, br s
28	14.2, CH ₃	0.98, d (6.0)	4	3, 4, 5	3, 5, 6a	0.98, d (6.8)
30	21.7, CH ₃	1.01, s		7, 8, 9, 14	5, 13, 11b	1.02, s
16-COCH ₃	170.6, C			16-COCH ₃		
16-COCH ₃	20.6, CH ₃	1.96, s				1.98, s


^aThe indiscernible signals from overlap or the complex multiplicity are reported without designating multiplicity.

The ¹H NMR data of **6** obtained via chemical derivatization were measured at low concentrations of the compound in CDCl₃.

Table S5 NMR data for **9** (^1H for 600 MHz and ^{13}C for 150 MHz in CDCl_3).**9**


Position	δ_{C} , type	δ_{H} (J in Hz) ^a	^1H - ^1H COSY	HMBC	NOESY
1	157.4, CH	7.28, d (10.1)	2	3, 5, 9, 10, 19	11a, 11b
2	127.9, CH	5.85, d (10.1)	1	4, 10	
3	203.2, C				
4	42.5, CH	2.73, dq (12.0, 6.7)	5, 28	3, 5, 6, 10, 28	6, 19
5	49.2, CH	1.96	4, 6	1, 4, 6, 7, 10, 19, 28	7, 28, 30
6	74.2, CH	3.71, dd (11.1, 8.2)	5, 7	5, 7, 10	4, 19
7	87.1, CH	3.51, d (8.2)	6	5, 6, 8, 9, 30	5
8	45.1, C				
9	42.7, CH	1.95	11a, 11b	8, 10, 11, 30	18
10	40.3, C				
11	24.5, CH_2	a: 1.71 b: 1.54 qd (13.3, 4.1)	9, 11b, 12a, 12b 9, 11a, 12a, 12b		1 1, 13
12	25.8, CH_2	a: 2.34 b: 1.80	11a, 11b, 12b, 13 11a, 11b, 12a, 13	11 13, 14, 17	
13	50.7, CH	2.60, br d (10.9)	12a, 12b	14, 17, 18, 20	11b, 16, 30
14	47.7, C				
15	40.9, CH_2	a: 2.20, dd (14.2, 8.5) b: 1.81	15b, 16 15a, 16	8, 14, 18 13, 14, 16, 17, 18	30
16	74.2, CH	5.89, br d (8.5)	15a, 15b	14, 17, 20, 16- COCH_3	13, 30
17	148.8, C				
18	20.8, CH_3	1.22, s		8, 13, 14, 15	9
19	27.5, CH_3	1.23, s		1, 5, 9, 10	4, 6
20	130.4, C				
21	173.8, C				
22	28.6, CH_2	a: 2.51 b: 2.44	22b, 23a, 23b 22a, 23a, 23b	17, 20, 21, 23, 24 17, 20, 21, 23, 24	24 24
23	28.3, CH_2	a: 2.13 b: 2.07	22a, 22b, 23b, 24 22a, 22b, 23a, 24	20, 22, 24, 25 20, 22, 24, 25	
24	122.9, CH	5.10, br t (7.4)	23a, 23b, 26, 27	23, 26, 27	22a, 22b, 26
25	132.7, C				
26	25.7, CH_3	1.68, br s	24	24, 25, 27	24
27	17.7, CH_3	1.60, br s	24	24, 25, 26	
28	17.3, CH_3	1.42, d (6.9)	4	3, 4, 5	5
30	21.4, CH_3	1.10, s		7, 8, 9, 14	5, 13, 15a, 16
16- COCH_3	171.0, C				
16- COCH_3	20.7, CH_3	1.98, s		16- COCH_3	

^aThe indiscernible signals from overlap or the complex multiplicity are reported without designating multiplicity.

Table S6 NMR data for **10** (^1H for 600 MHz and ^{13}C for 150 MHz in CDCl_3).**10**


Position	δ_{C} , type	δ_{H} (J in Hz) ^a	^1H - ^1H COSY	HMBC	NOESY
1	157.6, CH	7.27, d (10.3)	2	3, 5, 9, 10	
2	127.7, CH	5.86, d (10.3)	1	4, 10	
3	203.1, C				
4	43.0, CH	2.70, dq (11.9, 6.9)	5, 28	3, 5, 6, 10, 28	19
5	51.7, CH	2.16, t (11.6)	4, 6	1, 3, 4, 6, 7, 10, 19, 28	30
6	69.1, CH	3.91, ddd (10.7, 8.2, 6.7)	5, 7a, 7b	5, 7, 10	9, 19
7	45.6, CH ₂	a: 2.32, dd (13.8, 6.7) b: 1.17	6, 7b 6, 7a	5, 6, 8, 9, 14, 30 6, 30	18
8	39.2, C				
9	44.0, CH	1.65, dd (12.7, 2.8)	11a, 11b	1, 8, 10, 11, 19, 30	6, 18
10	39.8, C				
11	24.6, CH ₂	a: 1.74 b: 1.46	9, 11b, 12a, 12b 9, 11a, 12a, 12b	8, 9 8, 9, 12, 13	
12	26.0, CH ₂	a: 2.36 b: 1.72	11a, 11b, 12b, 13 11a, 11b, 12a, 13	11, 13	18
13	48.7, CH	2.57, br d (11.6)	12a, 12b	12, 14, 17, 18, 20	16, 30
14	48.2, C				
15	39.1, CH ₂	a: 2.06 b: 1.35, br d (14.2)	15b, 16 15a, 16	8, 14, 18 13, 16, 17, 18	30 18
16	73.9, CH	5.87, br d (8.2)	15a, 15b	14, 17, 20, 16- <u>COCH₃</u>	13
17	149.7, C				
18	18.3, CH ₃	1.01, s		8, 13, 14, 15	7a, 9, 12b, 15b
19	27.3, CH ₃	1.18, s		1, 5, 9, 10	4, 6
20	129.9, C				
21	172.9, C				
22	28.6, CH ₂	a: 2.51 b: 2.45	22b, 23a, 23b 22a, 23a, 23b	17, 20, 21, 23, 24 17, 20, 21, 23, 24	24 24
23	28.3, CH ₂	a: 2.14 b: 2.08	22a, 22b, 23b, 24 22a, 22b, 23a, 24	20, 22, 24, 25 20, 22, 24, 25	
24	122.8, CH	5.10, br t (6.9)	23a, 23b, 26, 27	23, 26, 27	22a, 22b, 26
25	132.8, C				
26	25.7, CH ₃	1.68, br s	24	24, 25, 27	24
27	17.7, CH ₃	1.60, br s	24	24, 25, 26	
28	17.0, CH ₃	1.43, d (6.9)	4	3, 4, 5	
30	21.0, CH ₃	1.10, s		7, 8, 9, 14	5, 13, 15a
16- <u>COCH₃</u>	170.5, C				
16-CO <u>CH₃</u>	20.6, CH ₃	1.98, s		16- <u>COCH₃</u>	

^aThe indiscernible signals from overlap or the complex multiplicity are reported without designating multiplicity.

Table S7 NMR data for **11** (¹H for 400 MHz and ¹³C for 100 MHz in CDCl₃).**11**


Position	δ_{C} , type	δ_{H} (<i>J</i> in Hz) ^a	¹ H- ¹ H COSY	HMBC	ROESY
1	159.2, CH	7.29, d (10.2)	2	3, 5, 10	11a, 11b
2	127.6, CH	5.81, d (10.2)	1	4, 10	
3	202.4, C				
4	42.4, CH	2.44	5, 28		19
5	44.5, CH	1.93	4, 6a, 6b	1, 4, 6, 7, 10, 19	28, 30
6	32.9, CH ₂	a: 1.98 b: 1.39	5, 6b, 7 5, 6a, 7	7	
7	79.7, CH	3.86, dd (8.7, 6.9)	6a, 6b	6, 9, 30	30
8	45.0, C				
9	43.0, CH	2.03	11a, 11b	8, 10, 19, 30	18, 19
10	39.0, C				
11	24.8, CH ₂	a: 1.82 b: 1.51, qd (14.4, 4.0)	9, 11b, 12a, 12b 9, 11a, 12a, 12b	8, 13	1 1
12	25.8, CH ₂	a: 2.33 b: 1.80	11a, 11b, 12b, 13 11a, 11b, 12a, 13	14 13	
13	50.8, CH	2.58, br d (10.4)	12a, 12b	12, 14, 17, 18, 20	16, 30
14	48.0, C				
15	40.7, CH ₂	a: 2.18, dd (14.4, 8.8) b: 1.73, br d (14.4)	15b, 16 15a, 16	14, 18 13, 14, 16, 17, 18	30
16	74.3, CH	5.86, br d (8.4)	15a, 15b	14, 17, 20, 16-COCH ₃	13
17	149.1, C				
18	21.2, CH ₃	1.21, s		8, 13, 14, 15	9
19	25.7, CH ₃	1.22, s		1, 5, 9, 10	4, 9
20	130.4, C				
21	174.5, C				
22	28.6, CH ₂	2.46	23	17, 20, 21, 23, 24	24
23	28.2, CH ₂	2.09	22, 24	22, 24, 25	
24	122.9, CH	5.09, br t (7.1)	23, 26, 27	23, 26, 27	22, 26
25	132.6, C				
26	25.7, CH ₃	1.67, br s	24	24, 25, 27	24
27	17.7, CH ₃	1.59, br s	24	24, 25, 26	
28	12.9, CH ₃	1.13, d (6.7)	4	3, 4, 5	5
30	21.2, CH ₃	0.98, s		7, 8, 9, 14	5, 7, 13, 15a
16-COCH ₃	170.8, C			16-COCH ₃	
16-COCH ₃	20.6, CH ₃	1.95, s			

^aThe indiscernible signals due to overlap or the complex multiplicity are reported without designating multiplicity.

Table S8 NMR data for **12** (¹H for 400 MHz and ¹³C for 100 MHz in CDCl₃).**12**


Position	δ_{C} , type	δ_{H} (<i>J</i> in Hz) ^a	¹ H- ¹ H COSY	HMBC	ROESY
1	33.8, CH ₂	a: 2.58	1b, 2a, 2b	19	30
		b: 1.80	1a, 2a, 2b	5, 10, 19	
2	34.9, CH ₂	a: 2.58	1a, 1b, 2b	3	
		b: 2.36	1a, 1b, 2a		
3	217.8, C				
4	45.1, CH	2.50	5, 28		6, 19
5	48.9, CH	1.87, t (10.6)	4, 6	6, 7, 19	7, 28, 30
6	73.9, CH	3.53, dd (10.4, 8.3)	5, 7	7	4, 9, 19
7	87.3, CH	3.48, d (8.2)	6	6, 30	5, 30
8	46.4, C				
9	46.2, CH	1.78	11	1, 5, 8, 10, 19, 30	6, 18, 19
10	38.5, C				
11	67.8, CH	4.36, br s	9, 12a, 12b	8, 9, 13	19
12	36.3, CH ₂	a: 2.28	11, 12b, 13	14	22
		b: 1.99	11, 12a, 13		18
13	46.3, CH	3.06, br d (12.7)	12a, 12b	12, 14, 17, 20	16, 30
14	48.3, C				
15	40.8, CH ₂	a: 2.31	15b, 16	14	30
		b: 1.79	15a, 16	8	18
16	74.5, CH	5.91, br d (8.3)	15a, 15b	14, 17, 20, 16-COCH ₃	13
17	149.9, C				
18	20.4, CH ₃	1.17, s		8, 13, 14, 15	9, 12b, 15b
19	23.8, CH ₃	1.02, s		1, 5, 9, 10	4, 6, 9, 11
20	130.2, C				
21	173.8, C				
22	28.8, CH ₂	2.45	23a, 23b	17, 20, 21, 23, 24,	12a, 24
23	28.3, CH ₂	a: 2.14	22, 23b, 24		
		b: 2.08	22, 23a, 24		
24	122.9, CH	5.09, br t (6.9)	23a, 23b, 26, 27	26, 27	22, 26
25	132.7, C				
26	25.7, CH ₃	1.67, br s	24	24, 25, 27	24
27	17.8, CH ₃	1.59, br s	24	24, 25, 26	
28	18.8, CH ₃	1.31, d (6.9)	4	3, 4, 5	5
30	25.8, CH ₃	1.45, s		7, 8, 9, 14	1a, 5, 7, 13, 15a
16-COCH ₃	171.1, C				
16-COCH ₃	20.7, CH ₃	1.97, s		16-COCH ₃	

^aThe indiscernible signals from overlap or the complex multiplicity are reported without designating multiplicity.

Table S9 NMR data for **13** (¹H for 600 MHz and ¹³C for 150 MHz in CDCl₃).**13**


Position	δ_c , type	δ_h (<i>J</i> in Hz) ^a	¹ H– ¹ H COSY	HMBC	NOESY
1	34.8, CH ₂	a: 1.97	1b, 2a, 2b	2, 10, 19	
		b: 1.77	1a, 2a, 2b	2, 3, 5, 10	
2	31.6, CH ₂	a: 1.91	1a, 1b, 2b, 3	3	
		b: 1.66	1a, 1b, 2a, 3	1, 3	
3	76.6, CH	3.13, td (10.8, 4.9)	2a, 2b, 4	2, 4, 5, 28	28
4	39.1, CH	1.48	3, 5, 28	3, 5	19
5	42.6, CH	1.41, td (11.8, 4.0)	4, 6a, 6b	3, 4, 6, 7, 10, 19	7, 28, 30
6	33.8, CH ₂	a: 2.03	5, 6b, 7	5, 7, 8, 10	19
		b: 1.16	5, 6a, 7	7	
7	79.0, CH	3.73, t (6.2)	6a, 6b	5, 6, 8, 9, 14, 30	5, 30
8	45.2, C				
9	46.5, CH	1.92, br s	11	1, 7, 8, 10, 11, 14, 19, 30	18, 19
10	36.8, C				
11	68.6, CH	4.40, br s	9, 12a, 12b	8, 13	19
12	35.9, CH ₂	a: 2.29	11, 12b, 13	11	
		b: 1.96	11, 12a, 13		
13	46.4, CH	3.06, br d (11.6)	12a, 12b	12, 14, 17, 18, 20	16, 30
14	48.6, C				
15	40.3, CH ₂	a: 2.26	15b, 16	8, 14, 18	30
		b: 1.62, br d (14.4)	15a, 16	13, 14, 16, 17, 18	18
16	74.4, CH	5.91, br d (8.4)	15a, 15b	13, 14, 17, 20, 16-COCH ₃	13
17	150.5, C				
18	21.3, CH ₃	1.17, s		8, 13, 14, 15	9, 15b
19	22.9, CH ₃	1.15, s		1, 5, 9, 10	4, 6a, 9, 11
20	130.0, C				
21	173.8, C				
22	28.8, CH ₂	2.46	23a, 23b	17, 20, 21, 23, 24	24
23	28.3, CH ₂	a: 2.16	22, 23b, 24	20, 22, 24, 25	
		b: 2.06	22, 23a, 24	20, 22, 24, 25	
24	123.0, CH	5.10, br t (6.6)	23a, 23b, 26, 27	23, 26, 27	22, 26
25	132.7, C				
26	25.7, CH ₃	1.67, br s	24	24, 25, 27	24
27	17.8, CH ₃	1.60, br s	24	24, 25, 26	
28	15.4, CH ₃	0.96, d (6.1)	4	3, 4, 5	3, 5
30	23.9, CH ₃	1.30, s		7, 8, 9, 14	5, 7, 13, 15a
16-COCH ₃	170.7, C			16-COCH ₃	
16-COCH ₃	20.6, CH ₃	1.97, s		16-COCH ₃	

^aThe indiscernible signals from overlap or the complex multiplicity are reported without designating multiplicity.

Table S10 NMR data for **14** (¹H for 400 MHz and ¹³C for 100 MHz in CDCl₃).**14**


Position	δ_{C} , type	δ_{H} (<i>J</i> in Hz) ^a	¹ H- ¹ H COSY	HMBC	ROESY
1	34.4, CH ₂	a: 2.58	1b, 2a, 2b	3, 5	5, 30
		b: 1.89			19
2	36.1, CH ₂	a: 2.53	1a, 1b, 2b	1, 3	19
		b: 2.41			
3	215.9, C				
4	46.0, CH	2.49	5, 28		6, 19
5	51.1, CH	2.10	4, 6	4, 6, 10, 19	1a, 30
6	69.7, CH	3.79	5, 7a, 7b		4, 9, 19, 28
7	44.7, CH ₂	a: 2.15	6, 7b	9, 14	9, 18
		b: 1.20, dd (14.0, 5.5)			
8	39.9, C				
9	48.4, CH	1.56, br s	11	1, 8, 10, 11, 19, 30	6, 7a, 12b, 18, 19
10	37.4, C				
11	67.6, CH	4.37, br s	9, 12a, 12b	8, 13	19
12	36.2, CH ₂	a: 2.30, br d (13.2)	11, 12b, 13	14	9, 18
		b: 1.90			
13	43.8, CH	3.06, br d (11.4)	12a, 12b	12, 14, 17, 18, 20	15a, 16, 30
14	48.4, C				
15	39.0, CH ₂	a: 2.20	15b, 16	18	13
		b: 1.36, br d (14.5)			18
16	74.2, CH	5.93, br d (8.2)	15a, 15b	14, 17, 20, 16-COCH ₃	13
17	150.1, C				
18	17.9, CH ₃	0.95, s		8, 13, 14, 15	7a, 9, 12b, 15b
19	24.8, CH ₃	1.05, s		1, 5, 9, 10	1b, 2b, 4, 6, 9, 11
20	130.2, C				
21	173.9, C				
22	28.8, CH ₂	2.45	23	17, 20, 21, 23, 24	24
23	28.3, CH ₂	2.11	22, 24	24	
24	122.9, CH	5.09, br t (6.5)	23, 26, 27	26, 27	22, 26
25	132.7, C				
26	25.7, CH ₃	1.67, br s	24	24, 25, 27	24
27	17.8, CH ₃	1.59, br s	24	24, 25, 26	
28	16.9, CH ₃	1.29, d (6.6)	4	3, 4, 5	6
30	24.2, CH ₃	1.41, s		7, 8, 9, 14	1a, 5, 13
16-COCH ₃	170.7, C				
16-COCH ₃	20.6, CH ₃	1.97, s		16-COCH ₃	

^aThe indiscernible signals from overlap or the complex multiplicity are reported without designating multiplicity.

Table S11 NMR data for **15** (¹H for 400 MHz and ¹³C for 100 MHz in CDCl₃).**15**


Position	δ_c , type	δ_h (<i>J</i> in Hz) ^a	¹ H— ¹ H COSY	HMBC	ROESY
1	35.7, CH ₂	a: 2.39 b: 1.99	1b, 2		
2	38.0, CH ₂	2.46	1a, 1b	3	19
3	213.5, C				
4	45.6, CH	2.35	5, 28	2	19
5	44.5, CH	1.82, td (11.8, 4.0)	4, 6a, 6b		7, 28, 30
6	34.5, CH ₂	a: 1.99 b: 1.29	5, 6b, 7		
7	78.9, CH	3.76, t (6.5)	6a, 6b	5, 8, 30	5, 30
8	45.4, C				
9	46.4, CH	2.01, br s	11	1, 7, 8, 10, 11, 12, 14, 19, 30	18, 19
10	36.8, C				
11	68.4, CH	4.44, br s	9, 12a, 12b	8, 13	19
12	36.2, CH ₂	a: 2.29 b: 1.99	11, 12b, 13	9, 11, 13, 14	
13	46.3, CH	3.07, br d (11.3)	12a, 12b	12, 14, 17, 18, 20	16, 30
14	48.5, C				
15	40.3, CH ₂	a: 2.28 b: 1.65	15b, 16	13, 14, 18	
16	74.4, CH	5.91, br d (8.4)	15a, 15b	14, 17, 20, 16-COCH ₃	13
17	150.2, C				
18	21.1, CH ₃	1.19, s		8, 13, 14, 15	9
19	22.3, CH ₃	1.29, s		1, 5, 9, 10	2, 4, 9, 11
20	130.4, C				
21	174.3, C				
22	28.7, CH ₂	2.45	23	17, 20, 21, 23, 24	24
23	28.3, CH ₂	2.11	22, 24	24, 25	
24	123.0, CH	5.09, br t (7.0)	23, 26, 27	26, 27	22, 26
25	132.7, C				
26	25.7, CH ₃	1.67, br s	24	24, 25, 27	24
27	17.8, CH ₃	1.59, br s	24	24, 25, 26	
28	12.3, CH ₃	1.01, d (6.6)	4	3, 4, 5	5
30	24.0, CH ₃	1.29, s		7, 8, 9, 14	5, 7, 13
16-COCH ₃	170.8, C			16-COCH ₃	
16-COCH ₃	20.6, CH ₃	1.96, s			

^aThe indiscernible signals from overlap or the complex multiplicity are reported without designating multiplicity.

Table S12 NMR data for **17** (¹H for 600 MHz and ¹³C for 150 MHz in CDCl₃).**17**


Position	δ_c , type	δ_h (J in Hz) ^a	¹ H- ¹ H COSY	HMBC	ROESY ^b
1	35.5, CH ₂	a: 1.97 b: 1.74	1b, 2a, 2b 1a, 2a, 2b	2, 3, 19 2, 3, 5	3 11
2	31.6, CH ₂	a: 1.95 b: 1.72	1a, 1b, 2b, 3 1a, 1b, 2a, 3	1 1, 3, 4	
3	76.7, CH	3.19, td (10.9, 5.3)	2a, 2b, 4	2, 4, 28	1a, 5, 28
4	35.3, CH	2.01	3, 5, 28	3, 5, 28	19
5	46.0, CH	1.65, br d (10.6)	4, 6	1, 3, 4, 19	3
6	72.8, CH	4.03, d (2.5)	5	5, 7, 8, 10	28
7	215.9, C				
8	52.8, C				
9	46.1, CH	2.30, br s	11	7, 8, 10, 11, 19, 30	18, 19
10	36.2, C				
11	68.1, CH	4.49, br s	9, 12a, 12b	8, 13	1b, 19
12	35.8, CH ₂	a: 2.32 b: 1.96	11, 12b, 13 11, 12a, 13	11	
13	44.4, CH	3.09, br d (11.5)	12a, 12b	12, 14, 17, 18, 20	16, 30
14	46.8, C				
15	40.4, CH ₂	a: 2.31 b: 1.91	15b, 16 15a, 16	18 13, 14, 16, 17, 18	
16	73.9, CH	5.91, br d (8.5)	15a, 15b	13, 14, 17, 20, 16-COCH ₃	13
17	148.7, C				
18	18.0, CH ₃	0.96, s		8, 13, 14, 15	9
19	25.1, CH ₃	1.28, s		1, 5, 9, 10	4, 9, 11
20	130.0, C				
21	173.2, C				
22	28.7, CH ₂	2.46	23a, 23b	17, 20, 21, 23, 24	24
23	28.3, CH ₂	a: 2.14 b: 2.07	22, 23b, 24 22, 23a, 24	20, 22, 24, 25 20, 22, 24, 25	
24	122.9, CH	5.10, br t (7.2)	23a, 23b, 26, 27	23, 26, 27	22, 26
25	132.8, C				
26	25.7, CH ₃	1.67, br s	24	24, 25, 27	24
27	17.8, CH ₃	1.60, br s	24	24, 25, 26	
28	15.1, CH ₃	1.08, d (6.3)	4	3, 4, 5	3, 6
30	21.5, CH ₃	1.47, s		7, 8, 9, 14	13
16-COCH ₃	170.6, C				
16-COCH ₃	20.6, CH ₃	1.98, s		16-COCH ₃	

^aThe indiscernible signals from overlap or the complex multiplicity are reported without designating multiplicity.^bThe data is recorded at 400 MHz.

Table S13 NMR data for **18** (¹H for 600 MHz and ¹³C for 150 MHz in CD₃OD).**18**

Position	δ_{C} , type	δ_{H} (<i>J</i> in Hz) ^a	¹ H- ¹ H COSY	HMBC	NOESY
1	34.7, CH ₂	a: 2.11 b: 1.71, dt (13.5, 3.6)	1b, 2a, 2b 1a, 2a, 2b	2, 3, 10, 19 3	3, 11 11, 19
2	32.3, CH ₂	a: 1.77 b: 1.55	1a, 1b, 2b, 3 1a, 1b, 2a, 3	1 10	
3	76.9, CH	3.00	2a, 2b, 4	2, 4, 28	1a, 5, 28
4	42.0, CH	1.29	3, 5, 28	3, 5	19
5	43.8, CH	1.85	4, 6a, 6b	3, 4, 6, 10, 19	3, 28, 30
6	35.1, CH ₂	a: 1.67 b: 1.59	5, 6b, 7 5, 6a, 7	7, 8	
7	71.4, CH	3.87, t (8.3)	6a, 6b	6, 8, 9, 14, 30	9, 18
8	46.2, C				
9	51.4, CH	1.51, d (1.4)	11	7, 8, 10, 11, 14, 19, 30	7, 18, 19
10	37.1, C				
11	68.5, CH	4.31, br s	9, 12a, 12b	8, 13	1a, 1b, 19
12	37.3, CH ₂	a: 2.29 b: 1.84	11, 12b, 13 11, 12a, 13	11, 14 13	18
13	45.3, CH	3.02	12a, 12b	11, 12, 14, 17, 18, 20	16, 30
14	49.2, C				
15	43.0, CH ₂	a: 2.25 b: 1.57	15b, 16 15a, 16	8, 14, 18 13, 14, 16, 17, 18	30
16	76.0, CH	5.75, br d (8.7)	15a, 15b	13, 14, 15, 17, 20, 16-COCH ₃	13
17	147.8, C				
18	16.7, CH ₃	0.99, s		8, 13, 14, 15	7, 9, 12b
19	25.7, CH ₃	0.99, s		1, 5, 9, 10	1b, 4, 9, 11
20	132.0, C				
21	174.6, C				
22	29.8, CH ₂	a: 2.55 b: 2.35	22b, 23 22a, 23	17, 20, 21, 23, 24 17, 20, 21, 23, 24	24
23	29.4, CH ₂	2.09	22a, 22b, 24	20, 22, 24, 25	
24	124.4, CH	5.13, br t (7.3)	23, 26, 27	23, 26, 27	22a, 22b, 26
25	133.3, C				
26	25.9, CH ₃	1.66, br s	24	24, 25, 27	24
27	17.9, CH ₃	1.60, br s	24	24, 25, 26	
28	15.8, CH ₃	0.95, d (6.3)	4	3, 4, 5	3, 5
30	15.0, CH ₃	1.26, s		7, 8, 9, 14	5, 13, 15a
16-COCH ₃	172.6, C				
16-COCH ₃	20.7, CH ₃	1.95, s		16-COCH ₃	


^aThe indiscernible signals from overlap or the complex multiplicity are reported without designating multiplicity.

Table S14 NMR data for **19** (¹H for 600 MHz and ¹³C for 150 MHz in CD₃OD).**19**

Position	δ_{C} , type	δ_{H} (<i>J</i> in Hz) ^a	¹ H- ¹ H COSY	HMBC	NOESY
1	35.5, CH ₂	1.90	2a, 2b	2, 3, 5, 10, 19	
2	32.7, CH ₂	a: 1.87	1, 2b, 3	1, 3	
		b: 1.67	1, 2a, 3	3	19
3	77.2, CH	3.03	2a, 2b, 4	2, 4, 5, 28	5, 28
4	38.2, CH	1.57	3, 5, 28	3, 5, 28	19
5	43.9, CH	1.50	4, 6a, 6b	1, 3, 4, 6, 7, 10, 19	3, 28, 30
6	41.1, CH ₂	a: 2.26	5, 6b	5, 7, 8, 10	28
		b: 2.18, t (14.6)	5, 6a	5, 7, 10	19
7	221.5, C				
8	54.6, C				
9	48.0, CH	1.86, br s	11	1, 7, 8, 10, 11, 14, 19, 30	18, 19
10	37.9, C				
11	67.5, CH	4.37, br d (1.6)	9, 12a, 12b	8, 10, 13	19
12	36.9, CH ₂	a: 2.32	11, 12b, 13		
		b: 1.84	11, 12a, 13	13	
13	44.8, CH	3.05	12a, 12b	12, 14, 17, 18, 20	16, 30
14	48.4, C				
15	41.8, CH ₂	a: 2.29	15b, 16	8, 14, 18	30
		b: 1.72, br d (14.7)	15a, 16	13, 14, 16, 17, 18	18
16	75.5, CH	5.79, br d (8.5)	15a, 15b	13, 14, 15, 17, 20, 16-COCH ₃	13
17	145.9, C				
18	17.5, CH ₃	0.82, s		8, 13, 14, 15	9, 15b
19	21.6, CH ₃	1.11, s		1, 5, 9, 10	2b, 4, 6b, 9, 11
20	133.6, C				
21	174.8, C				
22	29.9, CH ₂	a: 2.54	22b, 23	17, 20, 21, 23, 24	24
		b: 2.35	22a, 23	17, 20, 21, 23, 24	24
23	29.2, CH ₂	2.10	22a, 22b, 24	22, 24, 25	
24	124.4, CH	5.13, br t (7.3)	23, 26, 27	23, 26, 27	22a, 22b, 26
25	133.3, C				
26	25.9, CH ₃	1.66, br s	24	24, 25, 27	24
27	17.9, CH ₃	1.60, br s	24	24, 25, 26	
28	15.7, CH ₃	0.93, d (6.2)	4	3, 4, 5	3, 5, 6a
30	22.5, CH ₃	1.41, s		7, 8, 9, 14	5, 13, 15a
16-COCH ₃	172.6, C				
16-COCH ₃	20.7, CH ₃	1.95, s		16-COCH ₃	

^aThe indiscernible signals from overlap or the complex multiplicity are reported without designating multiplicity.


Table S15 NMR data for **20** (^1H for 600 MHz and ^{13}C for 150 MHz in CD_3OD).



20


Position	δ_{C} , type	δ_{H} (J in Hz) ^a	^1H - ^1H COSY	HMBC	NOESY
1	37.3, CH_2	a: 2.40 b: 1.98	1b, 2 1a, 2	2, 3, 10, 19 2, 5, 10	
2	38.6, CH_2	2.50	1a, 1b	1, 3, 10	
3	216.9, C				
4	42.9, CH	2.87, dq (13.3, 6.7)	5, 28	3, 5, 6, 10, 28	19
5	47.5, CH	1.88, dd (12.5, 1.8)	4, 6	1, 3, 4, 7, 10, 19, 28	
6	74.5, CH	3.82, br s	5	4, 5, 7, 8, 10	30
7	216.9, C				
8	54.5, C				
9	45.7, CH	2.53, br s	11	1, 5, 7, 8, 10, 11, 14, 19, 30	19
10	37.3, C				
11	67.7, CH	4.47, br s	9, 12a, 12b	8, 13	19
12	36.9, CH_2	a: 2.35 b: 1.92	11, 12b, 13 11, 12a, 13	11, 14 13	
13	44.9, CH	3.12, br d (12.0)	12a, 12b	12, 14, 17, 18, 20	30
14	48.0, C				
15	41.9, CH_2	a: 2.34 b: 1.81, br d (14.6)	15b, 16 15a, 16	8, 14, 18 13, 14, 16, 17, 18	
16	75.5, CH	5.81, br d (8.5)	15a, 15b	13, 14, 15, 17, 20, 16-COCH ₃	
17	147.1, C				
18	18.7, CH_3	0.92, s		8, 13, 14, 15	
19	24.8, CH_3	1.45, s		1, 5, 9, 10	4, 9, 11
20	132.7, C				
21	174.2, C				
22	29.8, CH_2	a: 2.55 b: 2.37	22b, 23a, 23b 22a, 23a, 23b	17, 20, 21, 23, 24 17, 20, 21, 23, 24	24
23	29.2, CH_2	a: 2.14 b: 2.08	22a, 22b, 23b, 24 22a, 22b, 23a, 24	22, 24, 25 22, 24, 25	27
24	124.2, CH	5.13, br t (7.2)	23a, 23b, 26, 27	23, 26, 27	22a, 22b, 26
25	133.4, C				
26	25.9, CH_3	1.66, br s	24	24, 25, 27	24
27	17.9, CH_3	1.60, br s	24	24, 25, 26	23a, 23b
28	12.8, CH_3	1.06, d (6.8)	4	3, 4, 5	
30	22.4, CH_3	1.44, s		7, 8, 9, 14	6, 13
16-COCH ₃	172.6, C				
16-COCH ₃	20.7, CH_3	1.96, s		16-COCH ₃	

^aThe indiscernible signals from overlap or the complex multiplicity are reported without designating multiplicity.

Table S16 NMR data for **21** (¹H for 600 MHz and ¹³C for 150 MHz in CDCl₃).**21**


Position	δ_{C} , type	δ_{H} (<i>J</i> in Hz) ^a	¹ H- ¹ H COSY	HMBC	NOESY
1	35.5, CH ₂	a: 2.42	1b, 2a, 2b	2, 10, 19	11
		b: 1.97	1a, 2a, 2b	2, 3, 5, 10, 19	11
2	38.2, CH ₂	a: 2.48	1a, 1b, 2b	1, 3	
		b: 2.37, br d (12.4)	1a, 1b, 2a	3, 10	
3	212.8, C				
4	46.5, CH	2.26	5, 28	2, 3, 5, 10, 28	19
5	44.5, CH	2.25	4, 6a, 6b	3, 4, 10, 19, 28	28, 30
6	35.0, CH ₂	a: 1.82	5, 6b, 7	4, 5, 7	
		b: 1.53	5, 6a, 7	5, 7, 10	
7	70.4, CH	3.96, t (7.9)	6a, 6b	5, 6, 8, 9, 14, 30	9, 18, 19
8	44.7, C				
9	49.8, CH	1.59	11	7, 8, 10, 11, 12, 14, 19, 30	7, 12b, 18, 19
10	36.1, C				
11	68.1, CH	4.37, br s	9, 12a, 12b	8, 9, 10, 12, 13	1a, 1b, 19
12	36.0, CH ₂	a: 2.30	11, 12b, 13	9, 11, 14	
		b: 1.92	11, 12a, 13	13	9, 18
13	44.3, CH	3.02, br d (12.1)	12a, 12b	11, 12, 14, 17, 18, 20	16, 30
14	47.9, C				
15	41.7, CH ₂	a: 2.27	15b, 16	14, 18	
		b: 1.56	15a, 16	8, 14, 16, 17, 18	
16	74.3, CH	5.85, br d (8.4)	15a, 15b	13, 14, 17, 20, 16-COCH ₃	13, 30
17	148.7, C				
18	16.7, CH ₃	1.00, s		8, 13, 14, 15	7, 9, 12b
19	24.4, CH ₃	1.19, s		1, 5, 9, 10	4, 7, 9, 11
20	130.0, C				
21	174.4, C				
22	28.7, CH ₂	2.43	23a, 23b	17, 20, 21, 23, 24	24
23	28.4, CH ₂	a: 2.13	22, 23b, 24	20, 22, 24, 25	
		b: 2.04	22, 23a, 24	20, 22, 24, 25	
24	123.0, CH	5.08, br t (6.8)	23a, 23b, 26, 27	23, 26, 27	22, 26
25	132.6, C				
26	25.7, CH ₃	1.66, br s	24	24, 25, 27	24
27	17.8, CH ₃	1.58, br s	24	24, 25, 26	
28	11.5, CH ₃	0.98, d (5.0)	4	3, 4, 5	5
30	14.4, CH ₃	1.23, s		7, 8, 9, 14	5, 13, 16
16-COCH ₃	171.0, C				
16-COCH ₃	20.6, CH ₃	1.94, s		16-COCH ₃	

^aThe indiscernible signals from overlap or the complex multiplicity are reported without designating multiplicity.

Table S17 NMR data for **22** (¹H for 600 MHz and ¹³C for 150 MHz in CDCl₃).**22**


Position	δ_c , type	δ_h (J in Hz) ^a	¹ H– ¹ H COSY ^b	HMBC ^b	ROESY ^b
1	34.7, CH ₂	a: 2.36	1b, 2	9, 10, 19	
		b: 2.05	1a, 2	3, 19	
2	37.7, CH ₂	2.52	1a, 1b	1, 3	19
3	212.2, C				
4	44.2, CH	2.40	5, 28	3, 5, 10	19
5	43.0, CH	1.99	4, 6a, 6b	4	30
6	40.4 ^c , CH ₂	a: 2.32	5, 6b	7, 10	
		b: 2.19, t (14.7)	5, 6a	5, 7, 10	
7	216.7, C				
8	53.2, C				
9	46.5, CH	1.94, d (1.3)	11	1, 7, 8, 10, 11, 19, 30	18, 19
10	36.6, C				
11	67.4, CH	4.51, br s	9, 12a, 12b	8, 13	19
12	35.7, CH ₂	a: 2.34	11, 12b, 13	11, 14	
		b: 1.91	11, 12a, 13		
13	43.9, CH	3.06, br d (11.8)	12a, 12b	12, 14, 17, 18, 20	16, 30
14	47.2, C				
15	40.5 ^c , CH ₂	a: 2.32	15b, 16	18	
		b: 1.89, br d (14.7)	15a, 16	13, 14, 16, 17	
16	73.8, CH	5.93, br d (8.3)	15a, 15b	14, 17, 16-COCH ₃	13
17	148.0, C				
18	17.1, CH ₃	0.85, s		8, 13, 14, 15	9
19	21.3 ^d , CH ₃	1.23, s		1, 5, 9, 10	2, 4, 9, 11
20	130.7, C				
21	174.1, C				
22	28.7, CH ₂	2.42	23	17, 20, 21, 23, 24	24
23	28.3, CH ₂	2.09	22, 24	22, 24, 25	
24	122.9, CH	5.09, br t (7.1)	23, 26, 27	26, 27	22, 26
25	132.7, C				
26	25.7, CH ₃	1.67, br s	24	24, 25, 27	24
27	17.8, CH ₃	1.59, br s	24	24, 25, 26	
28	12.6, CH ₃	1.03, d (6.7)	4	3, 4, 5	
30	21.4 ^d , CH ₃	1.41, s		7, 8, 9, 14	5, 13
16-COCH ₃	170.7, C				
16-COCH ₃	20.6, CH ₃	1.95, s		16-COCH ₃	

^aThe indiscernible signals from overlap or the complex multiplicity are reported without designating multiplicity.^bThe data were recorded at 400 MHz.^{c,d}Assignment might be interchanged.

Table S18 NMR data for **23** (^1H for 400 MHz and ^{13}C for 100 MHz in CDCl_3).**23**


Position	δ_{C} , type	δ_{H} (J in Hz) ^a	^1H - ^1H COSY	HMBC	ROESY
1	30.0, CH_2	a: 1.71	1b, 2a, 2b	19	
		b: 1.23	1a, 2a, 2b		
2	29.8, CH_2	a: 1.90	1a, 1b, 2b, 3		
		b: 1.70	1a, 1b, 2a, 3	3, 4, 10	
3	71.4, CH	3.89, br s	2a, 2b, 4	1, 2, 5, 28	
4	32.1, CH	2.23	3, 5, 28	5, 28	19
5	39.0, CH	2.12	4, 6,	1, 3, 4, 7, 10, 19	28, 30
6	73.8, CH	3.87, br s	5	4, 5, 7, 8, 10	28
7	217.7, C				
8	52.5, C				
9	41.7, CH	2.45	11a, 11b	1, 8, 10, 14, 19, 30	18, 19
10	35.6, C				
11	22.7, CH_2	a: 1.76	9, 11b, 12a, 12b	8	
		b: 1.38	9, 11a, 12a, 12b		13
12	26.1, CH_2	a: 2.27	11a, 11b, 12b, 13	9, 14	
		b: 1.71	11a, 11b, 12a, 13		
13	49.3, CH	2.51	12a, 12b	12, 14, 17, 18, 20	11b, 15a, 16, 30
14	46.7, C				
15	40.7, CH_2	a: 2.25	15b, 16	8, 14, 18	13
		b: 1.80	15a, 16	13, 14, 16, 17, 18	18
16	74.0, CH	5.80, br d (8.2)	15a, 15b	14, 17, 20, 16-COCH ₃	13
17	148.8, C				
18	18.2, CH_3	0.89, s		8, 13, 14, 15	9, 15b
19	23.0, CH_3	1.25, s		1, 5, 9, 10	4, 9
20	130.1, C				
21	174.1, C				
22	28.4, CH_2	2.43	23	17, 20, 21, 23, 24	24
23	28.4, CH_2	2.06	22, 24	20, 22, 24, 25	
24	123.0, CH	5.07, br t (6.7)	23, 26, 27	23, 26, 27	22, 26
25	132.5, C				
26	25.6, CH_3	1.65, br s	24	24, 25, 27	24
27	17.7, CH_3	1.57, br s	24	24, 25, 26	
28	15.0, CH_3	0.97, d (6.2)	4	3, 4, 5	5, 6
30	17.4, CH_3	1.25, s		7, 8, 9, 14	5, 13
16-COCH ₃	170.9, C				
16-COCH ₃	20.4, CH_3	1.93, s		16-COCH ₃	

^aThe indiscernible signals from overlap or the complex multiplicity are reported without designating multiplicity.

Table S19 NMR data for **24** (¹H for 600 MHz and ¹³C for 150 MHz in CDCl₃).**24**


Position	δ_{C} , type	δ_{H} (<i>J</i> in Hz) ^a	¹ H– ¹ H COSY	HMBC	ROESY
1	29.6, CH ₂	a: 1.60 b: 1.27, br d (12.1)	1b, 2a, 2b 1a, 2a, 2b	2, 9, 10, 19 2, 3, 5	
2	29.7, CH ₂	a: 1.77 b: 1.69	1a, 1b, 2b, 3 1a, 1b, 2a, 3	1 1	
3	71.3, CH	3.73, br s	2a, 2b, 4	1, 2, 5, 28	28
4	35.8, CH	1.55	3, 5, 28	5, 6, 28	19
5	34.7, CH	2.15	4, 6a, 6b	1, 3, 4, 6, 10, 19, 28	28, 30
6	33.4, CH ₂	a: 1.66 b: 1.37	5, 6b, 7 5, 6a, 7	4, 5, 7, 8, 10 4, 5, 7, 8, 10	
7	70.4, CH	4.00, dd (8.1, 4.7)	6a, 6b	5, 6, 8, 14, 30	9, 18, 19
8	44.5, C				
9	45.9, CH	1.48	11a, 11b	8, 10, 12, 19, 30	7, 18, 19
10	35.7, C				
11	23.4, CH ₂	a: 1.71 b: 1.35	9, 11b, 12a, 12b 9, 11a, 12a, 12b		
12	26.3, CH ₂	a: 2.23 b: 1.60	11a, 11b, 12b, 13 11a, 11b, 12a, 13	11, 14 9, 11, 13	
13	49.3, CH	2.48	12a, 12b	12, 14, 17, 18, 20	16, 30
14	48.2, C				
15	41.6, CH ₂	a: 2.24 b: 1.49	15b, 16 15a, 16	8, 14, 18 13, 14, 16, 17, 18	30 18
16	74.4, CH	5.83, br d (8.6)	15a, 15b	14, 17, 20, 16-COCH ₃	13
17	149.4, C				
18	17.9, CH ₃	0.99, s		8, 13, 14, 15	7, 9, 15b
19	22.2, CH ₃	0.87, s		1, 5, 9, 10	4, 7, 9
20	129.6, C				
21	174.1, C				
22	28.6, CH ₂	a: 2.50 b: 2.40	22b, 23a, 23b 22a, 23a, 23b	17, 20, 21, 23, 24 17, 20, 21, 23, 24	24 24
23	28.3, CH ₂	a: 2.11 b: 2.05	22a, 22b, 23b, 24 22a, 22b, 23a, 24	20, 22, 24, 25 20, 22, 24, 25	
24	123.0, CH	5.09, br t (7.1)	23a, 23b, 26, 27	23, 26, 27	22a, 22b, 26
25	132.6, C				
26	25.7, CH ₃	1.67, br s	24	24, 25, 27	24
27	17.7, CH ₃	1.59, br s	24	24, 25, 26	
28	15.8, CH ₃	0.90, d (6.8)	4	3, 4, 5	3, 5
30	12.3, CH ₃	1.08, s		7, 8, 9, 14	5, 13, 15a
16-COCH ₃	170.6, C				
16-COCH ₃	20.6, CH ₃	1.95, s		16-COCH ₃	

^aThe indiscernible signals from overlap or the complex multiplicity are reported without designating multiplicity.

Table S20 NMR data for **25** (¹H for 600 MHz and ¹³C for 150 MHz in CDCl₃).**25**


Position	δ_{C} , type	δ_{H} (<i>J</i> in Hz) ^a	¹ H- ¹ H COSY	HMBC	NOESY
1	28.2, CH ₂	a: 1.72	1b, 2a, 2b	2, 10, 19	
		b: 1.33	1a, 2a, 2b	2, 3, 5, 10	
2	29.7, CH ₂	a: 1.89	1a, 1b, 2b, 3		
		b: 1.75	1a, 1b, 2a, 3	3, 4, 10	
3	71.1, CH	3.82, br s	2a, 2b, 4	1, 5, 28	28
4	34.0, CH	1.81	3, 5, 28	5, 28	19
5	35.5, CH	2.21	4, 6a, 6b	1, 3, 4, 6, 7, 10, 19	28, 30
6	39.5, CH ₂	a: 2.20	5, 6b	4, 7, 8, 10	
		b: 2.07	5, 6a	5, 7, 10	19
7	218.2, C				
8	52.5, C				
9	43.3, CH	1.91	11a, 11b	1, 8, 10, 11, 19, 30	18, 19
10	36.1, C				
11	22.7, CH ₂	a: 1.74	9, 11b, 12a, 12b		
		b: 1.34	9, 11a, 12a, 12b	9	
12	26.1, CH ₂	a: 2.28	11a, 11b, 12b, 13		
		b: 1.65	11a, 11b, 12a, 13	11, 13	18
13	49.2, CH	2.51	12a, 12b	12, 14, 17, 18, 20	16, 30
14	47.1, C				
15	40.6, CH ₂	a: 2.28	15b, 16	8, 14, 18	
		b: 1.87	15a, 16	13, 14, 16, 17, 18	18
16	73.8, CH	5.85, br d (8.5)	15a, 15b	13, 14, 15, 17, 20, 16-COCH ₃	13
17	148.5, C				
18	17.4, CH ₃	0.85, s		8, 13, 14, 15	9, 12b, 15b
19	19.6, CH ₃	1.00, s		1, 5, 9, 10	4, 6b, 9
20	129.9, C				
21	174.0, C				
22	28.5, CH ₂	a: 2.50	22b, 23a, 23b	17, 20, 21, 23, 24	24
		b: 2.41	22a, 23a, 23b	17, 20, 21, 23, 24	24
23	28.3, CH ₂	a: 2.10	22a, 22b, 23b, 24	20, 22, 24, 25	27
		b: 2.04	22a, 22b, 23a, 24	20, 22, 24, 25	27
24	122.9, CH	5.08, br t (6.7)	23a, 23b, 26, 27	23, 26, 27	22a, 22b, 26
25	132.7, C				
26	25.7, CH ₃	1.67, br s	24	24, 25, 27	24
27	17.7, CH ₃	1.59, br s	24	24, 25, 26	23a, 23b
28	15.6, CH ₃	0.90, d (6.8)	4	3, 4, 5	3, 5
30	17.4, CH ₃	1.27, s		7, 8, 9, 14	5, 13
16-COCH ₃	170.3, C				
16-COCH ₃	20.5, CH ₃	1.94, s		16-COCH ₃	

^aThe indiscernible signals from overlap or the complex multiplicity are reported without designating multiplicity.

Table S21 NMR data for **26** (¹H for 400 MHz and ¹³C for 100 MHz in CDCl₃).**26**


Position	δ_{C} , type	δ_{H} (<i>J</i> in Hz) ^a	¹ H– ¹ H COSY	HMBC	ROESY
1	160.8, CH	8.06, d (10.2)	2	3, 5, 10	11
2	126.2, CH	5.83, d (10.2)	1	4, 10	
3	202.3, C				
4	39.9, CH	3.02, dq (13.1, 6.5)	5, 28	3, 5, 28	19
5	46.5, CH	2.38	4, 6	1, 3, 4, 10, 19	30
6	73.3, CH	4.0, br s	5	5, 7, 8, 10	28
7	215.3, C				
8	53.0, C				
9	45.4, CH	2.55, br s	11	1, 7, 8, 10, 11, 14, 19, 30	18, 19
10	38.7, C				
11	67.6, CH	4.68, br s	9, 12a, 12b	8, 13	1, 19
12	35.8, CH ₂	a: 2.37 b: 2.08	11, 12b, 13 11,12a, 13	11, 14	
13	44.2, CH	3.11, br d (11.9)	12a, 12b	12, 14, 17, 18, 20	16, 30
14	46.7, C				
15	40.7, CH ₂	a: 2.32 b: 1.91, br d (14.7)	15b, 16 15a, 16	18 13, 16, 17, 18	
16	74.0, CH	5.92, br d (8.2)	15a, 15b	14, 17, 20, 16-COCH ₃	13
17	149.1, C				
18	18.1, CH ₃	0.94, s		8, 13, 14, 15	9
19	28.4, CH ₃	1.55, s		1, 5, 9, 10	4, 9, 11
20	130.2, C				
21	173.9, C				
22	28.7, CH ₂	2.45	23	17, 20, 21, 23, 24	
23	28.4, CH ₂	2.13	22, 24	22, 24, 25	
24	122.8, CH	5.09, br t (6.6)	23, 26, 27	23, 26, 27	26
25	132.9, C				
26	25.7, CH ₃	1.68, br s	24	24, 25, 27	24
27	17.8, CH ₃	1.60, br s	24	24, 25, 26	
28	12.4, CH ₃	1.22, d (6.7)	4	3, 4, 5	6
30	21.7, CH ₃	1.36, s		7, 8, 9, 14	5, 13
16-COCH ₃	170.6, C				
16-COCH ₃	20.5, CH ₃	1.96, s		16-COCH ₃	

^aThe indiscernible signals from overlap or the complex multiplicity are reported without designating multiplicity.

Table S22 NMR data for **29** (¹H for 600 MHz and ¹³C for 150 MHz in CDCl₃).**29**


Position	δ_{C} , type	δ_{H} (<i>J</i> in Hz) ^a	¹ H- ¹ H COSY	HMBC	ROESY
1	140.1, CH	6.21, d (10.1)	2	3, 5, 9, 10, 19	3, 11, 19
2	127.5, CH	5.80, dd (10.1, 4.9)	1, 3	3, 4, 10	
3	68.2, CH	3.87, t (4.9)	2, 4	1, 2, 5, 28	1, 28
4	34.7, CH	1.76	3, 5, 28	5, 10, 28	19
5	33.2, CH	2.35	4, 6a, 6b	1, 3, 4, 6, 10, 19	28, 30
6	19.7, CH ₂	a: 1.72 b: 1.29	5, 6b, 7a, 7b 5, 6a, 7a, 7b	10	
7	30.1, CH ₂	a: 1.58 b: 1.22	6a, 6b, 7b 6a, 6b, 7a	8, 30 9	18, 19
8	39.4, C				
9	49.9, CH	1.71, d (1.8)	11	1, 7, 8, 10, 11, 14, 19, 30	12b, 18, 19
10	37.9, C				
11	67.6, CH	4.42, br s	9, 12a, 12b	8, 13	1, 19
12	34.1, CH ₂	a: 2.38 b: 1.88, td (12.7, 3.1)	11, 12b, 13 11, 12a, 13	14 13	9, 18
13	43.9, CH	3.01, br d (12.4)	12a, 12b	12, 14, 17, 18, 20	15a, 16, 30
14	48.8, C				
15	39.0, CH ₂	a: 2.21, dd (14.6, 9.0) b: 1.28, br d (14.4)	15b, 16 15a, 16	8, 14, 16, 18 13, 14, 16, 17, 18	13, 30 18
16	74.4, CH	5.86, br d (8.6)	15a, 15b	13, 14, 17, 20, 16-COCH ₃	13
17	149.7, C				
18	17.3, CH ₃	0.90, s		8, 13, 14, 15	7a, 9, 12b, 15b
19	27.8, CH ₃	1.00, s		1, 5, 9, 10	1, 4, 7a, 9, 11
20	129.9, C				
21	174.2, C				
22	28.8, CH ₂	2.45	23a, 23b	17, 20, 21, 23, 24	24
23	28.4, CH ₂	a: 2.16 b: 2.04	22, 23b, 24 22, 23a, 24	20, 22, 24, 25 20, 22, 24, 25	
24	123.0, CH	5.09, br t (7.1)	23a, 23b, 26, 27	23, 26, 27	22, 26
25	132.6, C				
26	25.7, CH ₃	1.67, br s	24	24, 25, 27	24
27	17.8, CH ₃	1.59, br s	24	24, 25, 26	
28	13.8, CH ₃	0.97, d (6.8)	4	3, 4, 5	3, 5
30	22.4, CH ₃	1.34, s		7, 8, 9, 14	5, 13, 15a
16-COCH ₃	170.7, C				
16-COCH ₃	20.6, CH ₃	1.96, s		16-COCH ₃	

^aThe indiscernible signals from overlap or the complex multiplicity are reported without designating multiplicity.

Table S23 NMR data for **30** (¹H for 600 MHz and ¹³C for 150 MHz in CDCl₃).**30**


Position	δ_{C} , type	δ_{H} (J in Hz) ^a	¹ H- ¹ H COSY	HMBC	NOESY
1	140.5, CH	6.16, d (10.0)	2	3, 5, 9, 10	11a, 19, 30
2	126.9, CH	5.62, dd (10.0, 4.1)	1, 3	4, 10	
3	68.7, CH	4.11, t (4.1)	2, 4	1, 2, 5	28
4	30.8, CH	2.51	3, 5, 28	5, 10, 28	19
5	39.7, CH	2.03, br d (10.9)	4, 6	1, 3, 4, 7, 10, 19	30
6	73.5, CH	4.02, br s	5	4, 5, 7, 8, 10	28
7	215.8, C				
8	52.2, C				
9	41.9, CH	2.46	11a, 11b	1, 8, 10, 11, 19, 30	18, 19
10	37.6, C				
11	24.0, CH ₂	a: 1.92 b: 1.45	9, 11b, 12a, 12b 9, 11a, 12a, 12b	12, 13 9	1, 19
12	26.0, CH ₂	a: 2.33 b: 1.75	11a, 11b, 12b, 13 11a, 11b, 12a, 13	9	18
13	49.5, CH	2.53	12a, 12b	12, 14, 17, 18, 20	16, 30
14	46.4, C				
15	40.8, CH ₂	a: 2.21, dd (15.2, 8.4) b: 1.92	15b, 16 15a, 16	8, 14, 18 13, 14, 16, 17, 18	30 18
16	73.8, CH	5.85, br d (8.3)	15a, 15b	14, 17, 20, 16-COCH ₃	13
17	148.1, C				
18	18.2, CH ₃	0.95, s		8, 13, 14, 15	9, 12b, 15b
19	28.7, CH ₃	1.31, s		1, 5, 9, 10	1, 4, 9, 11a
20	129.9, C				
21	173.5, C				
22	28.5, CH ₂	a: 2.51 b: 2.43	22b, 23a, 23b 22a, 23a, 23b	17, 20, 21, 23, 24 17, 20, 21, 23, 24	24
23	28.3, CH ₂	a: 2.12 b: 2.06	22a, 22b, 23b, 24 22a, 22b, 23a, 24	20, 22, 24, 25 20, 22, 24, 25	
24	122.9, CH	5.10, br t (7.0)	23a, 23b, 26, 27	23, 26, 27	22a, 22b, 26
25	132.8, C				
26	25.7, CH ₃	1.68, br s	24	24, 25, 27	24
27	17.7, CH ₃	1.60, br s	24	24, 25, 26	
28	13.4, CH ₃	1.11, d (7.0)	4	3, 4, 5	3, 6
30	17.5, CH ₃	1.14, s		7, 8, 9, 14	1, 5, 13, 15a
16-COCH ₃	170.6, C				
16-COCH ₃	20.6, CH ₃	1.97, s		16-COCH ₃	

^aThe indiscernible signals from overlap or the complex multiplicity are reported without designating multiplicity

Table S24 NMR data for **31** (¹H for 600 MHz and ¹³C for 150 MHz in CDCl₃).**31**


Position	δ_{C} , type	δ_{H} (<i>J</i> in Hz) ^a	¹ H- ¹ H COSY	HMBC	NOESY
1	158.7, CH	7.27, d (10.1)	2	3, 5, 9, 10	11a, 11b, 19
2	127.7, CH	5.83, d (10.1)	1	3, 4, 10	
3	202.3, C				
4	42.5, CH	2.35	5, 28	3, 5, 28	19
5	41.9, CH	2.35	4, 6a, 6b	3, 4, 6, 10, 19	28, 30
6	33.0, CH ₂	a: 1.81 b: 1.55	5, 6b, 7 5, 6a, 7	5, 7, 8, 10 7, 10	
7	69.2, CH	4.15, br d (7.4)	6a, 6b	5, 6, 8, 14, 30	
8	43.8, C				
9	44.4, CH	1.56	11a, 11b	7, 8, 10, 30	18
10	38.7, C				
11	25.1, CH ₂	a: 1.88 b: 1.48	9, 11b, 12a, 12b 9, 11a, 12a, 12b	9 9, 12, 13	1 1
12	25.7, CH ₂	a: 2.35 b: 1.70	11a, 11b, 12b, 13 11a, 11b, 12a, 13	13	
13	49.2, CH	2.52	12a, 12b	12, 14, 17, 18, 20	16
14	48.1, C				
15	41.2, CH ₂	a: 2.19 b: 1.49	15b, 16 15a, 16	8, 14, 18 13, 14, 18	30
16	74.3, CH	5.85, br d (8.3)	15a, 15b	13, 14, 17, 20, 16-COCH ₃	13
17	149.1, C				
18	18.7, CH ₃	1.01, s		8, 13, 14, 15	9
19	25.6, CH ₃	1.12, s		1, 5, 9, 10	1, 4
20	130.3, C				
21	174.1, C				
22	28.6, CH ₂	a: 2.50 b: 2.43	22b, 23a, 23b 22a, 23a, 23b	17, 20, 21, 23, 24 17, 20, 21, 23, 24	24 24
23	28.2, CH ₂	a: 2.13 b: 2.06	22a, 22b, 23b, 24 22a, 22b, 23a, 24	20, 22, 24, 25 20, 22, 24, 25	
24	122.9, CH	5.09, br t (6.9)	23a, 23b, 26, 27	23, 26, 27	22a, 22b, 26
25	132.7, C				
26	25.7, CH ₃	1.68, br s	24	24, 25, 27	24
27	17.7, CH ₃	1.59, br s	24	24, 25, 26	
28	12.6, CH ₃	1.12, d (6.0)	4	3, 4, 5	5
30	12.2, CH ₃	0.96, s		7, 8, 9, 14	5, 15a
16-COCH ₃	170.7, C			16-COCH ₃	
16-COCH ₃	20.6, CH ₃	1.95, s			

^aThe indiscernible signals from overlap or the complex multiplicity are reported without designating multiplicity.

Table S25 NMR data for **32** (¹H for 600 MHz and ¹³C for 150 MHz in CDCl₃).**32**


Position	δ_{C} , type	δ_{H} (<i>J</i> in Hz) ^a	¹ H- ¹ H COSY	HMBC	NOESY
1	140.6, CH	6.09, d (10.1)	2	3, 5, 9, 10	11a, 19
2	126.8, CH	5.65, dd (10.1, 4.6)	1, 3	3, 4, 10	
3	68.3, CH	3.90, t (4.4)	2, 4	1, 2, 5	28
4	33.5, CH	1.83	3, 5, 28	5, 10, 28	19
5	34.1, CH	2.14	4, 6a, 6b	1, 3, 4, 6, 7, 10, 19	28, 30
6	32.3, CH ₂	a: 1.76, td (14.1, 8.2) b: 1.46	5, 6b, 7 5, 6a, 7	4, 5, 7, 8, 10 5, 7, 10	19, 28 28
7	70.2, CH	4.07, dd (8.1, 3.9)	6a, 6b	5, 14, 30	9, 18, 19
8	44.5, C				
9	45.1, CH	1.51	11a, 11b	7, 8, 10, 11, 12, 19, 30	7, 18, 19
10	38.0, C				
11	24.9, CH ₂	a: 1.86 b: 1.33, qd (13.1, 4.1)	9, 11b, 12a, 12b 9, 11a, 12a, 12b		1 30
12	26.0, CH ₂	a: 2.29 b: 1.65	11a, 11b, 12b, 13 11a, 11b, 12a, 13	11, 13	18
13	49.2, CH	2.49	12a, 12b	12, 14, 17, 18, 20	16, 30
14	48.2, C				
15	41.7, CH ₂	a: 2.22, dd (14.9, 8.4) b: 1.49	15b, 16 15a, 16	8, 14, 18 13, 14, 16, 17, 18	30
16	74.3, CH	5.84, br d (8.6)	15a, 15b	13, 14, 17, 20, 16-COCH ₃	13
17	149.2, C				
18	18.2, CH ₃	1.00, s		8, 13, 14, 15	7, 9, 12b
19	26.6, CH ₃	0.91, s		1, 5, 9, 10	1, 4, 6a, 7, 9
20	129.7, C				
21	173.2, C				
22	28.7, CH ₂	a: 2.51 b: 2.42	22b, 23a, 23b 22a, 23a, 23b	17, 20, 21, 23, 24 17, 20, 21, 23, 24	24 24
23	28.3, CH ₂	a: 2.13 b: 2.06	22a, 22b, 23b, 24 22a, 22b, 23a, 24	20, 22, 24, 25 20, 22, 24, 25	
24	123.0, CH	5.10, br t (7.3)	23a, 23b, 26, 27	23, 26, 27	22a, 22b, 26
25	132.7, C				
26	25.7, CH ₃	1.68, br s	24	24, 25, 27	24
27	17.7, CH ₃	1.60, br s	24	24, 25, 26	
28	14.0, CH ₃	0.98, d (7.0)	4	3, 4, 5	3, 5, 6a, 6b
30	12.6, CH ₃	0.99, s		7, 8, 9, 14	5, 11b, 13, 15a
16-COCH ₃	170.6, C			16-COCH ₃	
16-COCH ₃	20.6, CH ₃	1.96, s		16-COCH ₃	

^aThe indiscernible signals from overlap or the complex multiplicity are reported without designating multiplicity.

Table S26 NMR data for **33** (¹H for 600 MHz and ¹³C for 150 MHz in CDCl₃).**33**


Position	δ_{C} , type	δ_{H} (<i>J</i> in Hz) ^a	¹ H- ¹ H COSY	HMBC	NOESY
1	157.4, CH	7.32, d (10.1)	2	3, 5, 10, 19	11a, 19, 30
2	128.4, CH	5.89, d (10.0)	1	3, 4, 10	
3	201.2, C				
4	41.9, CH	2.56	5, 28	3, 5, 6, 10, 28	19
5	43.7, CH	2.23	4, 6a, 6b	1, 3, 4, 6, 7, 10, 19, 28	30
6	39.8, CH ₂	a: 2.38 b: 2.31, t (14.6)	5, 6b 5, 6a	4, 5, 7, 8, 10 5, 7, 10	19
7	215.9, C				
8	52.1, C				
9	43.3, CH	2.06	11a, 11b	1, 8, 10, 11, 30	12b, 18, 19
10	38.4, C				
11	24.2, CH ₂	a: 1.93 b: 1.51, qd (13.0, 3.4)	9, 11b, 12a, 12b 9, 11a, 12a, 12b	12 8, 9	1, 19 30
12	25.9, CH ₂	a: 2.39 b: 1.76, qd (13.0, 3.8)	11a, 11b, 12b, 13 11a, 11b, 12a, 13	13	9, 18
13	49.3, CH	2.53	12a, 12b	12, 14, 17, 18, 20	16, 30
14	46.8, C				
15	40.6, CH ₂	a: 2.24 b: 1.91	15b, 16 15a, 16	8, 14, 18 13, 14, 16, 17, 18	18
16	73.6, CH	5.86, br d (8.5)	15a, 15b	13, 14, 17, 20, 16-COCH ₃	13
17	147.7, C				
18	17.4, CH ₃	0.89, s		8, 13, 14, 15	9, 12b, 15b
19	25.4, CH ₃	1.30, s		1, 5, 9, 10	1, 4, 6b, 9, 11a
20	130.2, C				
21	173.8, C				
22	28.6, CH ₂	a: 2.50 b: 2.43	22b, 23a, 23b 22a, 23a, 23b	17, 20, 21, 23, 24 17, 20, 21, 23, 24	24
23	28.3, CH ₂	a: 2.13 b: 2.07	22a, 22b, 23b, 24 22a, 22b, 23a, 24	20, 22, 24, 25 20, 22, 24, 25	
24	122.8, CH	5.10, br t (7.0)	23a, 23b, 26, 27	23, 26, 27	22a, 22b, 26
25	132.8, C				
26	25.7, CH ₃	1.68, br s	24	24, 25, 27	24
27	17.7, CH ₃	1.60, br s	24	24, 25, 26	
28	13.0, CH ₃	1.14, d (6.8)	4	3, 4, 5	
30	17.7, CH ₃	1.11, s		7, 8, 9, 14	1, 5, 11b, 13
16-COCH ₃	170.3, C			16-COCH ₃	
16-COCH ₃	20.5, CH ₃	1.95, s			

^aThe indiscernible signals from overlap or the complex multiplicity are reported without designating multiplicity.

Table S27 NMR data for **34** (¹H for 600 MHz and ¹³C for 150 MHz in CDCl₃).**34**


Position	δ_{C} , type	δ_{H} (<i>J</i> in Hz) ^a	¹ H– ¹ H COSY	HMBC	ROESY
1	139.4, CH	6.20, d (10.0)	2	3, 5, 9, 10	11a, 11b, 19
2	127.9, CH	5.67, dd (10.1, 4.1)	1, 3	3, 4, 10	
3	68.2, CH	4.03, t (4.3)	2, 4	1, 2, 5	28
4	32.5, CH	2.14	3, 5, 28	28	19
5	36.3, CH	2.01	4, 6a, 6b	1, 3, 4, 6, 7, 9, 10, 19	28, 30
6	38.9, CH ₂	a: 2.34 b: 2.12	5, 6b 5, 6a	4, 5, 7, 8, 10 4, 5, 7, 10	28 19, 28
7	217.7, C				
8	52.2, C				
9	43.2, CH	1.91	11a, 11b	1, 5, 7, 8, 10, 11, 12, 19	18, 19
10	37.9, C				
11	24.1, CH ₂	a: 1.89 b: 1.41	9, 11b, 12a, 12b 9, 11a, 12a, 12b	12 9	1, 19 1, 13, 30
12	26.0, CH ₂	a: 2.32 b: 1.71	11a, 11b, 12b, 13 11a, 11b, 12a, 13		18
13	49.3, CH	2.51	12a, 12b	12, 14, 17, 18, 20	11b, 15a, 16, 30
14	46.8, C				
15	40.6, CH ₂	a: 2.22, dd (14.8, 8.6) b: 1.89	15b, 16 15a, 16	8, 14, 18 13, 14, 16, 17, 18	13, 30 18
16	73.7, CH	5.86, br d (8.5)	15a, 15b	13, 14, 17, 20, 16-COCH ₃	13
17	147.7, C				
18	17.4, CH ₃	0.86, s		8, 13, 14, 15	9, 12b, 15b
19	25.9, CH ₃	1.07, s		1, 5, 9, 10	1, 4, 6b, 9, 11a
20	130.3, C				
21	173.7, C				
22	28.6, CH ₂	a: 2.49 b: 2.42	22b, 23a, 23b 22a, 23a, 23b	17, 20, 21, 23, 24 17, 20, 21, 23, 24	24 24
23	28.3, CH ₂	a: 2.12 b: 2.06	22a, 22b, 23b, 24 22a, 22b, 23a, 24	20, 22, 24, 25 20, 22, 24, 25	
24	122.9, CH	5.09, br t (7.1)	23a, 23b, 26, 27	23, 26, 27	22a, 22b, 26
25	132.7, C				
26	25.7, CH ₃	1.68, br s	24	24, 25, 27	24
27	17.7, CH ₃	1.60, br s	24	24, 25, 26	
28	13.9, CH ₃	0.99, d (6.8)	4	3, 4, 5	3, 5, 6a, 6b
30	17.6, CH ₃	1.11, s		7, 8, 9, 14	5, 11b, 13, 15a
16-COCH ₃	170.6, C			16-COCH ₃	
16-COCH ₃	20.6, CH ₃	1.95, s			

^aThe indiscernible signals from overlap or the complex multiplicity are reported without designating multiplicity.

Table S28 NMR data for **35** (¹H for 600 MHz and ¹³C for 150 MHz in CD₃OD).**35**


Position	δ_{C} , type	δ_{H} (<i>J</i> in Hz) ^a	¹ H- ¹ H COSY	HMBC	ROESY
1	84.7, CH	3.36, dd (9.5, 7.2)	2a, 2b	5, 19	11, 19
2	42.1, CH ₂	a: 2.94, dd (12.4, 9.5)	1, 2b	1, 3	5
		b: 2.59, dd (12.4, 7.2)	1, 2a	1, 3, 4, 10	
3	217.2, C				
4	46.9, CH	2.22	5, 28	3, 5, 6, 28	6, 19
5	43.6, CH	2.69, t (11.4)	4, 6	1, 3, 4, 6, 10, 19, 28	2a, 7, 28, 30
6	81.9, CH	3.78, br d (11.4)	5, 7	4, 5, 7, 8	4, 9, 19
7	86.1, CH	3.60, br s	6	5, 6, 8, 9, 14, 30	5, 15a, 15b, 30
8	42.1, C				
9	47.1, CH	2.45, d (5.5)	11	1, 7, 8, 10, 14, 19, 30	6, 18, 19
10	44.2, C				
11	78.5, CH	4.11, br dd (7.7, 5.7)	9, 12a, 12b	8, 13	1, 19
12	28.7, CH ₂	a: 2.52	11, 12b, 13	9, 11, 13, 14	
		b: 2.26	11, 12a, 13	11, 13, 17	18
13	45.9, CH	2.97, dd (12.1, 5.8)	12a, 12b	8, 12, 14, 17, 18, 20	16, 30
14	50.7, C				
15	39.0, CH ₂	a: 2.30	15b, 16	8, 14, 18	7, 30
		b: 1.46, br d (14.6)	15a, 16	13, 14, 16, 17, 18	7, 18
16	76.7, CH	5.86, br d (8.7)	15a, 15b	13, 14, 17, 20, 16-COCH ₃	13
17	145.5, C				
18	18.9, CH ₃	1.16, s		8, 13, 14, 15	9, 12b, 15b
19	22.7, CH ₃	0.93, s		1, 5, 9, 10	1, 4, 6, 9, 11
20	134.0, C				
21	174.9, C				
22	30.4, CH ₂	a: 2.54	22b, 23	17, 20, 21, 23, 24	24
		b: 2.37	22a, 23	17, 20, 21, 23, 24	24
23	28.8, CH ₂	2.11	22a, 22b, 24	22, 24, 25	
24	124.4, CH	5.14, br t (7.3)	23, 26, 27	23, 26, 27	22a, 22b, 26
25	133.4, C				
26	25.9, CH ₃	1.67, br s	24	24, 25, 27	24
27	17.8, CH ₃	1.61, br s	24	24, 25, 26	
28	18.5, CH ₃	1.28, d (7.1)	4	3, 4, 5	5
30	21.1, CH ₃	1.32, s		7, 8, 9, 14	5, 7, 13, 15a
16-COCH ₃	172.6, C				
16-COCH ₃	20.7, CH ₃	1.98, s		16-COCH ₃	

^aThe indiscernible signals from overlap or the complex multiplicity are reported without designating multiplicity.

Table S29 NMR data for **36** (¹H for 600 MHz and ¹³C for 150 MHz in CD₃OD).**36**


Position	δ_{C} , type	δ_{H} (<i>J</i> in Hz) ^a	¹ H– ¹ H COSY	HMBC	ROESY
1	163.9, CH	7.86, d (10.2)	2	3, 5, 9, 10	11, 19
2	126.1, CH	5.77, d (10.2)	1	4, 10	
3	205.6, C				
4	45.3, CH	2.65	5, 28	3, 5, 6, 10, 28	6, 19
5	50.9, CH	2.44, dd (11.8, 9.8)	4, 6	1, 3, 6, 7, 10, 19, 28	28, 30
6	69.5, CH	3.90	5, 7a, 7b	8, 10	4, 9, 19, 28
7	45.0, CH ₂	a: 2.09 b: 1.28	6, 7b 6, 7a	5, 6, 8, 14, 30 6	9, 18
8	40.3, C				
9	50.6, CH	1.68, br s	11	1, 8, 10, 11, 14, 19, 30	6, 7a, 12b, 18, 19
10	40.4, C				
11	67.4, CH	4.42, br s	9, 12a, 12b	8, 13	1, 19
12	36.8, CH ₂	a: 2.39 b: 1.94	11, 12b, 13 11, 12a, 13	13	9, 18
13	44.2, CH	3.08, br d (12.4)	12a, 12b	14, 17	15a, 16, 30
14	49.6, C				
15	40.1, CH ₂	a: 2.17 b: 1.29	15b, 16 15a, 16	8, 14, 18 13, 14, 16, 17, 18	13 18
16	75.7, CH	5.82, br d (8.4)	15a, 15b	14, 17, 20, 16-COCH ₃	13
17	146.6, C				
18	17.9, CH ₃	0.96, s		8, 13, 14, 15	7a, 9, 12b, 15b
19	28.6, CH ₃	1.22, s		1, 5, 9, 10	1, 4, 6, 9, 11
20	134.1, C				
21	175.1, C				
22	30.1, CH ₂	a: 2.57 b: 2.38	22b, 23 22a, 23	17, 20, 21, 23, 24 17, 20, 21, 23, 24	24 24
23	29.2, CH ₂	2.12	22a, 22b, 24	22, 24, 25	
24	124.5, CH	5.15, br t (7.0)	23, 26, 27	23, 26, 27	22a, 22b, 26
25	133.3, C				
26	25.9, CH ₃	1.67, br s	24	24, 25, 27	24
27	17.9, CH ₃	1.61, br s	24	24, 25, 26	
28	15.8, CH ₃	1.32, d (6.8)	4	3, 4, 5	5, 6
30	23.6, CH ₃	1.35, s		7, 8, 9, 14	5, 13
16-COCH ₃	172.7, C				
16-COCH ₃	20.7, CH ₃	1.97, s		16-COCH ₃	

^aThe indiscernible signals due to overlap or the complex multiplicity are reported without designating multiplicity.

Table S30 NMR data for **37** (¹H for 600 MHz and ¹³C for 150 MHz in CD₃OD).**37**


Position	δ_{C} , type	δ_{H} (J in Hz) ^a	¹ H- ¹ H COSY	HMBC	ROESY
1	163.9, CH	7.55, d (10.4)	2	2, 3, 5, 9, 10, 19	11, 19
2	125.9, CH	5.76, d (10.3)	1	10	
3	204.1, C				
4	44.8, CH	2.33	5, 28	3, 5, 6, 10, 28	19
5	43.3, CH	2.68, td (12.3, 7.6)	4, 6a, 6b	1, 3, 4, 6, 9, 10, 19, 28	28, 30
6	34.8, CH ₂	a: 1.91 b: 1.64	5, 6b, 7 5, 6a, 7	4, 5, 7, 8 5, 7, 10	28
7	71.0, CH	3.90, t (7.6)	6a, 6b	6, 8, 9, 14, 30	9, 18, 19
8	46.0, C				
9	51.2, CH	1.69, d (2.1)	11	1, 5, 7, 8, 10, 11, 14, 19, 30	7, 12b, 18, 19
10	39.5, C				
11	67.5, CH	4.45, br s	9, 12a, 12b	8, 9, 10, 13	1, 19
12	36.4, CH ₂	a: 2.39 b: 1.96	11, 12b, 13 11, 12a, 13	9, 11, 14 13	9, 18, 22a
13	44.9, CH	3.02, br d (12.4)	12a, 12b	12, 14, 17, 18, 20	15a, 16, 30
14	49.5, C				
15	43.1, CH ₂	a: 2.28, dd (15.1, 8.8) b: 1.60	15b, 16 15a, 16	8, 14, 18 13, 14, 16, 17, 18	13, 30 18
16	76.0, CH	5.77, br d (8.3)	15a, 15b	13, 14, 17, 20, 16-COCH ₃	13
17	146.9, C				
18	16.8, CH ₃	1.01, s		8, 13, 14, 15	7, 9, 12b, 15b
19	27.3, CH ₃	1.19, s		1, 5, 9, 10	1, 4, 7, 9, 11
20	132.8, C				
21	174.7, C				
22	30.0, CH ₂	a: 2.59 b: 2.38	22b, 23 22a, 23	17, 20, 21, 23, 24 17, 20, 21, 23, 24	12b, 24 24
23	29.3, CH ₂	2.12	22a, 22b, 24	22, 24, 25	
24	124.4, CH	5.14, br t (7.0)	23, 26, 27	23, 26, 27	22a, 22b, 26
25	133.4, C				
26	25.9, CH ₃	1.67, br s	24	24, 25, 27	24
27	17.9, CH ₃	1.61, br s	24	24, 25, 26	
28	12.6, CH ₃	1.09, d (6.7)	4	3, 4, 5	5, 6b
30	15.0, CH ₃	1.25, s		7, 8, 9, 14	5, 13, 15a
16-COCH ₃	172.6, C				
16-COCH ₃	20.7, CH ₃	1.95, s		16-COCH ₃	

^aThe indiscernible signals due to overlap or the complex multiplicity are reported without designating multiplicity

Table S31 NMR data for **38** (¹H for 400 MHz and ¹³C for 100 MHz in CD₃OD).**38**


Position	δ_{C} , type	δ_{H} (<i>J</i> in Hz) ^a	¹ H- ¹ H COSY	HMBC	ROESY
1	83.8, CH	3.44, dd (8.8, 7.5)	2a, 2b	5, 10, 19	11, 19
2	42.9, CH ₂	a: 2.91	1, 2b	1, 3	
		b: 2.62	1, 2a	1, 3, 10	
3	216.6, C				
4	45.2 ^b , CH	1.91	5, 28	3, 5, 28	19
5	37.1, CH	2.86	4, 6a, 6b		28, 30
6	33.4, CH ₂	a: 2.00	5, 6b, 7	5, 8	
		b: 1.54	5, 6a, 7		
7	71.5, CH	3.88, dd (9.0, 3.9)	6a, 6b	8, 30	9, 18
8	43.2, C				
9	52.5, CH	1.69	11	7, 19	7, 18, 19
10	43.8, C				
11	77.9, CH	4.06, br dd (7.0, 5.6)	9, 12a, 12b	8, 10, 13	1, 19
12	28.4, CH ₂	a: 2.56	11, 12b, 13	9, 11, 13, 14	
		b: 2.24, ddd (15.0, 12.4, 7.6)	11, 12a, 13	13	18
13	45.1 ^b , CH	2.93	12a, 12b	17	16, 30
14	49.9, C				
15	41.7, CH ₂	a: 2.40	15b, 16	14, 18	30
		b: 1.49, br d (15.5)	15a, 16	13, 14, 16, 17, 18	
16	76.8, CH	5.83, br d (8.6)	15a, 15b	14, 17, 20, 16-COCH ₃	13
17	144.8, C				
18	16.0, CH ₃	0.96, s		8, 13, 14, 15	7, 9, 12b
19	21.7, CH ₃	0.85, s		1, 5, 9, 10	1, 4, 9, 11
20	133.4, C				
21	174.5				
22	30.4, CH ₂	a: 2.57	22b, 23	17, 23	
		b: 2.38	22a, 23	17, 23	
23	28.8, CH ₂	2.11	22a, 22b, 24	22, 24, 25	
24	124.4, CH	5.15, br t (6.8)	23, 26, 27	23, 26, 27	26
25	133.4, C				
26	25.9, CH ₃	1.67, br s	24	24, 25, 27	24
27	17.8, CH ₃	1.61, br s	24	24, 25, 26	
28	15.5, CH ₃	1.07, d (7.1)	4	3, 4, 5	5
30	18.2, CH ₃	1.38, s		7, 8, 9, 14	5, 13, 15a
16-COCH ₃	172.5, C			16-COCH ₃	
16-COCH ₃	20.7, CH ₃	1.97, s			

^aThe indiscernible signals due to overlap or the complex multiplicity are reported without designating multiplicity.^bThe data are interchangeable.

Table S32 NMR data for **39** (¹H for 600 MHz and ¹³C for 150 MHz in CD₃OD).**39**


Position	δ_{C} , type	δ_{H} (J in Hz) ^a	¹ H- ¹ H COSY	HMBC	ROESY
1	163.8, CH	8.27, d (10.3)	2	3, 5, 9, 10	11
2	127.0, CH	5.79, d (10.3)	1	4, 10	
3	203.7, C				
4	43.1, CH	2.60	5, 28	3, 5, 6, 10, 28	19
5	44.6, CH	2.37	4, 6a, 6b	1, 4, 6, 7, 10, 19	28, 30
6	41.1, CH ₂	a: 2.43 b: 2.31	5, 6b 5, 6a	5, 10, 7 4, 5, 8, 10	19 28
7	219.3, C				
8	54.5, C				
9	47.8, CH	2.02, br s	11	1, 7, 8, 10, 11, 14, 19, 30	18, 19
10	40.5, C				
11	67.4, CH	4.55, br s	9, 12a, 12b	8, 13	1, 19
12	36.5, CH ₂	a: 2.40 b: 1.96	11, 12b, 13 11, 12a, 13	11 13	18, 22a
13	44.6, CH	3.10, br d (11.8)	12a, 12b	12, 14, 17, 18, 20	15a, 16, 30
14	48.3, C				
15	42.0, CH ₂	a: 2.29 b: 1.79, br d (14.8)	15b, 16 15a, 16	14, 18 13, 14, 16, 17, 18	13, 30 18
16	75.5, CH	5.80, br d (8.3)	15a, 15b	14, 17, 20, 16-COCH ₃	13
17	145.2, C				
18	17.6, CH ₃	0.86, s		8, 13, 14, 15	9, 12b, 15b
19	25.8, CH ₃	1.37, s		1, 5, 9, 10	4, 6a, 9, 11
20	134.1, C				
21	175.1, C				
22	30.0, CH ₂	a: 2.56 b: 2.38	22b, 23 22a, 23	17, 20, 21, 23, 24 17, 20, 21, 23, 24	12b, 24 24
23	29.3, CH ₂	2.13	22a, 22b, 24	22, 24, 25	
24	124.4, CH	5.15, br t (7.2)	23, 26, 27	23, 26, 27	22a, 22b, 26
25	133.4, C				
26	25.9, CH ₃	1.67, br s	24	24, 25, 27	24
27	17.9, CH ₃	1.61, br s	24	24, 25, 26	
28	13.1, CH ₃	1.11, d (6.8)	4	3, 4, 5	5, 6b
30	22.5, CH ₃	1.32, s		7, 8, 9, 14	5, 13, 15a
16-COCH ₃	172.6, C				
16-COCH ₃	20.7, CH ₃	1.96, s		16-COCH ₃	

^aThe indiscernible signals from overlap or the complex multiplicity are reported without designating multiplicity.

Table S33 NMR data for **40** (¹H for 400 MHz and ¹³C for 100 MHz in CD₃OD).**40**


Position	δ_c , type	δ_h (<i>J</i> in Hz) ^a	¹ H– ¹ H COSY	HMBC	ROESY
1	84.1, CH	3.46, t (8.0)	2a, 2b	5, 19	11, 19
2	42.9, CH ₂	a: 2.89, dd (13.4, 9.2)	1, 2b	1, 3	
		b: 2.63	1, 2a	3, 10	
3	216.9, C				
4	45.3, CH	1.93	5, 28		19
5	36.9, CH	2.62	4, 6a, 6b	3, 10	28, 30
6	34.0, CH ₂	a: 2.38	5, 6b, 7		
		b: 1.26	5, 6a, 7		
7	73.7, CH	3.93, br d (8.4)	6a, 6b	5, 9, 30	
8	41.8, C				
9	47.0, CH	2.52	11	1, 8, 10, 11, 12, 14, 30	12b, 18, 19
10	43.9, C				
11	78.7, CH	4.14, br t (6.6)	9, 12a, 12b	8, 13	1, 19
12	28.7, CH ₂	a: 2.50	11, 12b, 13		
		b: 2.26	11, 12a, 13		9
13	46.3, CH	2.96, dd (11.7, 5.7)	12a, 12b		30
14	50.8, C				
15	38.9, CH ₂	a: 2.31	15b, 16	18	
		b: 1.47, br d (14.6)	15a, 16	13, 14, 16, 17, 18	
16	76.7, CH	5.86, br d (8.8)	15a, 15b	14, 17, 20, 16- <u>COCH₃</u>	
17	146.6, C				
18	19.0, CH ₃	1.17, s		8, 13, 14, 15	9
19	21.3, CH ₃	0.96, s		1, 5, 9, 10	1, 4, 9, 11
20	133.0, C				
21	174.1, C				
22	30.3, CH ₂	a: 2.54	22b, 23	21	
		b: 2.37	22a, 23		
23	28.8, CH ₂	2.11	22a, 22b, 24	24	
24	124.3, CH	5.14, br t (6.7)	23, 26, 27	23, 26, 27	26
25	133.5, C				
26	25.9, CH ₃	1.67, br s	24	24, 25, 27	24
27	17.8, CH ₃	1.61, br s	24	24, 25, 26	
28	15.5, CH ₃	1.04, d (7.1)	4	3, 4, 5	5
30	22.6, CH ₃	1.25, s		7, 8, 9, 14	5, 13
16- <u>COCH₃</u>	172.5, C				
16- <u>COCH₃</u>	20.7, CH ₃	1.97, s		16- <u>COCH₃</u>	

^aThe indiscernible signals from overlap or the complex multiplicity are reported without designating multiplicity.

Table S34 NMR data for **41** (¹H for 400 MHz and ¹³C for 100 MHz in CD₃OD).**41**


Position	δ_{C} , type	δ_{H} (<i>J</i> in Hz) ^a	¹ H– ¹ H COSY	HMBC	ROESY
1	141.2, CH	6.09, d (10.2)	2	3, 5, 10	11a, 11b, 19
2	127.5, CH	5.55, dd (10.1, 4.4)	1, 3	4, 10	
3	70.4, CH	3.79, t (4.4)	2, 4		28
4	36.0, CH	2.16	3, 5, 28		19
5	43.0, CH	1.90, t (11.2)	4, 6	3, 4, 6, 7, 10, 19	7, 28, 30
6	77.7, CH	3.59, dd (10.8, 4.5)	5, 7		9, 19, 28
7	85.9, CH	3.51, d (4.6)	6	5, 9	5, 30
8	45.6, C				
9	42.9, CH	2.05	11a, 11b	1, 8, 10, 19, 30	6, 18, 19
10	40.6, C				
11	26.1, CH ₂	a: 1.83 b: 1.42, qd (13.3, 4.3)	9, 11b, 12a, 12b 9, 11a, 12a, 12b		1, 19 1, 30
12	27.4, CH ₂	a: 2.27 b: 1.72	11a, 11b, 12b, 13 11a, 11b, 12a, 13		18
13	50.7, CH	2.61	12a, 12b	14, 17, 18	16, 30
14	49.6, C				
15	41.3, CH ₂	a: 2.15 b: 1.61	15b, 16 15a, 16	18 13, 16, 17	30 18
16	76.0, CH	5.78, br d (8.6)	15a, 15b	14, 17, 20, 16-COCH ₃	13
17	146.8, C				
18	21.5, CH ₃	1.19, s		8, 13, 14, 15	9, 12b, 15b
19	27.5, CH ₃	1.11, s		1, 5, 9, 10	1, 4, 6, 9, 11a
20	133.5, C				
21	175.3, C				
22	29.9, CH ₂	a: 2.54 b: 2.35	22b, 23 22a, 23		24 24
23	29.1, CH ₂	2.09	22a, 22b, 24	24, 25	
24	124.6, CH	5.13, br t (7.2)	23, 26, 27	26, 27	22a, 22b, 26
25	133.1, C				
26	25.9, CH ₃	1.67, br s	24	24, 25, 27	24
27	17.8, CH ₃	1.61, br s	24	24, 25, 26	
28	17.0, CH ₃	1.19, d (6.4)	4	3, 4, 5	3, 5, 6
30	19.6, CH ₃	1.08, s		7, 8, 9, 14	5, 7, 11b, 13, 15a
16-COCH ₃	172.8, C				
16-COCH ₃	20.8, CH ₃	1.96, s		16-COCH ₃	

^aThe indiscernible signals from overlap or the complex multiplicity are reported without designating multiplicity.

Table S35 NMR data for **42** (¹H for 600 MHz and ¹³C for 150 MHz in CD₃OD).**42**

Position	δ_{C} , type	δ_{H} (J in Hz) ^a	¹ H- ¹ H COSY	HMBC	ROESY
1	138.4, CH	6.16, d (10.1)	2	3, 5, 9, 10	11a, 11b, 19
2	129.1, CH	5.67, dd (10.1, 4.4)	1, 3	3, 4, 10	
3	67.9, CH	3.90, t (4.6)	2, 4	1, 2, 5	28
4	31.1, CH	2.22	3, 5, 28	5, 10, 28	19
5	53.4, CH	3.35, d (11.9)	4	1, 3, 4, 6, 10, 19	28, 30
6	216.1, C				
7	52.8, CH ₂	a: 2.46, d (17.6) b: 2.18, d (17.6)	7b 7a	5, 6, 8, 14, 30 6, 8, 9, 30	9, 18 30
8	43.2, C				
9	47.5, CH	1.64, dd (13.1, 3.2)	11a, 11b	8, 10, 19, 30	7a, 18, 19
10	43.3, C				
11	26.7, CH ₂	a: 1.87, dq (13.3, 3.0) b: 1.45, qd (13.0, 4.1)	9, 11b, 12a, 12b 9, 11a, 12a, 12b		1, 19 1, 13
12	27.0, CH ₂	a: 2.36 b: 1.69	11a, 11b, 12b, 13 11a, 11b, 12a, 13	11, 13, 14	18, 22a
13	49.6, CH	2.66, br d (10.9)	12a, 12b	12, 14, 17, 18, 20	11b, 15a, 16, 30
14	49.5, C				
15	40.2, CH ₂	a: 2.11 b: 1.24, br d (14.2)	15b, 16 15a, 16	8, 13, 14, 18 14, 16, 17, 18	13, 30 18
16	75.4, CH	5.80, br d (8.5)	15a, 15b	13, 14, 17, 20, 16-COCH ₃	13
17	146.3, C				
18	19.0, CH ₃	0.97, s		8, 13, 14, 15	7a, 9, 12b, 15b
19	28.4, CH ₃	0.93, s		1, 5, 9, 10	1, 4, 9, 11a
20	133.8, C				
21	174.7, C				
22	29.9, CH ₂	a: 2.55 b: 2.36	22b, 23 22a, 23	17, 20, 21, 23, 24 17, 20, 21, 23, 24	12b, 24 24
23	29.1, CH ₂	2.10	22a, 22b, 24	22, 24, 25	
24	124.4, CH	5.13, br t (7.3)	23, 26, 27	23, 26, 27	22a, 22b, 26
25	133.3, C				
26	25.9, CH ₃	1.67, br s	24	24, 25, 27	24
27	17.8, CH ₃	1.61, br s	24	24, 25, 26	
28	14.1, CH ₃	1.07, d (6.7)	4	3, 4, 5	3, 5
30	21.1, CH ₃	1.39, s		7, 8, 9, 14	5, 7b, 13, 15a
16-COCH ₃	172.6, C			16-COCH ₃	
16-COCH ₃	20.7, CH ₃	1.96, s			


^aThe indiscernible signals from overlap or the complex multiplicity are reported without designating multiplicity.

Table S36 NMR data for **43** (^1H for 600 MHz and ^{13}C for 150 MHz in CD_3OD).**43**

Position	δ_{C} , type	δ_{H} (J in Hz) ^a	^1H - ^1H COSY	HMBC	ROESY
1	141.3, CH	6.14, d (10.1)	2	3, 5, 9, 10, 19	11a, 11b, 19
2	128.3, CH	5.53, dd (10.0, 4.2)	1, 3	3, 4, 10	
3	69.1, CH	3.88, t (4.5)	2, 4	1, 2, 4, 5	28
4	34.3, CH	1.99	3, 5, 28	5, 10, 28	19
5	38.5, CH	1.74	4. 6a, 6b	1, 3, 4, 6, 7, 10, 19	7, 30
6	32.3, CH ₂	a: 1.89 b: 1.24, td (12.6, 9.6)	5, 6b, 7 5, 6a, 7	4, 7, 8, 10 5, 7, 10	
7	81.3, CH	3.78, dd (9.2, 6.9)	6a, 6b	5, 6, 8, 9, 30	5, 30
8	46.4, C				
9	44.6, CH	1.93	11a, 11b	1, 8, 10, 11, 19, 30	18, 19
10	39.4, C				
11	25.9, CH ₂	a: 1.77 b: 1.47	9, 11b, 12a, 12b 9, 11a, 12a, 12b	9, 12	1 1, 13
12	27.4, CH ₂	a: 2.30 b: 1.74	11a, 11b, 12b, 13 11a, 11b, 12a, 13	9, 11, 13, 14	
13	51.5, CH	2.60, br d (11.5)	12a, 12b	12, 14, 17, 18, 20	11b, 15a, 16, 30
14	49.5, C				
15	41.7, CH ₂	a: 2.15, dd (14.5, 8.8) b: 1.72	15b, 16 15a, 16	8, 14, 16, 18 13, 14, 16, 17, 18	13, 30 18
16	76.0, CH	5.78, br d (8.5)	15a, 15b	13, 14, 17, 20, 16-COCH ₃	13
17	147.2, C				
18	21.3, CH ₃	1.18, s		8, 13, 14, 15	9, 15b
19	26.6, CH ₃	1.01, s		1, 5, 9, 10	1, 4, 9
20	133.0, C				
21	174.8, C				
22	29.8, CH ₂	a: 2.56 b: 2.35	22b, 23 22a, 23	17, 20, 21, 23, 24 17, 20, 21, 23, 24	24 24
23	29.1, CH ₂	2.10	22a, 22b, 24	22, 24, 25	
24	124.5, CH	5.13, br t (7.3)	23, 26, 27	23, 26, 27	22a, 22b, 26
25	133.2, C				
26	25.9, CH ₃	1.67, br s	24	24, 25, 27	24
27	17.8, CH ₃	1.61, br s	24	24, 25, 26	
28	14.7, CH ₃	0.96, d (7.0)	4	3, 4, 5	3
30	21.8, CH ₃	1.03, s		7, 8, 9, 14	5, 7, 13, 15a
16-COCH ₃	172.8, C				
16-COCH ₃	20.8, CH ₃	1.95, s		16-COCH ₃	

^aThe indiscernible signals from overlap or the complex multiplicity are reported without designating multiplicity.


Table S37 NMR data for **44** (¹H for 600 MHz and ¹³C for 150 MHz in CDCl₃).



44


Position	δ_{C} , type	δ_{H} (J in Hz) ^a	¹ H- ¹ H COSY	HMBC	NOESY
1	158.0, CH	7.25, d (10.3)	2	3, 5, 9, 10	11a, 19
2	126.9, CH	5.86, d (10.3)	1	4, 10	
3	201.2, C				
4	43.2, CH	2.64, dq (12.6, 6.7)	5, 28	3, 5, 6, 10, 28	19
5	45.8, CH	2.40, t (11.7)	4, 6	1, 3, 4, 6, 10, 19, 28	7, 28, 30
6	80.1, CH	4.78, dd (10.8, 2.5)	5, 7	4, 5, 7, 6-COCH ₃	19, 28
7	80.7, CH	3.59, d (2.0)	6	5, 6, 8, 9, 14, 30	5, 30
8	43.4, C				
9	40.7, CH	2.32	11a, 11b	1, 7, 8, 10, 11, 12, 14, 19, 30	18, 19
10	39.1, C				
11	25.4, CH ₂	a: 1.99 b: 1.45, qd (13.0, 3.8)	9, 11b, 12a, 12b 9, 11a, 12a, 12b	12, 13	1 30
12	25.5, CH ₂	a: 2.31 b: 1.81, qd (12.5, 3.8)	11a, 11b, 12b, 13 11a, 11b, 12a, 13	11, 13	18
13	49.7, CH	2.57, br d (11.2)	12a, 12b	11, 14, 17, 18, 20	30
14	48.4, C				
15	39.9, CH ₂	a: 2.16 b: 1.56, br d (14.4)	15b, 16 15a, 16	8, 14, 16, 18 13, 14, 16, 17, 18	30 18
16	74.2, CH	5.85, br d (8.2)	15a, 15b	14, 17, 20, 16-COCH ₃	
17	149.6, C				
18	21.4, CH ₃	1.21, s		8, 13, 14, 15	9, 12b, 15b
19	26.5, CH ₃	1.38, s		1, 5, 9, 10	1, 4, 6, 9
20	130.3, C				
21	173.6, C				
22	28.7, CH ₂	a: 2.49 b: 2.43	22b, 23a, 23b 22a, 23a, 23b	17, 20, 21, 23, 24 17, 20, 21, 23, 24	24 24
23	28.2, CH ₂	a: 2.13 b: 2.06	22a, 22b, 23b, 24 22a, 22b, 23a, 24	20, 22, 24, 25 20, 22, 24, 25	
24	122.9, CH	5.10, br t (6.8)	23a, 23b, 26, 27	26, 27	22a, 22b, 26
25	132.7, C				
26	25.7, CH ₃	1.68, br s	24	24, 25, 27	24
27	17.7, CH ₃	1.60, br s	24	24, 25, 26	
28	14.4, CH ₃	1.13, d (6.8)	4	3, 4, 5	5, 6
30	18.2, CH ₃	1.00, s		7, 8, 9, 14	5, 7, 11b, 13, 15a
6-COCH ₃	171.5, C				
6-COCH ₃	21.5, CH ₃	2.10, s		6-COCH ₃	
16-COCH ₃	170.7, C				
16-COCH ₃	20.6, CH ₃	1.96, s		16-COCH ₃	

^a The indiscernible signals from overlap or the complex multiplicity are reported without designating multiplicity.

Table S38 NMR data for **45** (¹H for 600 MHz and ¹³C for 150 MHz in CDCl₃).**45**


Position	δ_{C} , type	δ_{H} (<i>J</i> in Hz) ^a	¹ H- ¹ H COSY	HMBC	ROESY
1	157.5, CH	7.25, d (10.2)	2	3, 5, 9, 10	11a, 11b, 19
2	127.3, CH	5.86, d (10.2)	1	4, 10	
3	202.0, C				
4	43.8, CH	2.63	5, 28	3, 5, 6, 10, 28	6, 19
5	48.1, CH	2.25, t (11.2)	4, 6	1, 3, 4, 6, 7, 10, 28	7, 28, 30
6	75.3, CH	3.66, dd (10.4, 2.4)	5, 7	4, 5, 7, 8	4, 19, 28
7	83.8, CH	4.67, d (2.2)	6	5, 6, 8, 9, 14, 30, 7-COCH ₃	5, 15a, 15b, 30
8	42.5, C				
9	41.6, CH	2.23	11a, 11b	1, 8, 10, 11, 12, 14, 30	12b, 18, 19
10	38.7, C				
11	25.5, CH ₂	a: 1.99 b: 1.47, qd (13.4, 4.5)	9, 11b, 12a, 12b 9, 11a, 12a, 12b	9, 12	1, 19 1, 13, 30
12	25.6, CH ₂	a: 2.35, br d (11.5) b: 1.76, qd (12.5, 3.9)	11a, 11b, 12b, 13 11a, 11b, 12a, 13	9, 14 13	9, 18
13	49.5, CH	2.59	12a, 12b	12, 17, 18, 20	11b, 16, 30
14	48.1, C				
15	39.9, CH ₂	a: 2.18 b: 1.29	15b, 16 15a, 16	8, 14, 18 13, 16, 17, 18	7, 30 7
16	73.8, CH	5.88, br d (8.3)	15a, 15b	14, 17, 20, 16-COCH ₃	13
17	148.5, C				
18	21.2, CH ₃	1.08, s		8, 13, 14, 15	9, 12b
19	22.1, CH ₃	1.26, s		1, 5, 9, 10	1, 4, 6, 9, 11a
20	130.9, C				
21	173.5, C				
22	28.7, CH ₂	a: 2.49 b: 2.43	22b, 23a, 23b 22a, 23a, 23b	17, 20, 21, 23, 24 17, 20, 21, 23, 24	24 24
23	28.2, CH ₂	a: 2.14 b: 2.07	22a, 22b, 23b, 24 22a, 22b, 23a, 24	22, 24, 25 22, 24, 25	
24	122.9, CH	5.10, br t (6.8)	23a, 23b, 26, 27	23, 26, 27	22a, 22b, 26
25	132.8, C				
26	25.7, CH ₃	1.68, br s	24	24, 25, 27	24
27	17.8, CH ₃	1.60, br s	24	24, 25, 26	
28	15.3, CH ₃	1.33, d (6.8)	4	3, 4, 5	5, 6
30	17.4, CH ₃	1.14, s		7, 8, 9, 14	5, 7, 11b, 13, 15a
7-COCH ₃	170.9, C				
7-COCH ₃	21.8, CH ₃	2.09, s		7-COCH ₃	
16-COCH ₃	170.6, C				
16-COCH ₃	20.5, CH ₃	1.97, s		16-COCH ₃	

^a The indiscernible signals from overlap or the complex multiplicity are reported without designating multiplicity.

Table S39 NMR data for **46** (¹H for 600 MHz and ¹³C for 150 MHz in CDCl₃).**46**


Position	δ_{C} , type	δ_{H} (J in Hz) ^a	¹ H– ¹ H COSY	HMBC	NOESY
1	158.5, CH	7.27, d (10.1)	2	3, 5, 10	19
2	127.6, CH	5.84, d (10.1)	1	4, 10	
3	201.7, C				
4	42.7, CH	2.39	5, 28	3, 5, 10, 28	19
5	43.1, CH	2.09	4, 6a, 6b	4, 6, 7, 9, 10, 19	28, 30
6	29.7, CH ₂	a: 2.15 b: 1.33	5, 6b, 7 5, 6a, 7	5, 7, 10 4, 7, 10	
7	77.5, CH	4.96, t (6.8)	6a, 6b	6, 9, 14, 30, 7-COCH ₃	30
8	43.6, C				
9	42.7, CH	2.19	11a, 11b	7, 8, 10, 11, 12, 19, 30	18
10	38.7, C				
11	24.9, CH ₂	a: 1.92 b: 1.48	9, 11b, 12a, 12b 9, 11a, 12a, 12b	9, 12	19 30
12	25.7, CH ₂	a: 2.35 b: 1.79	11a, 11b, 12b, 13 11a, 11a, 12b, 13	13	18
13	50.3, CH	2.57, br d (11.9)	12a, 12b	11, 14, 17, 18, 20	30
14	48.0, C				
15	40.3, CH ₂	a: 2.14 b: 1.33	15b, 16 15a, 16	8, 14, 18 13, 14, 16, 17, 18	
16	73.9, CH	5.87, br d (8.5)	15a, 15b	14, 17, 20, 16-COCH ₃	
17	148.4, C				
18	21.1, CH ₃	1.14, s		8, 13, 14, 15	9, 12b
19	25.6, CH ₃	1.25, s		1, 5, 9, 10	1, 4, 11a
20	130.7, C				
21	173.4, C				
22	28.7, CH ₂	a: 2.50 b: 2.43	22b, 23a, 23b 22a, 23a, 23b	17, 20, 21, 24 17, 20, 21, 24	
23	28.2, CH ₂	a: 2.14 b: 2.07	22a, 22b, 23b, 24 22a, 22b, 23a, 24	20, 24, 25 20, 24, 25	
24	122.9, CH	5.10, br t (6.7)	23a, 23b, 26, 27	26, 27	26
25	132.8, C				
26	25.7, CH ₃	1.68, br s	24	24, 25, 27	24
27	17.8, CH ₃	1.60, br s	24	24, 25, 26	
28	12.7, CH ₃	1.12, d (6.8)	4	3, 4, 5	5
30	20.2, CH ₃	1.05, s		7, 8, 9, 14	5, 7, 11b, 13
7-COCH ₃	169.7, C				
7-COCH ₃	21.9, CH ₃	2.02, s		7-COCH ₃	
16-COCH ₃	170.5, C				
16-COCH ₃	20.5, CH ₃	1.96, s		16-COCH ₃	

^aThe indiscernible signals from overlap or the complex multiplicity are reported without designating multiplicity.

Table S40 NMR data for **47** (¹H for 600 MHz and ¹³C for 150 MHz in CD₃OD).**47**


Position	δ_{C} , type	δ_{H} (<i>J</i> in Hz) ^a	¹ H- ¹ H COSY	HMBC	ROESY
1	32.3, CH ₂	a: 2.39 b: 1.49	1b, 2a, 2b 1a, 2a, 2b	2, 10, 19 2, 3, 5, 10	11 11
2	31.0, CH ₂	a: 1.91 b: 1.68	1a, 1b, 2b, 3 1a, 1b, 2a, 3	1, 4 4	
3	73.5, CH	3.64	2a, 2b, 4	1, 5, 28	
4	38.5, CH	1.87	3, 5, 28	5, 28	6, 19
5	44.2, CH	2.10	4, 6	1, 3, 4, 6, 7, 9, 10, 19, 28	28, 30
6	79.4, CH	3.46, dd (9.4, 2.0)	5, 7	4, 5, 7, 8	4, 19, 28
7	83.8, CH	3.44, d (2.0)	6	5, 6, 8, 9, 14, 30	15a, 15b, 30
8	45.1, C				
9	46.7, CH	2.00, d (2.0)	11	1, 7, 8, 10, 11, 14, 19, 30	18, 19
10	38.3, C				
11	68.9, CH	4.36	9, 12a, 12b	8, 13	1a, 1b, 19
12	37.3, CH ₂	a: 2.29, dt (13.0, 3.0) b: 1.90	11, 12b, 13 11, 12a, 13	11, 13, 14 9, 13	
13	46.3, CH	3.11, br d (11.5)	12a, 12b	12, 14, 17, 18, 20	15a, 30
14	49.8, C				
15	40.6, CH ₂	a: 2.20, dd (14.1, 8.6) b: 1.45, br d (14.2)	15b, 16 15a, 16	8, 14, 16, 18 13, 14, 16, 17, 18	7, 13, 30 7, 18
16	76.0, CH	5.81, br d (8.6)	15a, 15b	13, 14, 15, 17, 20, 16-COCH ₃	
17	148.6, C				
18	21.8, CH ₃	1.15, s		8, 13, 14, 15	9, 15b
19	24.2, CH ₃	1.20, s		1, 5, 9, 10	4, 6, 9, 11
20	132.8, C				
21	174.6, C				
22	30.0, CH ₂	a: 2.53 b: 2.35	22b, 23 22a, 23	17, 20, 21, 23, 24 17, 20, 21, 23, 24	
23	29.3, CH ₂	2.10	22a, 22b, 24	22, 24, 25	
24	124.5, CH	5.13, br t (7.3)	23, 26, 27	23, 26, 27	26
25	133.3, C				
26	25.9, CH ₃	1.66, br s	24	24, 25, 27	24
27	17.9, CH ₃	1.60, br s	24	24, 25, 26	
28	18.5, CH ₃	1.10, br d (7.0)	4	3, 4, 5	5, 6
30	22.0, CH ₃	1.36, s		7, 8, 9, 14	5, 7, 13, 15a
16-COCH ₃	172.8, C				
16-COCH ₃	20.7, CH ₃	1.96, s		16-COCH ₃	

^aThe indiscernible signals from overlap or the complex multiplicity are reported without designating multiplicity.

Table S41 NMR data for **48** (¹H for 600 MHz and ¹³C for 150 MHz in CD₃OD).**48**

Position	δ_c , type	δ_h (<i>J</i> in Hz) ^a	¹ H– ¹ H COSY	HMBC	ROESY
1	31.2, CH ₂	a: 2.32	1b, 2a, 2b	2, 10, 19	
		b: 1.48	1a, 2a, 2b	2, 3, 9, 10	11
2	30.8, CH ₂	a: 1.84	1a, 1b, 2b, 3	1	
		b: 1.69	1a, 1b, 2a, 3	3, 4, 10	
3	73.4, CH	3.64	2a, 2b, 4	1, 5, 28	28
4	38.9, CH	1.78	3, 5, 28	5, 28	6
5	43.9, CH	2.20, dd (11.9, 9.5)	4, 6	1, 3, 4, 6, 10, 19	28, 30
6	70.5, CH	3.73, br dd (9.4, 6.7)	5, 7a, 7b	4, 5, 7, 8, 10	4, 19, 28
7	43.6, CH ₂	a: 1.95	6, 7b	5, 6, 8, 9, 14, 30	
		b: 1.25	6, 7a	6, 8, 9, 14, 30	
8	40.4, C				
9	51.7, CH	1.57, d (1.3)	11	1, 8, 10, 11, 12, 14, 19, 30	18, 19
10	37.6, C				
11	68.3, CH	4.33	9, 12a, 12b	8, 9, 13	1b, 19
12	37.3, CH ₂	a: 2.30	11, 12b, 13	11, 13, 14	
		b: 1.85	11, 12a, 13	13, 14	
13	44.4, CH	3.09, br d (11.6)	12a, 12b	12, 14, 17, 18, 20	15a, 16, 30
14	49.4, C				
15	39.9, CH ₂	a: 2.18	15b, 16	8, 14, 18	13, 30
		b: 1.25	15a, 16	8, 13, 14, 16, 17, 18	18
16	75.6, CH	5.80, br d (8.6)	15a, 15b	13, 14, 17, 20, 16-COCH ₃	13
17	148.4, C				
18	17.6, CH ₃	0.91, s		8, 13, 14, 15	9, 15b
19	25.9, CH ₃	0.99, s		1, 5, 9, 10	6, 9, 11
20	132.2, C				
21	174.3, C				
22	29.8, CH ₂	a: 2.53	22b, 23a, 23b	17, 20, 21, 23, 24	24
		b: 2.35	22a, 23a, 23b	17, 20, 21, 23, 24	24
23	29.3, CH ₂	a: 2.12	22a, 22b, 23b, 24	20, 22, 24, 25	
		b: 2.06	22a, 22b, 23a, 24	20, 22, 24, 25	
24	124.3, CH	5.12, br t (7.3)	23, 26, 27	23, 26, 27	22a, 22b, 26
25	133.3, C				
26	26.0, CH ₃	1.66, br s	24	24, 25, 27	24
27	17.9, CH ₃	1.60, br s	24	24, 25, 26	
28	18.6, CH ₃	1.12, d (7.0)	4	3, 4, 5	3, 5, 6
30	23.1, CH ₃	1.44, s		7, 8, 9, 14	5, 13, 15a
16-COCH ₃	172.5, C				
16-COCH ₃	20.7, CH ₃	1.96, s		16-COCH ₃	


^aThe indiscernible signals from overlap or the complex multiplicity are reported without designating multiplicity.

Table S42 NMR data for **49** (¹H for 600 MHz and ¹³C for 150 MHz in CD₃OD).**49**

Position	δ_{C} , type	δ_{H} (J in Hz) ^a	¹ H– ¹ H COSY	HMBC	ROESY
1	31.8, CH ₂	a: 2.21	1b, 2a, 2b	2, 3, 9, 10, 19	
		b: 1.50	1a, 2a, 2b	2, 3, 5	11
2	31.2, CH ₂	a: 1.88	1a, 1b, 2b, 3		
		b: 1.68	1a, 1b, 2a, 3	3	
3	72.4, CH	3.68	2a, 2b, 4	1, 5	28
4	36.8, CH	1.65	3, 5, 28	5, 28	19
5	38.0, CH	1.94	4, 6a, 6b	1, 3, 4, 6, 7, 10, 19	7, 28, 30
6	34.0, CH ₂	a: 1.82, ddd (13.4, 6.7, 3.6)	5, 6b, 7	5, 7	28
		b: 1.14, td (12.4, 7.6)	5, 6a, 7	5, 7, 8	
7	80.9, CH	3.67	6a, 6b	5, 6, 9, 30	5, 30
8	47.0, C				
9	48.5, CH	1.87, d (1.9)	11	1, 8, 10, 11, 14, 19, 30	18, 19
10	38.4, C				
11	68.8, CH	4.30	9, 12a, 12b	8, 13	1b, 19
12	37.4, CH ₂	a: 2.30, dt (12.9, 2.8)	11, 12b, 13	11, 13, 14	
		b: 1.90	11, 12a, 13	13	22a
13	47.3, CH	3.04, br d (11.4)	12a, 12b	12, 14, 17, 18, 20	15a, 16, 30
14	49.9, C				
15	41.5, CH ₂	a: 2.22	15b, 16	8, 14, 16, 18	13, 30
		b: 1.65	15a, 16	13, 14, 16, 17, 18	18
16	76.1, CH	5.81, br d (8.5)	15a, 15b	13, 14, 17, 20, 16-COCH ₃	13
17	148.3, C				
18	21.3, CH ₃	1.16, s		8, 13, 14, 15	9, 15b
19	22.0, CH ₃	1.09, s		1, 5, 9, 10	4, 9, 11
20	132.9, C				
21	174.7, C				
22	30.0, CH ₂	a: 2.54	22b, 23	17, 20, 21, 23, 24	12b, 24
		b: 2.35	22a, 23	17, 20, 21, 23, 24	24
23	29.3, CH ₂	2.10	22a, 22b, 24	22, 24, 25	
24	124.5, CH	5.13, br t (7.1)	23, 26, 27	23, 26, 27	22a, 22b, 26
25	133.2, C				
26	25.9, CH ₃	1.66, br s	24	24, 25, 27	24
27	17.9, CH ₃	1.60, br s	24	24, 25, 26	
28	16.6, CH ₃	0.89, d (6.8)	4	3, 4, 5	3, 5, 6a
30	25.3, CH ₃	1.36, s		7, 8, 9, 14	5, 7, 13, 15a
16-COCH ₃	172.8, C			16-COCH ₃	
16-COCH ₃	20.8, CH ₃	1.96, s			

^aThe indiscernible signals from overlap or the complex multiplicity are reported without designating multiplicity.


Table S43 NMR data for **50** (^1H for 400 MHz and ^{13}C for 100 MHz in CD_3OD).



50


Position	δ_{C} , type	δ_{H} (J in Hz) ^a	^1H - ^1H COSY	HMBC	ROESY
1	36.4, CH_2	a: 2.70 b: 1.95	1b, 2 1a, 2	3, 10, 19	
2	37.6, CH_2	2.48	1a, 1b	1, 3, 10	
3	218.4, C				
4	47.7, CH	2.54	5, 28	5, 28	6, 19
5	51.3, CH	2.04	4, 6	1, 4, 6, 7, 10, 19, 28	7, 30
6	75.2, CH	3.47, dd (9.4, 3.4)	5, 7	4, 5, 7, 8	4, 19, 28
7	84.6, CH	4.74, d (3.4)	6	5, 6, 9, 30, 7- <u>COCH₃</u>	5, 15b, 30
8	45.0, C				
9	47.0, CH	2.03	11	1, 7, 8, 10, 11, 14, 19, 30	18, 19
10	38.2, C				
11	68.0, CH	4.37, br s	9, 12a, 12b	8, 10, 13	19
12	37.3, CH_2	a: 2.32 b: 1.92	11, 12b, 13 11, 12a, 13	9, 11, 14 13	
13	46.3, CH	3.14, br d (11.6)	12a, 12b	12, 14, 17, 18, 20	15a, 16, 30
14	49.3, C				
15	40.9, CH_2	a: 2.21, dd (14.6, 8.9) b: 1.23	15b, 16 15a, 16	14, 18 16, 17	13, 30 7
16	75.5, CH	5.81, br d (8.4)	15a, 15b	13, 14, 17, 20, 16- <u>COCH₃</u>	13
17	147.7, C				
18	21.2, CH_3	1.03, s		8, 13, 14, 15	9
19	24.7, CH_3	1.23, s		1, 5, 9, 10	4, 6, 9, 11
20	133.4, C				
21	174.2, C				
22	29.9, CH_2	a: 2.53 b: 2.37	22b, 23 22a, 23	17, 20, 21, 23, 24 17, 20, 21, 23, 24	24
23	29.2, CH_2	2.12	22a, 22b, 24	22, 24, 25	
24	124.3, CH	5.13, br t (6.6)	23, 26, 27	23, 26, 27	22a, 22b, 26
25	133.4, C				
26	25.9, CH_3	1.66, br s	24	24, 25, 27	24
27	17.9, CH_3	1.60, br s	24	24, 25, 26	
28	16.1, CH_3	1.17, d (6.7)	4	3, 4, 5	6
30	22.3, CH_3	1.44, s		7, 8, 9, 14	5, 7, 13, 15a
7- <u>COCH₃</u>	171.9, C				
7- <u>COCH₃</u>	22.0, CH_3	2.03, s		7- <u>COCH₃</u>	
16- <u>COCH₃</u>	172.6, C				
16- <u>COCH₃</u>	20.7, CH_3	1.95, s		16- <u>COCH₃</u>	

^aThe indiscernible signals from overlap or the complex multiplicity are reported without designating multiplicity.

Table S44 NMR data for **51** (¹H for 400 MHz and ¹³C for 100 MHz in CDCl₃).**51**


Position	δ_c , type	δ_h (<i>J</i> in Hz) ^a	¹ H- ¹ H COSY	HMBC	ROESY
1	35.9, CH ₂	a: 2.59	1b, 2	2	
		b: 2.00	1a, 2	3, 10	
2	37.4, CH ₂	2.47	1a, 1b	1, 3	
3	212.8, C				
4	46.2, CH	2.54	5, 28	3	6, 19
5	47.2, CH	2.28, t (10.5)	4, 6	4, 6, 10, 19	7, 28, 30
6	80.7, CH	4.63, br d (9.4)	5, 7	4, 5, 7, 8, 6-COCH ₃	4, 19, 28
7	79.8, CH	3.46, br s	6	5, 6, 9, 30	5, 15b, 30
8	43.7, C				
9	44.8, CH	2.16, br s	11	8, 10, 11, 14, 19, 30	18, 19
10	36.7, C				
11	68.3, CH	4.48, br s	9, 12a, 12b	8, 13	19
12	36.3, CH ₂	a: 2.25	11, 12b, 13	11, 14	
		b: 2.00	11, 12a, 13		
13	45.4, CH	3.09, br d (11.6)	12a, 12b	12, 14, 17, 18, 20	16, 30
14	48.4, C				
15	39.6, CH ₂	a: 2.21	15b, 16	18	
		b: 1.48, br d (14.2)	15a, 16	13, 14, 16, 17	7
16	74.2, CH	5.90, br d (8.4)	15a, 15b	14, 17, 20, 16-COCH ₃	13
17	150.1, C				
18	21.5, CH ₃	1.16, s		8, 13, 14, 15	9
19	24.4, CH ₃	1.40, s		1, 5, 9, 10	4, 6, 9, 11
20	130.6, C				
21	174.0, C				
22	28.8, CH ₂	2.43	23	17, 20, 21, 23, 24	24
23	28.3, CH ₂	2.09	22, 24	22, 24	
24	123.0, CH	5.09, br t (6.7)	23, 26, 27	26, 27	22, 26
25	132.7, C				
26	25.7, CH ₃	1.67, br s	24	24, 25, 27	24
27	17.8, CH ₃	1.59, br s	24	24, 25, 26	
28	13.7, CH ₃	0.99, d (6.5)	4	3, 4, 5	5, 6
30	21.1, CH ₃	1.26, s		7, 8, 9, 14	5, 7, 13
6-COCH ₃	171.3, C				
6-COCH ₃	21.6, CH ₃	2.06, s		6-COCH ₃	
16-COCH ₃	170.8, C				
16-COCH ₃	20.6, CH ₃	1.96, s		16-COCH ₃	

^aThe indiscernible signals from overlap or the complex multiplicity are reported without designating multiplicity.

Table S45 NMR data for **52** (¹H for 400 MHz and ¹³C for 100 MHz in CD₃OD).**52**

Position	δ_c , type	δ_h (<i>J</i> in Hz) ^a	¹ H- ¹ H COSY	HMBC	ROESY ^b
1	36.0, CH ₂	a: 2.61 b: 1.98	1b, 2 1a, 2	2	5 11
2	37.8, CH ₂	2.46	1a, 1b		
3	217.0, C				
4	47.1, CH	2.54	5, 28		6, 19
5	49.6, CH	2.37, dd (12.4, 9.8)	4, 6	6, 10, 19	1a, 28, 30
6	74.1, CH	4.95, ddd (10.2, 6.9, 3.6)	5, 7a, 7b		4, 19, 28
7	41.6, CH ₂	a: 2.14 b: 1.20	6, 7b 6, 7a	30	9, 18
8	40.5, C				
9	50.3, CH	1.67	11	8, 10, 11, 14, 19, 30	7a, 12b, 18, 19
10	37.9, C				
11	67.8, CH	4.33, br s	9, 12a, 12b	8, 13	1b, 19
12	37.4, CH ₂	a: 2.32 b: 1.89, td (13.0, 2.0)	11, 12b, 13 11, 12a, 13	11, 14	9, 18
13	44.4, CH	3.07, br d (11.9)	12a, 12b	12, 17	15a, 16, 30
14	49.4, C				
15	39.8, CH ₂	a: 2.13 b: 1.23	15b, 16 15a, 16	14 13	13, 30 18
16	75.6, CH	5.80, br d (8.5)	15a, 15b	14, 17, 16-COCH ₃	13
17	147.0, C				
18	17.8, CH ₃	0.95, s		8, 13, 14, 15	7a, 9, 12b, 15b
19	25.5, CH ₃	1.18, s		1, 5, 9, 10	4, 6, 9, 11
20	132.8, C				
21	#				
22	30.0, CH ₂	a: 2.53 b: 2.37	22b, 23 22a, 23		24 24
23	29.2, CH ₂	2.11	22a, 22b, 24		
24	124.5, CH	5.13, br t (6.5)	23, 26, 27	26, 27	22a, 22b, 26
25	133.3, C				
26	25.9, CH ₃	1.66, br s	24	24, 25, 27	24
27	17.8, CH ₃	1.60, br s	24	24, 25, 26	
28	14.9, CH ₃	1.01, d (6.6)	4	3, 4, 5	5, 6
30	23.7, CH ₃	1.37, s		7, 8, 9, 14	5, 13, 15a
6-COCH ₃	172.4, C				
6-COCH ₃	21.7, CH ₃	2.00, s		6-COCH ₃	
16-COCH ₃	172.7, C				
16-COCH ₃	20.7, CH ₃	1.96, s		16-COCH ₃	


^aThe indiscernible signals from overlap or the complex multiplicity are reported without designating multiplicity.^bThe data were measured in CD₃OD at 600 MHz; # The data is not observed.

Table S46 NMR data for **55** (¹H for 600 MHz and ¹³C for 150 MHz in CD₃OD).**55**

Position	δ_{C} , type	δ_{H} (<i>J</i> in Hz) ^a	¹ H- ¹ H COSY	HMBC	ROESY
1	33.7, CH ₂	a: 2.20 b: 1.53	1b, 2a, 2b 1a, 2a, 2b	2, 5, 10, 19 2, 3, 5, 10	11
2	31.3, CH ₂	a: 1.94 b: 1.71	1a, 1b, 2b, 3 1a, 1b, 2a, 3	3, 4, 10	19
3	72.3, CH	3.81, br s	2a, 2b, 4	1, 4, 5	28
4	33.4, CH	2.19	3, 5, 28	5, 10, 28	19
5	40.7, CH	2.12	4, 6	1, 3, 4, 7, 10, 19	28, 30
6	75.0, CH	3.80, br s	5	4, 5, 7, 8, 10	28
7	218.3, C				
8	54.5, C				
9	46.7, CH	2.39, d (1.5)	11	1, 7, 8, 10, 11, 14, 19, 30	12b, 18, 19
10	38.0, C				
11	67.9, CH	4.41, br s	9, 12a, 12b	8, 10, 13	1b, 19
12	37.0, CH ₂	a: 2.34 b: 1.88, td (12.6, 2.3)	11, 12b, 13 11, 12a, 13	13	9, 18
13	45.2, CH	3.10, br d (11.7)	12a, 12b	12, 14, 17, 18, 20	16, 30
14	48.0, C				
15	42.0, CH ₂	a: 2.33 b: 1.81, br d (14.6)	15b, 16 15a, 16	8, 14, 18 13, 14, 16, 17, 18	30 18
16	75.6, CH	5.81, br d (8.5)	15a, 15b	13, 14, 15, 17, 20, 16-COCH ₃	13
17	147.5, C				
18	18.7, CH ₃	0.90, s		8, 13, 14, 15	9, 12b, 15b
19	24.3, CH ₃	1.33, s		1, 5, 9, 10	2a, 4, 9, 11
20	132.5, C				
21	174.2, C				
22	29.8, CH ₂	a: 2.56 b: 2.37	22b, 23 22a, 23	17, 20, 21, 23, 24 17, 20, 21, 23, 24	24 24
23	29.3, CH ₂	2.11	22a, 22b, 24	22, 24, 25	
24	124.3, CH	5.13, br t (7.3)	23, 26, 27	23, 26, 27	22a, 22b, 26
25	133.4, C				
26	25.9, CH ₃	1.67, br s	24	24, 25, 27	24
27	17.9, CH ₃	1.61, br s	24	24, 25, 26	
28	16.1, CH ₃	0.97, d (6.7)	4	3, 4, 5	3, 5, 6
30	22.8, CH ₃	1.49, s		7, 8, 9, 14	5, 13, 15a
16-COCH ₃	172.6, C				
16-COCH ₃	20.7, CH ₃	1.96, s		16-COCH ₃	

^aThe indiscernible signals from overlap or the complex multiplicity are reported without designating multiplicity.


Table S47 NMR data for **56** (^1H for 600 MHz and ^{13}C for 150 MHz in CD_3OD).



56


Position	δ_{C} , type	δ_{H} (J in Hz) ^a	^1H - ^1H COSY	HMBC	ROESY
1	30.6, CH ₂	a: 2.31 b: 1.44	1b, 2a, 2b 1a, 2a, 2b	5, 10, 19	11
2	30.8, CH ₂	a: 1.81 b: 1.68	1a, 1b, 2b, 3 1a, 1b, 2a, 3		19
3	72.0, CH	3.63, br s	2a, 2b, 4	1, 2, 5	28
4	38.9, CH	1.49	3, 5, 28	10, 28	19
5	37.2, CH	2.33	4, 6a, 6b	4, 6	28, 30
6	34.9, CH ₂	a: 1.60 b: 1.48	5, 6b, 7 5, 6a, 7	4, 5, 7, 8 7, 10	
7	71.4, CH	3.88, t (8.3)	6a, 6b	6, 8, 9, 14, 30	9, 18, 19
8	46.3, C				
9	51.8, CH	1.55, br s	11	7, 8, 10, 11, 19, 30	7, 18, 19
10	37.4, C				
11	68.5, CH	4.34, br s	9, 12a, 12b	8, 13	1b, 19
12	37.2, CH ₂	a: 2.30 b: 1.84	11, 12b, 13 11, 12a, 13	13	18, 22a
13	45.3, CH	3.04, br d (11.8)	12a, 12b	12, 14, 17, 18, 20	16, 30
14	49.2, C				
15	43.0, CH ₂	a: 2.27, dd (14.9, 8.9) b: 1.57, br d (14.9)	15b, 16 15a, 16	8, 14, 18 13, 14, 16, 17, 18	30
16	76.0, CH	5.76, br d (8.7)	15a, 15b	13, 14, 15, 17, 20, 16-COCH ₃	13
17	147.6, C				
18	16.6, CH ₃	0.99, s		8, 13, 14, 15	7, 9, 12b
19	25.0, CH ₃	0.97, s		1, 5, 9, 10	2a, 4, 7, 9, 11
20	132.1, C				
21	174.7, C				
22	29.9, CH ₂	a: 2.55 b: 2.35	22b, 23a, 23b 22a, 23a, 23b	17, 20, 21, 23, 24 17, 20, 21, 23, 24	12b, 24 24
23	29.4, CH ₂	a: 2.13 b: 2.08	22a, 22b, 23b, 24 22a, 22b, 23a, 24	20, 22, 24, 25 20, 22, 24, 25	
24	124.4, CH	5.13, br t (7.3)	23a, 23b, 26, 27	23, 26, 27	22a, 22b, 26
25	133.3, C				
26	25.9, CH ₃	1.67, br s	24	24, 25, 27	24
27	17.9, CH ₃	1.61, br s	24	24, 25, 26	
28	16.2, CH ₃	0.90, d (6.8)	4	3, 4, 5	3, 5
30	14.9, CH ₃	1.32, s		7, 8, 9, 14	5, 13, 15a
16-COCH ₃	172.6, C				
16-COCH ₃	20.7, CH ₃	1.95, s		16-COCH ₃	

^aThe indiscernible signals from overlap or the complex multiplicity are reported without designating multiplicity.

Table S48 NMR data for **57** (^1H for 600 MHz and ^{13}C for 150 MHz in CD_3OD).**57**


Position	δ_{C} , type	δ_{H} (J in Hz) ^a	$^1\text{H}-^1\text{H}$ COSY	HMBC	ROESY
1	31.7, CH_2	a: 2.21	1b, 2a, 2b	2, 10, 19	
		b: 1.62	1a, 2a, 2b	2, 3, 5, 10	11, 19
2	31.2, CH_2	a: 1.92	1a, 1b, 2b, 3		19
		b: 1.75	1a, 1b, 2a, 3		
3	71.9, CH	3.74, br s	2a, 2b, 4	1, 5	28
4	35.3, CH	1.81	3, 5, 28	5, 28	19
5	37.2, CH	2.23 ^b	4, 6	3, 4, 6, 7, 10, 19	30
6	40.8, CH_2	2.13	5	5, 7, 8, 10	
7	222.1, C				
8	54.7, C				
9	48.2, CH	1.85	11	1, 7, 8, 10, 11, 14, 19, 30	18, 19
10	38.4, C				
11	67.5, CH	4.37, br s	9, 12a, 12b	8, 13	1b, 19
12	36.9, CH_2	a: 2.32	11, 12b, 13	11, 14	
		b: 1.85	11, 12a, 13	11, 13, 14	
13	44.9, CH	3.07, br d (11.8)	12a, 12b	12, 14, 17, 18, 20	16, 30
14	48.4, C				
15	41.8, CH_2	a: 2.31	15b, 16	8, 14, 18	30
		b: 1.73, br d (14.8)	15a, 16	13, 14, 16, 17, 18	18
16	75.5, CH	5.79, br d (8.5)	15a, 15b	13, 14, 15, 17, 20, 16- COCH_3	13
17	146.5, C				
18	17.6, CH_3	0.82, s		8, 13, 14, 15	9, 15b
19	20.6, CH_3	1.08, s		1, 5, 9, 10	1b, 2a, 4, 9, 11
20	133.2, C				
21	174.6, C				
22	29.9, CH_2	a: 2.54	22b, 23	17, 20, 21, 23, 24	24
		b: 2.35	22a, 23	17, 20, 21, 23, 24	24
23	29.3, CH_2	2.09	22a, 22b, 24	22, 24, 25	
24	124.3, CH	5.13, br t (7.3)	23, 26, 27	23, 26, 27	22a, 22b, 26
25	133.4, C				
26	25.9, CH_3	1.66, br s	24	24, 25, 27	24
27	17.9, CH_3	1.60, br s	24	24, 25, 26	
28	16.4, CH_3	0.88, br d (6.8)	4	3, 4, 5	3
30	22.4, CH_3	1.48, s		7, 8, 9, 14	5, 13, 15a
16- COCH_3	172.6, C				
16- COCH_3	20.7, CH_3	1.95, s		16- COCH_3	

^aThe indiscernible signals from overlap or the complex multiplicity are reported without designating multiplicity.^bThe chemical shift was confirmed by $^1\text{H}-^1\text{H}$ COSY, HMBC and ROESY.

Table S49 NMR data for **58** (¹H for 400 MHz and ¹³C for 100 MHz in CD₃OD).**58**


Position	δ_c , type	δ_h (<i>J</i> in Hz) ^a	¹ H- ¹ H COSY	HMBC	ROESY
1	36.6, CH ₂	a: 2.49 b: 2.01	1b, 2 1a, 2	19 3, 5	
2	38.2, CH ₂	2.51	1a, 1b	3, 10	
3	215.4, C				
4	43.1, CH	2.61	5, 28	3, 5, 28	6, 19
5	47.1, CH	2.23, br d (12.1)	4, 6	3, 4, 7, 10, 19, 28	28, 30
6	74.9, CH	5.17, br s	5	4, 5, 7, 8, 10, 6-COCH ₃	4, 28
7	211.7, C				
8	54.9, C				
9	46.2, CH	2.44, br s	11	7, 8, 10, 11, 12, 19, 30	12b, 18, 19
10	37.3, C				
11	67.6, CH	4.50, br s	9, 12a, 12b	8, 10, 13	19
12	36.8, CH ₂	a: 2.37 b: 1.99	11, 12b, 13 11, 12a, 13	9, 11, 14 13	9
13	44.9, CH	3.13, br d (12.0)	12a, 12b	11, 12, 14, 17, 18, 20	16, 30
14	48.2, C				
15	41.7, CH ₂	a: 2.34 b: 1.74, br d (14.5)	15b, 16 15a, 16	8, 14, 18 13, 14, 16, 17, 18	30 18
16	75.3, CH	5.81, br d (8.1)	15a, 15b	13, 14, 17, 20, 16-COCH ₃	13
17	146.7, C				
18	18.4, CH ₃	0.87, s		8, 13, 14, 15	9, 15b
19	24.7, CH ₃	1.39, s		1, 5, 9, 10	4, 9, 11
20	133.0, C				
21	174.1, C				
22	29.8, CH ₂	a: 2.55 b: 2.38	22b, 23 22a, 23	17, 20, 21, 23, 24 17, 20, 21, 23, 24	
23	29.2, CH ₂	2.12	22a, 22b, 24	22, 24, 25	
24	124.2, CH	5.14, br t (6.9)	23, 26, 27	23, 26, 27	26
25	133.4, C				
26	25.9, CH ₃	1.67, br s	24	24, 25, 27	24
27	17.9, CH ₃	1.61, br s	24	24, 25, 26	
28	13.2, CH ₃	1.10, d (6.3)	4	3, 4, 5	5, 6
30	22.4, CH ₃	1.52, s		7, 8, 9, 14	5, 13, 15a
6-COCH ₃	170.8, C				
6-CO <u>CH</u> ₃	20.7, CH ₃	2.08, s		6-COCH ₃	
16-CO <u>CH</u> ₃	172.4, C				
16-COCH ₃	20.7, CH ₃	1.96, s		16-COCH ₃	

^aThe indiscernible signals from overlap or the complex multiplicity are reported without designating multiplicity.

Table S50 NMR data for **59** (^1H for 400 MHz and ^{13}C for 100 MHz in CD_3OD).**59**


Position	δ_{C} , type	δ_{H} (J in Hz) ^a	^1H - ^1H COSY	HMBC	ROESY
1	36.9, CH_2	a: 1.99	1b, 2a, 2b		
		b: 1.84	1a, 2a, 2b	2, 3, 10	
2	32.5, CH_2	a: 1.88	1a, 1b, 2b, 3	3, 4	
		b: 1.66	1a, 1b, 2a, 3		
3	77.3, CH	3.07	2a, 2b, 4	1	28
4	47.5, CH	1.75	3, 5, 28	5, 6	19
5	36.4, CH	1.73	4, 6	6	28, 30
6	75.1, CH	5.24, br s	5	4, 7, 8, 10, 6- $\underline{\text{COCH}_3}$	28
7	212.5, C				
8	54.7, C				
9	47.3, CH	2.31, br s	11	7, 8, 10, 11, 14, 19, 30	18, 19
10	37.5, C				
11	67.8, CH	4.43, br s	9, 12a, 12b	8, 9, 10, 13	19
12	36.9, CH_2	a: 2.34	11, 12b, 13	14	
		b: 1.92	11, 12a, 13	13	
13	45.0, CH	3.09	12a, 12b	12, 14, 17, 18, 20	16, 30
14	48.2, C				
15	41.5, CH_2	a: 2.28	15b, 16	8, 14, 18	
		b: 1.71	15a, 16	13, 14, 16, 17	
16	75.4, CH	5.81, br d (8.3)	15a, 15b	14, 15, 17, 20, 16- $\underline{\text{COCH}_3}$	13
17	146.7, C				
18	18.3, CH_3	0.87, s		8, 13, 14, 15	9
19	25.1, CH_3	1.29, s		1, 5, 9, 10	4, 9, 11
20	133.0, C				
21	174.2, C				
22	29.8, CH_2	a: 2.55	22b, 23	17, 20, 21, 23	
		b: 2.36	22a, 23	17, 20, 21, 23	
23	29.2, CH_2	2.10	22a, 22b, 24	22, 24, 25	
24	124.3, CH	5.13, br t (7.2)	23, 26, 27	23, 26, 27	26
25	133.4, C				
26	25.9, CH_3	1.67, br s	24	24, 25, 27	24
27	17.9, CH_3	1.61, br s	24	24, 25, 26	
28	15.7, CH_3	1.03, d (4.6)	4	3, 4, 5	3, 5, 6
30	22.7, CH_3	1.51, s		7, 8, 9, 14	5, 13
6- $\underline{\text{COCH}_3}$	170.9, C				
6- $\underline{\text{COCH}_3}$	20.8, CH_3	2.05, s		6- $\underline{\text{COCH}_3}$	
16- $\underline{\text{COCH}_3}$	172.5, C				
16- $\underline{\text{COCH}_3}$	20.7, CH_3	1.95, s		16- $\underline{\text{COCH}_3}$	

^aThe indiscernible signals from overlap or the complex multiplicity are reported without designating multiplicity.

Table S51 NMR data for **60** (¹H for 600 MHz and ¹³C for 150 MHz in CDCl₃).**60**


Position	δ_c , type	δ_h (<i>J</i> in Hz) ^a	¹ H- ¹ H COSY	HMBC	ROESY
1	29.7, CH ₂	a: 1.75 b: 1.23	1b, 2a, 2b 1a, 2a, 2b	2, 10, 19 3, 5, 10	
2	29.5, CH ₂	a: 1.83 b: 1.69	1a, 1b, 2b, 3 1a, 1b, 2a, 3	1 3, 4, 10	
3	71.0, CH	3.84, br s	2a, 2b, 4	1, 2, 5, 28	28
4	32.3, CH	1.99	3, 5, 28	5, 28	19
5	39.3, CH	2.26	4, 6	1, 3, 4, 7, 10, 19	28, 30
6	74.5, CH	5.14, br s	5	4, 5, 7, 8, 10, 6-COCH ₃	28
7	210.2, C				
8	52.8, C				
9	41.9, CH	2.40	11a, 11b	1, 7, 8, 10, 11, 12, 19, 30	12b, 18, 19
10	35.8, C				
11	22.6, CH ₂	a: 1.77 b: 1.40, qd (13.1, 3.4)	9, 11b, 12a, 12b 9, 11a, 12a, 12b	9	13
12	26.1, CH ₂	a: 2.29 b: 1.69	11a, 11b, 12b, 13 11a, 11b, 12a, 13	13	9
13	49.1, CH	2.52, br d (11.9)	12a, 12b	12, 14, 17, 18, 20	11b, 16, 30
14	46.8, C				
15	40.4, CH ₂	a: 2.24 b: 1.83, br d (14.5)	15b, 16 15a, 16	8, 14, 18 13, 14, 16, 17, 18	30 18
16	73.6, CH	5.81, br d (8.5)	15a, 15b	13, 14, 17, 20, 16-COCH ₃	13
17	148.1, C				
18	17.9, CH ₃	0.86, s		8, 13, 14, 15	9, 15b
19	22.7, CH ₃	1.18, s		1, 5, 9, 10	4, 9
20	130.2, C				
21	174.6, C				
22	28.4, CH ₂	a: 2.47 b: 2.40	22b, 23a, 23b 22a, 23a, 23b	17, 20, 21, 23, 24 17, 20, 21, 23, 24	24 24
23	28.3, CH ₂	a: 2.09 b: 2.01	22a, 22b, 23b, 24 22a, 22b, 23a, 24	22, 24, 25 22, 24, 25	
24	122.8, CH	5.06, br t (7.1)	23a, 23b, 26, 27	23, 26, 27	22a, 22b, 26
25	132.6, C				
26	25.6, CH ₃	1.65, br s	24	24, 25, 27	24
27	17.6, CH ₃	1.57, br s	24	24, 25, 26	
28	15.3, CH ₃	0.99, d (6.8)	4	3, 4, 5	3, 5, 6
30	17.9, CH ₃	1.30, s		7, 8, 9, 14	5, 13, 15a
6-COCH ₃	169.1, C				
6-COCH ₃	20.8, CH ₃	2.03, s		6-COCH ₃	
16-COCH ₃	170.2, C				
16-COCH ₃	20.4, CH ₃	1.89, s		16-COCH ₃	

^aThe indiscernible signals from overlap or the complex multiplicity are reported without designating multiplicity.

Table S52 NMR data for **61** (^1H for 400 MHz and ^{13}C for 100 MHz in CDCl_3).**61**

Position	δ_{C} , type	δ_{H} (J in Hz) ^a	^1H - ^1H COSY	HMBC	ROESY
1	160.6, CH	8.19, d (10.2)	2	3, 5, 9, 10	11
2	126.3, CH	5.81, d (10.2)	1	4, 10	
3	201.7, C				
4	40.3, CH	2.74, dq (13.2, 6.6)	5, 28	3, 5, 28	6, 19
5	46.5, CH	2.42	4, 6	1, 3, 4, 10, 19, 28	28, 30
6	73.6, CH	5.23, br s	5	4, 5, 7, 8, 10, 6- COCH_3	4, 28
7	208.8, C				
8	53.3, C				
9	45.3, CH	2.46	11	1, 7, 8, 10, 11, 14, 19, 30	12b, 18, 19
10	38.7, C				
11	67.2, CH	4.69, br s	9, 12a, 12b	8, 10, 13	1, 19
12	35.7, CH_2	a: 2.39 b: 2.06	11, 12b, 13 11, 12a, 13	9, 11 13	9, 18
13	43.9, CH	3.12, br d (12.1)	12a, 12b	11, 12, 14, 17, 18, 20	16, 30
14	46.7, C				
15	40.5, CH_2	a: 2.31, dd (15.0, 8.9) b: 1.91, br d (15.3)	15b, 16 15a, 16	8, 14, 18 13, 14, 16, 17, 18	30 18
16	73.8, CH	5.91, br d (8.3)	15a, 15b	13, 14, 17, 20, 16- COCH_3	13
17	148.2, C				
18	17.8, CH_3	0.88, s		8, 13, 14, 15	9, 12b, 15b
19	27.8, CH_3	1.47, s		1, 5, 9, 10	4, 9, 11
20	130.4, C				
21	174.1, C				
22	28.7, CH_2	2.44	23a, 23b	17, 20, 21, 24	24
23	28.4, CH_2	a: 2.15 b: 2.04	22, 23b, 24 22, 23a, 24	20, 22, 24, 25 20, 22, 24, 25	
24	122.8, CH	5.09, br t (7.0)	23a, 23b, 26, 27	23, 26, 27	22, 26
25	132.9, C				
26	25.7, CH_3	1.66, br s	24	24, 25, 27	24
27	17.8, CH_3	1.58, br s	24	24, 25, 26	
28	13.0, CH_3	1.24, d (6.7)	4	3, 4, 5	5, 6
30	22.3, CH_3	1.38, s		7, 8, 9, 14,	5, 13, 15a
6- COCH_3	168.9, C				
6- COCH_3	20.6, CH_3	2.08, s		6- COCH_3	
16- COCH_3	170.5, C				
16- COCH_3	20.4, CH_3	1.93, s		16- COCH_3	

^aThe indiscernible signals from overlap or the complex multiplicity are reported without designating multiplicity.


Table S53 NMR data for **62** (^1H for 600 MHz and ^{13}C for 150 MHz in CD_3OD).**62**

Position	δ_{C} , type	δ_{H} (J in Hz) ^a	^1H - ^1H COSY	HMBC	ROESY
1	143.7, CH	6.79, d (10.2)	2	3, 5, 10	11, 19
2	126.0, CH	5.49, dd (10.2, 4.3)	1, 3	4, 10	
3	69.4, CH	3.97, t (4.4)	2, 4	1, 2, 5	28
4	32.3, CH	2.46	3, 5, 28	28	19
5	41.1, CH	2.08, dd (11.2, 1.5)	4, 6	1, 3, 4, 10, 19	28, 30
6	74.6, CH	3.91, d (1.5)	5	4, 5, 7, 8, 10	28
7	217.9, C				
8	54.3, C				
9	46.7, CH	2.43, br s	11	1, 7, 8, 10, 11, 14, 19, 30	12b, 18, 19
10	39.4, C				
11	67.9, CH	4.53, br s	9, 12a, 12b	8, 13	1, 19
12	36.8, CH ₂	a: 2.37 b: 1.91, br t (13.0)	11, 12b, 13 11, 12a, 13	13	9, 18
13	44.7, CH	3.10, br d (11.4)	12a, 12b		15a, 30
14	47.9, C				
15	42.1, CH ₂	a: 2.27, dd (15.3, 8.7) b: 1.82, br d (14.7)	15b, 16 15a, 16	14, 18 13, 14, 16, 18	13, 30 18
16	75.7, CH	5.81, br d (8.2)	15a, 15b	14	
17	#				
18	18.6, CH ₃	0.93, s		8, 13, 14, 15	9, 12b, 15b
19	29.6, CH ₃	1.35, s		1, 5, 9, 10	1, 4, 9, 11
20	#				
21	#				
22	30.2, CH ₂	a: 2.56 b: 2.37	22b, 23 22a, 23		
23	29.3, CH ₂	2.13	22a, 22b, 24		
24	124.6, CH	5.15, br t (6.1)	23, 26, 27	23, 26, 27	26
25	133.1, C				
26	25.9, CH ₃	1.67, br s	24	24, 25, 27	24
27	17.9, CH ₃	1.61, br s	24	24, 25, 26	
28	14.2, CH ₃	1.06, d (6.9)	4	3, 4, 5	3, 5, 6
30	22.5, CH ₃	1.37, s		7, 8, 9, 14	5, 13, 15a
16-COCH ₃	172.8, C				
16-COCH ₃	20.9, CH ₃	1.97, s		16-COCH ₃	

^aThe indiscernible signals from overlap or the complex multiplicity are reported without designating multiplicity.

#Data are not observed in NMR spectra.

Table S54 NMR data for **63** (¹H for 600 MHz and ¹³C for 150 MHz in pyridine-*d*₅).




63

Position	δ_c , type	δ_H (J in Hz) ^a	¹ H- ¹ H COSY	HMBC	ROESY	δ_c , type ^b	δ_H (J in Hz) ^{a,b}
1	138.2, CH	6.19, d (10.0)	2	3, 5, 10	11a, 11b, 19	140.2, CH	6.18, d (10.0)
2	129.7, CH	5.97, dd (9.7, 3.5)	1, 3	4, 10		128.8, CH	5.58, dd (10.1, 4.0)
3	67.8, CH	4.33, br s	2, 4	1, 2, 5	28	69.0, CH	4.01, t (4.3)
4	31.8, CH	2.50	3, 5, 28	3, 5, 10, 28	19	32.3, CH	2.36
5	41.1, CH	2.51	4, 6	1, 3, 4, 7, 9, 10, 19	30	41.8, CH	2.10
6	74.8, CH	5.74, br s	5	4, 5, 7, 8, 10, 6- <u>COCH</u> ₃	28	75.5, CH	5.19, br s
7	210.7, C					212.0, C	
8	53.0, C					54.0, C	
9	42.1, CH	2.62	11a, 11b	1, 7, 8, 10, 11, 19, 30	18, 19	43.2, CH	2.50
10	38.0, C					38.8, C	
11	24.0, CH ₂	a: 1.90 b: 1.46	9, 11b, 12a, 12b 9, 11a, 12a, 12b	8, 13	1 1, 30	24.8, CH ₂ b: 1.56	a: 1.96 b: 1.77
12	26.5, CH ₂	a: 2.43 b: 1.81, br q (13.6)	11a, 11b, 12b, 13 11a, 11b, 12a, 13	14 11, 13	18	27.4, CH ₂	a: 2.38 b: 1.77
13	49.1, CH	2.60	12a, 12b	12, 14, 17, 18	16, 30	50.0, CH	2.65, br d (11.4)
14	47.0, C					47.8, C	
15	41.3, CH ₂	a: 2.35, dd (14.2, 8.8) b: 2.17	15b, 16 15a, 16	8, 14, 18 13, 14, 16, 17, 18	30 18	41.8, CH ₂ b: 1.73	a: 2.23, dd (14.8, 9.0)
16	74.2, CH	6.43, br d (8.4)	15a, 15b	13, 14, 17, 20, 13 16- <u>COCH</u> ₃	13	75.2, CH	5.77, br d (8.3)
17	144.6, C					146.1, C	
18	18.1, CH ₃	1.13, s		8, 13, 14, 15	9, 12b, 15b	18.4, CH ₃	0.87, s
19	28.3, CH ₃	1.42, s		1, 5, 9, 10	1, 4, 9	28.4, CH ₃	1.30, s
20	133.1, C					132.8, C	
21	173.0, C					#	
22	29.5, CH ₂	a: 2.94 b: 2.84	22b, 23a, 23b 22a, 23a, 23b	17, 20, 21, 23, 24 17, 20, 21, 23, 24	24 24	29.7, CH ₂ b: 2.38	a: 2.57 b: 2.38
23	29.1, CH ₂	a: 2.57 b: 2.44	22a, 22b, 23b, 24 22a, 22b, 23a, 24	22, 24, 25 22, 24, 25		29.1, CH ₂	2.11
24	124.3, CH	5.41, br t (6.4)	23a, 23b, 26, 27	23, 26, 27	22a, 22b, 26	124.3, CH	5.14, br t (7.3)
25	132.2, C					133.4, C	
26	25.8, CH ₃	1.72, br s	24	24, 25, 27	24	25.9, CH ₃	1.68, br s
27	17.8, CH ₃	1.69, br s	24	24, 25, 26		17.8, CH ₃	1.61, br s
28	14.5, CH ₃	1.37, d (4.2)	4	3, 4, 5	3, 6	14.0, CH ₃	1.04, d (6.8)
30	18.2, CH ₃	1.13, s		7, 8, 9, 14	5, 11b, 13, 15a	18.6, CH ₃	1.22, s
6- <u>COCH</u> ₃	169.4, C					170.9, C	
6- <u>COCH</u> ₃	20.7, CH ₃	2.13, s		6- <u>COCH</u> ₃		20.7, CH ₃	2.07, s
16- <u>COCH</u> ₃	170.4, C					172.5, C	
16- <u>COCH</u> ₃	20.6, CH ₃	1.91, s		16- <u>COCH</u> ₃		20.6, C	1.95, s

^aThe indiscernible signals from overlap or the complex multiplicity are reported without designating multiplicity.

^bThe data were measured in CD₃OD (¹H NMR for 400 MHz and ¹³C NMR for 100 MHz).


#The data is not observed in NMR spectra.

Table S55 NMR data for **64** (^1H for 600 MHz and ^{13}C for 150 MHz in CD_3OD).**64**

Position	δ_{C} , type	δ_{H} (J in Hz) ^a	^1H - ^1H COSY	HMBC	ROESY
1	141.3, CH	6.09, d (10.2)	2	3, 5, 10, 19	11a, 11b, 19
2	127.2, CH	5.59, dd (10.2, 4.7)	1, 3	3, 4, 10	
3	70.1, CH	3.78, t (4.0)	2, 4	1, 2, 5	28
4	36.4, CH	2.07	3, 5, 28	5	19
5	42.0, CH	2.09	4, 6	1, 3, 4, 6, 10, 19	28, 30
6	75.6, CH	3.52, br d (9.8)	5, 7	4, 5, 7, 8	19
7	84.5, CH	4.81, br s	6	6, 8, 9, 14, 30, 7- <u>COCH₃</u>	30
8	43.8, C				
9	42.8, CH	2.22, dd (13.4, 3.7)	11a, 11b	1, 5, 8, 10, 11, 14, 19, 30	12b, 18, 19
10	39.6, C				
11	26.2, CH ₂	a: 2.00 b: 1.39, qd (13.0, 4.4)	9, 11b, 12a, 12b 9, 11ba 12a, 12b	9, 12	1 1, 13, 30
12	27.2, CH ₂	a: 2.29 b: 1.69	11a, 11b, 12b, 13 11a, 11b, 12a, 13	11, 13	9, 18
13	50.2, CH	2.63, br d (11.2)	12a, 12b	12, 14, 17, 18, 20	11b, 15a, 16, 30
14	49.5, C				
15	41.0, CH ₂	a: 2.18, dd (14.4, 9.2) b: 1.20, br d (14.4)	15b, 16 15a, 16	8, 14, 18, 13, 16, 17, 18	13 18
16	75.5, CH	5.78, br d (8.6)	15a, 15b	14, 17, 20, 16- <u>COCH₃</u>	13
17	146.9, C				
18	21.6, CH ₃	1.03, s		8, 13, 14, 15	9, 12b, 15b, 7- <u>COCH₃</u>
19	27.7, CH ₃	1.14, s		1, 5, 9, 10	1, 4, 6, 9
20	133.6, C				
21	174.5, C				
22	29.8, CH ₂	a: 2.54, dt (13.2, 7.6) b: 2.35	22b, 23 22a, 23	17, 20, 21, 23, 24 17, 20, 21, 23, 24	24 24
23	29.0, CH ₂	2.08	22a, 22b, 24	22, 24, 25	
24	124.4, CH	5.12, br t (7.2)	23, 26, 27	23, 26, 27	22a, 22b, 26
25	133.3, C				
26	25.9, CH ₃	1.67, br s	24	24, 25, 27	24
27	17.8, CH ₃	1.60, br s	24	24, 25, 26	
28	16.5, CH ₃	1.13, d (5.8)	4	3, 4, 5	3, 5
30	17.3, CH ₃	1.18, s		7, 8, 9, 14	5, 7, 11b, 13
7- <u>COCH₃</u>	171.9, C				
7- <u>COCH₃</u>	22.0, CH ₃	2.03, s		7- <u>COCH₃</u>	18
16- <u>COCH₃</u>	172.6, C				
16- <u>COCH₃</u>	20.6, CH ₃	1.95, s		16- <u>COCH₃</u>	

^aThe indiscernible signals from overlap or the complex multiplicity are reported without designating multiplicity

Table S56 NMR data for **65** (^1H for 600 MHz and ^{13}C for 150 MHz in CD_3OD).




65

Position	δ_{C} , type	δ_{H} (J in Hz) ^a	^1H - ^1H COSY	HMBC	ROESY
1	140.4, CH	6.06, d (10.1)	2	3, 5, 9, 10, 19	11a, 11b, 19
2	127.6, CH	5.62, dd (10.1, 4.8)	1, 3	3, 4, 10	
3	69.8, CH	3.79, t (4.3)	2, 4	1, 2, 4, 5, 28	28
4	36.0, CH	2.06	3, 5, 28	5, 28	6, 19
5	39.9, CH	2.47, t (11.0)	4, 6	1, 3, 4, 6, 7, 9, 10, 19	28, 30
6	73.1, CH	5.01, ddd (10.8, 7.3, 2.4)	5, 7a, 7b	4, 5, 8, 6-COCH ₃	4, 19, 28
7	41.0, CH ₂	a: 2.12, dd (14.9, 7.4) b: 1.27, dd (14.9, 2.3)	6, 7b 6, 7a	5, 6, 8, 9, 14, 30 6, 8, 9, 14, 30	18
8	40.0, C				
9	47.7, CH	1.76, dd (13.3, 3.1)	11a, 11b	1, 5, 10, 11, 19, 30	18, 19
10	39.3, C				
11	26.1, CH ₂	a: 1.92 b: 1.30, qd (13.0, 4.0)	9, 11b, 12a, 12b 9, 11ba 12a, 12b	9 8, 9, 12	1 1, 13, 30
12	27.8, CH ₂	a: 2.30 b: 1.69	11a, 11b, 12b, 13 11a, 11b, 12a, 13	11, 13	18
13	48.9, CH	2.61, br d (11.5)	12a, 12b	12, 14, 17, 18, 20	11b, 15a, 16, 30
14	49.4, C				
15	40.1, CH ₂	a: 2.06 b: 1.19, br d (14.6)	15b, 16 15a, 16	14, 16, 18 13, 16, 17, 18	13 18
16	75.4, CH	5.75, br d (8.6)	15a, 15b	14, 15, 17, 20, 16-COCH ₃	13
17	147.3, C				
18	17.9, CH ₃	0.95, s		8, 13, 14, 15	7a, 9, 12b, 15b
19	28.6, CH ₃	1.04, s		1, 5, 9, 10	1, 4, 6, 9
20	132.5, C				
21	174.4, C				
22	29.7, CH ₂	a: 2.55, dt (13.1, 7.6) b: 2.36	22b, 23 22a, 23	17, 20, 21, 23, 24 17, 20, 21, 23, 24	24 24
23	29.1, CH ₂	2.09	22a, 22b, 24	22, 24, 25	
24	124.4, CH	5.12, br t (7.3)	23, 26, 27	23, 26, 27	22a, 22b, 26
25	133.3, C				
26	25.9, CH ₃	1.67, br s	24	24, 25, 27	24
27	17.8, CH ₃	1.60, br s	24	24, 25, 26	
28	15.8, CH ₃	0.97, d (7.0)	4	3, 4, 5	3, 5, 6
30	19.4, CH ₃	1.17, s		7, 8, 9, 14	5, 11b, 13
6-COCH ₃	172.6, C				
6-COCH ₃	21.9, CH ₃	2.01, s		6-COCH ₃	
16-COCH ₃	172.6, C				
16-COCH ₃	20.6, CH ₃	1.95, s		16-COCH ₃	

^aThe indiscernible signals from overlap or the complex multiplicity are reported without designating multiplicity.


Table S57 NMR data for **66** (^1H for 600 MHz and ^{13}C for 150 MHz in CD_3OD).



66


Position	δ_{C} , type	δ_{H} (J in Hz) ^a	^1H - ^1H COSY	HMBC	ROESY
1	160.4, CH	7.46, d (9.3)	2	3, 5, 9, 10	11a, 11b
2	128.0, CH	5.84, d (9.5)	1	3, 4, 10	
3	204.5, C				
4	44.0, CH	2.65	5, 28	3, 5, 6, 10, 28	6, 19
5	50.1, CH	2.45, t (10.9)	4, 6	1, 3, 4, 6, 7, 10, 19, 28	28, 30
6	72.5, CH	5.05	5, 7a, 7b	4, 5, 7, 10, 6-COCH ₃	4, 9, 19
7	42.1, CH ₂	a: 2.32 b: 1.27	6, 7b 6, 7a	6, 8, 14, 30 6, 8, 30	18
8	40.1, C				
9	45.9, CH	1.81	11a, 11b	1, 8, 11, 19, 30	6, 18, 19
10	40.9, C				
11	25.8, CH ₂	a: 1.85 b: 1.53	9, 11b, 12a, 12b 9, 11a, 12a, 12b	8 9, 12	1 1, 30
12	27.3, CH ₂	a: 2.37 b: 1.76	11a, 11b, 12b, 13 11a, 11b, 12a, 13		
13	48.9, CH	2.63	12a, 12b	12, 14, 17, 18, 20	16, 30
14	49.3, C				
15	40.1, CH ₂	a: 2.04 b: 1.24	15b, 16 15a, 16	8, 14, 18 8, 14, 16, 17, 18	30 18
16	75.3, CH	5.78, br d (7.1)	15a, 15b	14, 17, 20, 16-COCH ₃	13
17	146.6, C				
18	18.4, CH ₃	1.01, s		8, 13, 14, 15	7a, 9, 15b
19	27.5, CH ₃	1.24, s		1, 5, 9, 10	4, 6, 9
20	133.3, C				
21	174.6, C				
22	29.8, CH ₂	a: 2.55 b: 2.38	22b, 23 22a, 23	17, 20, 21, 23, 24 17, 20, 21, 23, 24	24 24
23	29.1, CH ₂	2.10	22a, 22b, 24	20, 22, 24, 25	
24	124.4, CH	5.13	23, 26, 27	23, 26, 27	22a, 22b, 26
25	133.3, C				
26	25.9, CH ₃	1.67, br s	24	24, 25, 27	24
27	17.8, CH ₃	1.61, br s	24	24, 25, 26	
28	16.3, CH ₃	1.21, d (5.3)	4	3, 4, 5	5
30	20.9, CH ₃	1.13, s		7, 8, 9, 14	5, 11b, 13, 15a
6-COCH ₃	172.3, C				
6-COCH ₃	21.6, CH ₃	2.03, s		6-COCH ₃	
16-COCH ₃	172.6, C				
16-COCH ₃	20.7, CH ₃	1.96, s		16-COCH ₃	

^aThe indiscernible signals from overlap or the complex multiplicity are reported without designating multiplicity

Table S58 NMR data for **67** (^1H for 400 MHz and ^{13}C for 100 MHz in acetone- d_6).**67**


Position	δ_{C} , type	δ_{H} (J in Hz) ^a	^1H - ^1H COSY	HMBC	ROESY
1	30.8, CH ₂	a: 2.59 b: 1.49, br d (13.8)	1b, 2a, 2b 1a, 2a, 2b	3, 5	11, 19
2	31.0, CH ₂	a: 1.79 b: 1.67	1a, 1b, 2b, 3 1a, 1b, 2a, 3		
3	71.8, CH	3.66, br s	2a, 2b, 4	1, 5	28
4	38.3, CH	1.79	3, 5, 28		6, 19
5	40.2, CH	2.67, t (10.4)	4, 6	1, 3, 4, 6, 10, 19	28, 30
6	73.3, CH	4.84, br dd (9.6, 7.1)	5, 7a, 7b	8, 6-COCH ₃	4, 19, 28
7	40.4, CH ₂	a: 1.92 b: 1.19	6, 7b 6, 7a	8, 30 6, 8, 9	
8	39.5, C				
9	51.2, CH	1.61	11	8, 10, 11, 14, 19, 30	12b, 18, 19
10	36.8, C				
11	67.6, CH	4.43, br s	9, 12a, 12b	8, 13	1b, 19
12	37.3, CH ₂	a: 2.36 b: 1.90	11, 12b, 13 11, 12a, 13	9, 11, 14 13	9, 18
13	44.1, CH	3.16, br d (11.8)	12a, 12b	12, 14, 17, 18, 20	15a, 16, 30
14	48.8, C				
15	39.6, CH ₂	a: 2.12 b: 1.21	15b, 16 15a, 16	14, 18 13, 14, 16, 17, 18	13, 30 18
16	74.7, CH	5.82, br d (8.4)	15a, 15b	14, 17, 20, 16-COCH ₃	13
17	149.0, C				
18	17.5, CH ₃	0.92, s		8, 13, 14, 15	9, 12b, 15b
19	25.9, CH ₃	1.04, s		1, 5, 9, 10	1b, 4, 6, 9, 11
20	131.1, C				
21	171.3, C				
22	29.5, CH ₂	a: 2.52 b: 2.41	22b, 23 22a, 23	17, 20, 21 17, 20, 21	24 24
23	29.2, CH ₂	2.10	22a, 22b, 24	24	
24	124.3, CH	5.14, br t (7.0)	23, 26, 27	26, 27	22a, 22b, 26
25	132.6, C				
26	25.8, CH ₃	1.66, br s	24	24, 25, 27	24
27	17.8, CH ₃	1.60, br s	24	24, 25, 26	
28	17.5, CH ₃	0.88, d (6.9)	4	3, 4, 5	3, 5, 6
30	22.5, CH ₃	1.44, s		7, 8, 9, 14	5, 13, 15a
6-COCH ₃	170.6, C				
6-COCH ₃	21.9, CH ₃	1.96, s		6-COCH ₃	
16-COCH ₃	170.3, C				
16-COCH ₃	20.6, CH ₃	1.88, s		16-COCH ₃	

^aThe indiscernible signals from overlap or the complex multiplicity are reported without designating multiplicity.

Table S59 NMR data for **68** (¹H for 400 MHz and ¹³C for 100 MHz in CD₃OD).**68**


Position	δ_{C} , type	δ_{H} (<i>J</i> in Hz) ^a	¹ H- ¹ H COSY	HMBC	ROESY
1	33.3, CH ₂	a: 2.28	1b, 2a, 2b	3, 5	11
		b: 1.58			
2	31.0, CH ₂	a: 1.90	1a, 1b, 2b, 3	3, 5	28
		b: 1.74			
3	71.8, CH	3.79, br s	2a, 2b, 4	1, 5	19
4	33.7, CH	2.02	3, 5, 28		
5	41.1, CH	2.41, dd (10.8, 1.4)	4, 6	3, 4, 7, 10, 19	28, 30
6	75.8, CH	5.14, d (1.4)	5	4, 5, 7, 8, 10, 6-COCH ₃	28
7	212.8, C				
8	54.9, C				
9	47.5, CH	2.31, br s	11	1, 7, 8, 10, 11, 14, 19, 30	18, 19
10	38.1, C				
11	67.7, CH	4.44, br s	9, 12a, 12b	8, 13	1b, 19
12	37.0, CH ₂	a: 2.35	11, 12b, 13	13	
		b: 1.92	11, 12a, 13		
13	45.1, CH	3.11, br d (11.6)	12a, 12b	12, 14, 17, 18, 20	16, 30
14	48.2, C				
15	41.6, CH ₂	a: 2.31	15b, 16	8, 14, 18	30
		b: 1.72, br d (14.6)	15a, 16	13, 14, 16, 17	
16	75.4, CH	5.81, br d (8.4)	15a, 15b	14, 17, 20, 16-COCH ₃	13
17	146.8, C				
18	18.3, CH ₃	0.86, s		8, 13, 14, 15	9
19	24.3, CH ₃	1.29, s		1, 5, 9, 10	4, 9, 11
20	133.0, C				
21	174.3, C				
22	29.8, CH ₂	a: 2.55	22b, 23	17, 20, 21, 23	
		b: 2.38	22a, 23	17, 20, 21, 23	
23	29.2, CH ₂	2.12	22a, 22b, 24	22, 24, 25	
24	124.3, CH	5.13	23, 26, 27	23, 26, 27	26
25	133.4, C				
26	25.9, CH ₃	1.67, br s	24	24, 25, 27	24
27	17.9, CH ₃	1.61, br s	24	24, 25, 26	
28	16.1, CH ₃	0.96, d (6.8)	4	3, 4, 5	3, 5, 6
30	22.8, CH ₃	1.56, s		7, 8, 9, 14	5, 13, 15a
6-COCH ₃	171.1, C				
6-COCH ₃	20.8, CH ₃	2.04, s		6-COCH ₃	
16-COCH ₃	172.5, C				
16-COCH ₃	20.7, CH ₃	1.95, s		16-COCH ₃	

^aThe indiscernible signals due to overlap or the complex multiplicity are reported without designating multiplicity.

Table S60 NMR data for **69** (¹H for 600 MHz and ¹³C for 150 MHz in CD₃OD).**69**

Position	δ_{C} , type	δ_{H} (<i>J</i> in Hz) ^a	¹ H- ¹ H COSY	HMBC	ROESY
1	142.1, CH	6.71, d (10.2)	2	3, 5, 10	11
2	126.5, CH	5.56, dd (10.1, 4.4)	1, 3	10	
3	69.0, CH	3.96, t (4.5)	2, 4		28
4	32.4, CH	2.28	3, 5, 28		19
5	41.1, CH	2.45, dd (11.2, 2.4)	4, 6	3, 4, 9, 10, 19	28, 30
6	75.1, CH	5.27, d (2.3)	5	4, 5, 7, 10, 6-COCH ₃	28
7	212.0, C				
8	54.5, C				
9	47.5, CH	2.34, d (1.6)	11	1, 5, 7, 8, 10, 11, 14, 19, 30	12b, 18, 19
10	39.3, C				
11	67.9, CH	4.56	9, 12a, 12b	8, 13	1, 19
12	36.6, CH ₂	a: 2.39 b: 1.96	11, 12b, 13 11, 12a, 13	13	9, 18
13	44.7, CH	3.09, br d (11.6)	12a, 12b		15a, 16, 30
14	48.1, C				
15	41.6, CH ₂	a: 2.25 b: 1.73, br d (14.6)	15b, 16 15a, 16	8, 14, 18 13, 14, 16, 17, 18	13, 30 18
16	75.5, CH	5.81, br d (8.4)	15a, 15b	13, 14, 16-COCH ₃	13
17	144.4, C ^b				
18	18.1, CH ₃	0.90, s		8, 13, 14, 15	9, 12b, 15b
19	29.0, CH ₃	1.28, s		1, 5, 9, 10	4, 9, 11
20	#				
21	#				
22	30.1, CH ₂	a: 2.55 b: 2.37	22b, 23 22a, 23	23, 24 23, 24	
23	29.2, CH ₂	2.12	22a, 22b, 24	22, 24, 25	
24	124.6, CH	5.15, br t (7.2)	23, 26, 27	23, 26, 27	26
25	133.2, C				
26	25.9, CH ₃	1.67, br s	24	24, 25, 27	24
27	17.9, CH ₃	1.61, br s	24	24, 25, 26	
28	14.3, CH ₃	1.01, d (6.7)	4	3, 4, 5	3, 5, 6
30	22.1, CH ₃	1.46, s		7, 8, 9, 14	5, 13, 15a
6-COCH ₃	171.1, C				
6-COCH ₃	20.8, CH ₃	2.06, s		6-COCH ₃	
16-COCH ₃	172.7, C				
16-COCH ₃	20.8, CH ₃	1.97, s		16-COCH ₃	

^aThe indiscernible signals from overlap or the complex multiplicity are reported without designating multiplicity.^bThe data is observed in the HMBC spectrum. #The data are not observed in NMR spectra.

Table S61 NMR data for **81** (¹H for 600 MHz and ¹³C for 150 MHz in CDCl₃).**81**

Position	δ_c , type	δ_h (J in Hz) ^a	¹ H– ¹ H COSY	HMBC	ROESY
1	139.4, CH	6.06, br d (10.4)	2, 3	3, 5, 10	11a, 11b, 19
2	128.1, CH	5.44, dd (10.0, 2.3)	1, 3	4, 10	11a, 11b, 19
3	76.6, CH	3.77, br d (7.9)	1, 2, 4	1, 2, 4, 28	5, 28
4	37.7, CH	1.77	3, 5, 28	3, 5, 10, 28	19
5	44.1, CH	1.65	4, 6a, 6b	1, 3, 4, 6, 7, 9, 10, 19	3, 30
6	19.7, CH ₂	a: 1.57 b: 1.10	5, 6b, 7a, 7b 5, 6a, 7a, 7b	4, 5, 7, 8, 10 4, 5, 7, 10	
7	33.6, CH ₂	a: 1.91, br dd (14.3, 7.1) b: 1.19	6a, 6b, 7b 6a, 6b, 7a	5, 6, 8, 14, 30 6, 8, 9, 30	18
8	38.5, C				
9	43.8, CH	1.53, dd (12.8, 2.5)	11a, 11b	1, 5, 8, 10, 11, 19, 30	18, 19
10	37.7, C				
11	24.7, CH ₂	a: 1.70 b: 1.34, qd (12.9, 3.5)	9, 11b, 12a, 12b 9, 11a, 12a, 12b	9, 12	1, 2 1, 2, 13
12	26.2, CH ₂	a: 2.27 b: 1.65	11a, 11b, 12b, 13 11a, 11b, 12a, 13	9, 14 11, 13	
13	49.0, CH	2.52	12a, 12b	12, 14, 17, 18, 20	11b, 15a, 16, 30
14	48.5, C				
15	39.1, CH ₂	a: 2.00, dd (14.6, 8.9) b: 1.27, br d (14.2)	15b, 16 15a, 16	8, 13, 14, 18, 14, 16, 17, 18	13, 30 18
16	74.1, CH	5.85, br d (8.3)	15a, 15b	14, 17, 20, 16-COCH ₃	13
17	149.4, C				
18	18.3, CH ₃	0.94, s		8, 13, 14, 15	7a, 9, 15b
19	27.8, CH ₃	1.03, s		1, 5, 9, 10	1, 2, 4, 9
20	130.4, C				
21	174.3, C				
22	28.6, CH ₂	a: 2.50 b: 2.42	22b, 23a, 23b 22a, 23a, 23b	17, 20, 21, 23, 24 17, 20, 21, 23, 24	24 24
23	28.2, CH ₂	a: 2.11 b: 2.05	22a, 22b, 23b, 24 22a, 22b, 23a, 24	20, 22, 24, 25 20, 22, 24, 25	
24	123.1, CH	5.09, br t (7.0)	23a, 23b, 26, 27	23, 26, 27	22a, 22b, 26
25	132.5, C				
26	25.7, CH ₃	1.67, br s	24	24, 25, 27	24
27	17.7, CH ₃	1.59, br s	24	24, 25, 26	
28	16.5, CH ₃	1.02, d (6.4)	4	3, 4, 5	3
30	21.5, CH ₃	0.98, s		7, 8, 9, 14	5, 13, 15a
16-COCH ₃	171.0, C			16-COCH ₃	
16-COCH ₃	20.7, CH ₃	1.96, s			

^aThe indiscernible signals from overlap or the complex multiplicity are reported without designating multiplicity.

Table S62 The Boltzmann distribution for two possible structures (**34-A** and **34-B**) of **34**.

34-A		34-B	
Conformer	Contribution (%)	Conformer	Contribution (%)
1	26.06	1	35.62
2	6.25	2	8.36
3	4.73	3	3.78
4	13.84	4	28.83
5	20.92	5	5.26
6	6.75	6	9.30
7	3.37	7	3.12
8	3.72	8	4.34
9	10.83	9	1.40
10	3.53		

Table S63 The Boltzmann distribution for two possible structures (**35-A** and **35-B**) of **35**.

35-A		35-B			
Conformer	Contribution (%)	Conformer	Contribution (%)	Conformer	Contribution (%)
1	12.68	1	3.46	20	4.99
2	2.45	2	1.22	21	5.47
3	3.92	3	3.29	22	3.67
4	8.85	4	3.43	23	4.2
5	2.77	5	1.59	24	3.7
6	2.37	6	2.6	25	3.89
7	7.07	7	2.53	26	1.97
8	11.51	8	4.53	27	1.89
9	4.60	9	1.25	28	1.16
10	3.52	10	4.23	29	1.59
11	7.83	11	1.52	30	1.57
12	5.75	12	1.52	31	3.22
13	3.38	13	2.62	32	1.08
14	2.42	14	1.48	33	1.08
15	5.83	15	5.81	34	1.92
16	4.98	16	2.03	35	1.51
17	3.00	17	1.96	36	1.86
18	5.11	18	1.25	37	3.51
19	1.95	19	1.59	38	3.64


Table S64 The Boltzmann distribution for two possible structures (**38-A** and **38-B**) of **38**.

38-A		38-B			
Conformer	Contribution (%)	Conformer	Contribution (%)	Conformer	Contribution (%)
1	3.47	1	1.39	18	2.10
2	1.95	2	4.95	19	2.51
3	4.52	3	3.57	20	1.59
4	2.73	4	2.25	21	1.52
5	10.94	5	1.61	22	11.29
6	14.42	6	2.65	23	7.94
7	6.07	7	1.69	24	3.79
8	8.12	8	1.64	25	2.50
9	2.72	9	5.98	26	1.88
10	1.86	10	3.98	27	2.95
11	1.25	11	7.19	28	1.85
12	5.06	12	8.06		
13	1.44	13	5.54		
14	12.36	14	3.25		
15	15.71	15	1.30		
16	4.66	16	3.08		
17	2.71	17	1.97		

Table S65 The Boltzmann distribution for two possible structures (**42-A** and **42-B**) of **42**.

42-A		42-B	
Conformer	Contribution (%)	Conformer	Contribution (%)
1	4.02	1	25.98
2	12.98	2	8.08
3	14.16	3	28.67
4	1.28	4	16.30
5	4.30	5	3.24
6	4.74	6	3.61
7	4.37	7	2.06
8	14.27	8	3.93
9	2.54	9	1.25
10	8.11	10	4.38
11	15.68	11	2.51
12	9.19		
13	4.37		

Table S66 Comparison of the chemical shifts of compounds **38** and **40**.



	40	38
Position	δ_c , type	δ_c , type
1	84.1, CH	83.8, CH
2	42.9, CH ₂	42.9, CH ₂
3	216.9, C	216.6, C
4	45.3, CH	45.2, CH
5	36.9, CH	37.1, CH
10	43.9, C	43.8, C
19	21.3, CH ₃	21.7, CH ₃

The relative configuration of **40** is assigned as $1S^*, 4S^*, 5S^*, 7S^*, 8S^*, 9S^*, 10S^*, 11R^*, 13R^*, 14S^*, 16S^*$.

Table S67 R square (R^2) of the linear correlations, mean absolute error (MAE) values and DP4+ probabilities of **34-A/34-B** and **42-A/42-B** of **34** and **42**, respectively.

No.	34	34-A		34-B		42	42-A		42-B	
	δ_{exptl}	$\delta_{\text{corr.}}$	AE	$\delta_{\text{corr.}}$	AE	δ_{exptl}	$\delta_{\text{corr.}}$	AE	$\delta_{\text{corr.}}$	AE
1	139.4	138.32	1.08	136.27	3.13	138.4	138.33	0.07	136.31	2.09
2	127.9	126.08	1.82	127.11	0.79	129.1	126.17	2.93	127.85	1.25
3	68.2	69.61	1.41	75.69	7.49	67.9	69.72	1.82	75.83	7.93
4	32.5	35.03	2.53	38.45	5.95	31.1	33.18	2.08	36.22	5.12
5	36.3	37.37	1.07	41.05	4.75	53.4	52.94	0.46	56.49	3.09
6	38.9	40.52	1.62	40.19	1.29	216.1	215.36	0.74	214.25	1.85
7	217.7	218.77	1.07	218.63	0.93	52.8	53.90	1.10	52.87	0.07
8	52.2	56.16	3.96	55.59	3.39	43.2	46.83	3.63	45.76	2.56
9	43.2	43.50	0.30	42.65	0.55	47.5	47.33	0.17	46.30	1.20
10	37.9	41.64	3.74	40.32	2.42	43.3	47.39	4.09	46.05	2.75
11	24.1	25.61	1.51	24.66	0.56	26.7	28.08	1.38	27.20	0.50
12	26.0	27.44	1.44	26.58	0.58	27	28.28	1.28	27.50	0.50
13	49.3	51.63	2.33	50.88	1.58	49.6	53.06	3.46	52.39	2.79
14	46.8	50.68	3.88	49.86	3.06	49.5	51.87	2.37	51.14	1.64
15	40.6	40.46	0.14	39.64	0.96	40.2	40.17	0.03	39.40	0.80
16	73.7	74.92	1.22	74.26	0.56	75.4	76.17	0.77	75.69	0.29
17	147.7	155.59	7.89	155.39	7.69	146.3	158.72	12.42	158.67	12.37
18	17.4	15.85	1.55	14.61	2.79	19	19.53	0.53	18.73	0.27
19	25.9	24.64	1.26	25.73	0.17	28.4	27.46	0.94	28.48	0.08
20	130.3	128.78	1.52	128.31	1.99	133.8	130.01	3.79	129.82	3.98
21	173.7	166.36	7.34	165.96	7.74	174.7	167.50	7.20	167.44	7.26
22	28.6	24.68	3.92	23.76	4.84	29.9	25.82	4.08	24.99	4.91
23	28.3	14.91	13.39	13.96	14.34	29.1	15.94	13.16	15.03	14.07
28	13.9	14.02	0.12	14.96	1.06	14.1	13.83	0.27	15.15	1.05
30	17.6	18.86	1.26	18.10	0.50	21.1	22.09	0.99	21.01	0.09
16-COCH ₃	170.6	167.67	2.93	167.39	3.21	172.6	169.84	2.76	169.85	2.75
16-COCH ₃	20.6	20.25	0.35	19.35	1.25	20.7	21.29	0.59	20.44	0.26
MAE		2.20		2.66			2.71		3.02	
R ²		0.9955		0.9940			0.9943		0.9932	
DP4+		100.0%		0.00%			100.00%		0.00%	

AE: absolute error; MAE: mean absolute error.

Based on the values of MAE, R^2 and DP4+, the relative configuration of **34** is assigned as $3R^*, 4S^*, 5S^*, 8S^*, 9S^*, 10S^*, 13R^*, 14S^*, 16S^*$, and the relative configuration of **42** is assigned as $3R^*, 4S^*, 5S^*, 8S^*, 9S^*, 10R^*, 13R^*, 14S^*, 16S^*$.

Table S68 R square (R^2) of the linear correlations, mean absolute error (MAE) values and DP4+ probabilities of **35-A/35-B** and **38-A/38-B** of **35** and **38**, respectively.

No.	35	35-A		35-B		38	38-A		38-B	
	δ_{exptl}	$\delta_{\text{corr.}}$	AE	$\delta_{\text{corr.}}$	AE	δ_{exptl}	$\delta_{\text{corr.}}$	AE	$\delta_{\text{corr.}}$	AE
1	84.7	74.02	10.68	73.57	11.13	83.4	74.73	8.67	74.04	9.76
2	42.1	47.98	5.88	47.19	5.09	42.9	48.53	5.63	49.67	6.77
3	217.2	216.63	0.57	216.95	0.25	216.6	213.53	3.07	211.17	5.43
4	46.9	46.92	0.02	47.73	0.83	45.2	50.17	4.97	46.18	0.98
5	43.6	44.81	1.21	46.89	3.29	37.1	39.85	2.75	39.71	2.61
6	81.9	77.25	4.65	73.91	7.99	33.4	35.77	2.37	33.84	0.44
7	86.1	88.19	2.09	88.85	2.75	71.5	71.50	0.00	69.91	1.59
8	42.1	49.59	7.49	50.55	8.45	43.2	48.76	5.56	49.75	6.55
9	47.1	49.03	1.93	47.58	0.48	52.5	53.16	0.66	49.66	2.84
10	44.2	50.25	6.05	49.45	5.25	43.8	46.66	2.86	48.01	4.21
11	78.5	71.09	7.41	69.82	8.68	77.9	70.11	7.79	69.16	8.74
12	28.7	36.87	8.17	37.21	8.51	28.4	37.35	8.95	38.07	9.67
13	45.9	48.64	2.74	49.80	3.90	45.1	48.46	3.36	49.33	4.23
14	50.7	52.91	2.21	53.22	2.52	49.9	51.86	1.96	52.69	2.79
15	39.0	41.01	2.01	41.15	2.15	41.7	43.33	1.63	41.74	0.04
16	76.7	75.60	1.10	76.76	0.06	76.8	75.65	1.15	76.13	0.67
17	145.5	159.03	13.53	159.77	14.27	144.8	159.01	14.21	162.87	18.07
18	18.9	19.60	0.70	18.54	0.36	16	18.21	2.21	21.59	5.59
19	22.7	21.73	0.97	17.64	5.06	31.7	25.44	6.26	16.14	5.56
20	134.0	130.04	3.96	130.29	3.71	133.4	130.64	2.76	131.64	1.76
21	174.9	168.51	6.39	167.77	7.13	174.5	168.42	6.08	167.40	7.10
22	30.4	25.13	5.27	25.96	4.44	30.4	26.24	4.16	26.50	3.90
23	28.8	16.20	12.60	15.79	13.01	28.8	16.48	12.32	16.74	12.06
28	18.5	14.41	4.09	19.64	1.14	15.5	13.06	2.44	13.37	2.13
30	21.1	26.53	5.43	26.01	4.91	18.2	15.43	2.77	16.69	1.51
16-COCH ₃	172.6	170.55	2.05	170.29	2.31	172.5	170.74	1.76	171.13	1.37
16-COCH ₃	20.7	20.97	0.27	21.39	0.69	20.7	22.90	2.20	23.08	2.38
MAE		4.42		4.75			4.39		4.77	
R ²		0.9884		0.9867			0.9892		0.9864	
DP4+		99.98%		0.02%			100.00%		0.00%	

AE: absolute error; MAE: mean absolute error.

Based on the values of MAE, R^2 and DP4+, the relative configuration of **35** is assigned as *1S*,4S*,5S*,6R*,7R*,8S*,9S*,10S*,11R*,13R*,14S*,16S**, and the relative configuration of **38** is assigned as *1S*,4S*,5S*,7R*,8S*,9S*,10S*,11R*,13R*,14S*,16S**.

Table S69 Comparison of the coupling constants of compounds containing C1–C2 double bond and C3-hydroxyl group.

Compound	6	81	29	30	32	34
$^3J_{(H-3, H-4)}$ in Hz	4.4	7.9	4.9	4.1	4.4	4.3
Compound	41	42	43	63	64	65
$^3J_{(H-3, H-4)}$ in Hz	4.4	4.6	4.5	4.3	4.0	4.3
Compound	69					
$^3J_{(H-3, H-4)}$ in Hz	4.5					

Based on the coupling constants between H-3 and H-4, 3-OH in **29**, **30**, **32**, **34**, **41–43**, **63–65**, and **69** were determined to be α -oriented.

Table S70 Primers used for constructing recombinant plasmids.

Primer name	Sequence (5' to 3')	Usage
Inf-pBarI-HindIII-F	TGATTACGCCAAGCTCGACTCCAATC TTCAAGAGC	
Inf-pTA-Tamy-R1	AACCGCGCTCGCGAGCAAGTACCATAC AGTACCGCG	
Inf-pTA-Parm-F1	GCTCGCGAGCGCGTTCCACTGCATCA TCAGTCTAG	Construction of recombinant pBarI and pPTRI plasmids containing one or two genes using the ClonExpress®II One Step Cloning Kit or ClonExpress®MultiS One Step Cloning Kit
Inf-pBarI-HindIII-R	GCAGGGCATGCAAGCTGTAAAGATAACAT GAGCTTCGG	
Inf-pPTRI-HindIII-F	TGATTACGCCAAGCTCGACTCCAATC TTCAAGAGC	
Inf-pPTRI-HindIII-R	GCAGGGCATGCAAGCTGTAAAGATAACAT GAGCTTCGG	

Table S71 Plasmids used in the study.

Plasmid	Characteristic	Source
pTAex3	Plasmid containing <i>argB</i> marker gene cassette for gene expression in <i>A. oryzae</i> NSAR1, (<i>Amp^R</i>)	Fujii, et al. ³
pBarI	Plasmid containing <i>bar</i> marker gene cassette for gene expression in <i>A. oryzae</i> NSAR1, (<i>Amp^R</i>)	Matsuda, et al. ⁴
pPTRI	Plasmid containing <i>ptrA</i> marker gene cassette for gene expression in <i>A. oryzae</i> NSAR1, (<i>Amp^R</i>)	TaKaRa
pTAex3- <i>helB3</i>	pTAex3 containing <i>helB3</i> whose expression is regulated by <i>amyB</i> promoter, (<i>Amp^R</i>)	Lv, et al. ⁵
pTAex3- <i>helD1</i>	pTAex3 containing <i>helD1</i> whose expression is regulated by <i>amyB</i> promoter, (<i>Amp^R</i>)	
pTAex3- <i>helE</i>	pTAex3 containing <i>helE</i> whose expression is regulated by <i>amyB</i> promoter, (<i>Amp^R</i>)	
pTAex3- <i>fusC1</i>	pTAex3 containing <i>fusC1</i> whose expression is regulated by <i>amyB</i> promoter, (<i>Amp^R</i>)	Cao, et al. ⁶
pTAex3- <i>fusB1</i>	pTAex3 containing <i>fusB1</i> whose expression is regulated by <i>amyB</i> promoter, (<i>Amp^R</i>)	
pPTRI- <i>fusC1</i>	pPTRI containing <i>fusC1</i> whose expression is regulated by <i>amyB</i> promoter, (<i>Amp^R</i>)	
pTAex3- <i>cepB4</i>	pTAex3 containing <i>cepB4</i> whose expression is regulated by <i>amyB</i> promoter, (<i>Amp^R</i>)	Cao, et al. ⁷
pTAex3- <i>cepD2</i>	pTAex3 containing <i>cepD2</i> whose expression is regulated by <i>amyB</i> promoter, (<i>Amp^R</i>)	
pPTRI- <i>cepB4</i>	pPTRI containing <i>cepB4</i> whose expression is regulated by <i>amyB</i> promoter, (<i>Amp^R</i>)	
pPTRI- <i>cepD2</i>	pPTRI containing <i>cepD2</i> whose expression is regulated by <i>amyB</i> promoter, (<i>Amp^R</i>)	
pPTRI- <i>helD1</i>	pPTRI containing <i>helD1</i> whose expression is regulated by <i>amyB</i> promoter, (<i>Amp^R</i>)	This work
pPTRI- <i>helB3</i>	pPTRI containing <i>helB3</i> whose expression is regulated by <i>amyB</i> promoter, (<i>Amp^R</i>)	This work
pPTRI- <i>helB3-fusC1</i>	pPTRI containing <i>helB3</i> and <i>fusC1</i> whose expression are independently regulated by <i>amyB</i> promoter, (<i>Amp^R</i>)	This work
pPTRI- <i>helB3-helD1</i>	pPTRI containing <i>helB3</i> and <i>helD1</i> whose expression are independently regulated by <i>amyB</i> promoter, (<i>Amp^R</i>)	This work
pPTRI- <i>fusB1-helD1</i>	pPTRI containing <i>fusB1</i> and <i>helD1</i> whose expression are independently regulated by <i>amyB</i> promoter, (<i>Amp^R</i>)	This work
pPTRI- <i>cepB4-cepD2</i>	pPTRI containing <i>cepB4</i> and <i>cepD2</i> whose expression are independently regulated by <i>amyB</i> promoter, (<i>Amp^R</i>)	Cao, et al. ⁷
pPTRI- <i>cepB4-cepC2</i>	pPTRI containing <i>cepB4</i> and <i>cepC2</i> whose expression are independently regulated by <i>amyB</i> promoter, (<i>Amp^R</i>)	
pBarI- <i>helE-cepB4</i>	pBarI containing <i>helE</i> and <i>cepB4</i> whose expression are independently regulated by <i>amyB</i> promoter, (<i>Amp^R</i>)	This work
pBarI- <i>helE-fusB1</i>	pBarI containing <i>helE</i> and <i>fusB1</i> whose expression are independently regulated by <i>amyB</i> promoter, (<i>Amp^R</i>)	This work
pBarI- <i>helE-fusC1</i>	pBarI containing <i>helE</i> and <i>fusC1</i> whose expression are independently regulated by <i>amyB</i> promoter, (<i>Amp^R</i>)	This work
pBarI- <i>helB3-fusB1</i>	pBarI containing <i>helB3</i> and <i>fusB1</i> whose expression are independently regulated by <i>amyB</i> promoter, (<i>Amp^R</i>)	This work
pBarI- <i>helB3-fusC1</i>	pBarI containing <i>helB3</i> and <i>fusC1</i> whose expression are independently regulated by <i>amyB</i> promoter, (<i>Amp^R</i>)	This work
pBarI- <i>fusB1-cepB4</i>	pBarI containing <i>fusB1</i> and <i>cepB4</i> whose expression are independently regulated by <i>amyB</i> promoter, (<i>Amp^R</i>)	This work
pBarI- <i>fusC1-cepD2</i>	pBarI containing <i>fusC1</i> and <i>cepD2</i> whose expression are independently regulated by <i>amyB</i> promoter, (<i>Amp^R</i>)	This work

Table S72 Strains used in the study.

Strain	Characteristic	Source
<i>E. coli</i> DH5 α	Host for general plasmid cloning	TaKaRa
<i>A. oryzae</i> NSAR1	Host for gene expression, a quadruple auxotrophic mutant strain (<i>niaD</i> ⁻ , <i>sC</i> ⁻ , Δ <i>argB</i> , <i>adeA</i> ⁻)	Jin, et al. ⁸
AOS0	<i>A. oryzae</i> NSAR1 transformant harboring <i>helA</i> , <i>helB1</i> , <i>helC</i> , <i>helB2</i> , <i>helD2</i> and <i>helB4</i>	Lv, et al. ⁵
AOS1	Transformant with addition of <i>helE</i> and <i>fusB1</i> into AOS0	This work
AOS2	Transformant with addition of <i>helE</i> and <i>fusC1</i> into AOS0	This work
AOS3	Transformant with addition of <i>helE</i> and <i>cepB4</i> into AOS0	This work
AOS4	Transformant with addition of <i>fusB1</i> and <i>cepB4</i> into AOS0	This work
AOS5	Transformant with addition of <i>helB3</i> and <i>fusB1</i> into AOS0	This work
AOS6	Transformant with addition of <i>helB3</i> and <i>fusC1</i> into AOS0	This work
AOS7	Transformant with addition of <i>helE</i> , <i>fusB1</i> and <i>helB3</i> into AOS0	This work
AOS8	Transformant with addition of <i>helE</i> , <i>fusB1</i> and <i>fusC1</i> into AOS0	This work
AOS9	Transformant with addition of <i>helE</i> , <i>fusC1</i> and <i>helB3</i> into AOS0	This work
AOS10	Transformant with addition of <i>helE</i> , <i>cepB4</i> and <i>fusB1</i> into AOS0	This work
AOS11	Transformant with addition of <i>helE</i> , <i>cepB4</i> and <i>fusC1</i> into AOS0	This work
AOS12	Transformant with addition of <i>helE</i> , <i>cepB4</i> and <i>cepD2</i> into AOS0	This work
AOS13	Transformant with addition of <i>fusB1</i> , <i>cepB4</i> and <i>fusC1</i> into AOS0	This work
AOS14	Transformant with addition of <i>fusB1</i> , <i>cepB4</i> and <i>cepD2</i> into AOS0	This work
AOS15	Transformant with addition of <i>fusB1</i> , <i>helB3</i> and <i>fusC1</i> into AOS0	This work
AOS16	Transformant with addition of <i>fusB1</i> , <i>helB3</i> and <i>helD1</i> into AOS0	This work
AOS17	Transformant with addition of <i>helB3</i> , <i>fusC1</i> and <i>helD1</i> into AOS0	This work
AOS18	Transformant with addition of <i>helE</i> , <i>fusB1</i> , <i>helB3</i> and <i>helD1</i> into AOS0	This work
AOS19	Transformant with addition of <i>helE</i> , <i>fusB1</i> , <i>helB3</i> and <i>fusC1</i> into AOS0	This work
AOS20	Transformant with addition of <i>helE</i> , <i>fusC1</i> , <i>helB3</i> and <i>helD1</i> into AOS0	This work
AOS21	Transformant with addition of <i>helE</i> , <i>fusB1</i> , <i>cepB4</i> and <i>cepC2</i> into AOS0	This work
AOS22	Transformant with addition of <i>helE</i> , <i>fusB1</i> , <i>cepB4</i> and <i>cepD2</i> into AOS0	This work
AOS23	Transformant with addition of <i>helE</i> , <i>fusC1</i> , <i>cepB4</i> and <i>cepD2</i> into AOS0	This work
AOS24	Transformant with addition of <i>fusB1</i> , <i>cepB4</i> , <i>fusC1</i> and <i>cepD2</i> into AOS0	This work
AOS25	Transformant with addition of <i>fusB1</i> , <i>fusC1</i> , <i>helB3</i> and <i>helD1</i> into AOS0	This work
AOS26	Transformant with addition of <i>helE</i> , <i>fusB1</i> , <i>fusC1</i> , <i>helB3</i> and <i>helD1</i> into AOS0	This work
AOS27	Transformant with addition of <i>helE</i> , <i>fusB1</i> , <i>fusC1</i> , <i>cepB4</i> and <i>cepD2</i> into AOS0	This work
AOS28	<i>A. oryzae</i> NSAR1 transformant harboring <i>helB3</i>	This work
COS6	<i>A. oryzae</i> NSAR1 transformant harboring <i>cepB4</i>	Cao, et al. ⁷
COS7	<i>A. oryzae</i> NSAR1 transformant harboring <i>cepD2</i>	

References

1. F.L.P. Costa, A.C.F. De Albuquerque, F.M. dos Santos Jr, M.B. de Amorim. GIAO-HDFT scaling factor for ^{13}C NMR chemical shifts calculation. *J Phys Org Chem* **23**,2010,972–977.
2. N. Grimblat, M.M. Zanardi, A.M. Sarotti. Beyond DP4: An improved probability for the stereochemical assignment of isomeric compounds using quantum chemical calculations of NMR shifts. *J Org Chem* **80**,2015,12526–12534.
3. T. Fujii, H. Yamaoka, K. Gomi, K. Kitamoto, C. Kumagai. Cloning and nucleotide sequence of the ribonuclease T1 gene (*rntA*) from *Aspergillus oryzae* and its expression in *Saccharomyces cerevisiae* and *Aspergillus oryzae*. *Biosci Biotechnol Biochem* **59**,1995,1869–1874.
4. Y. Matsuda, T. Wakimoto, T. Mori, T. Awakawa, I. Abe. Complete biosynthetic pathway of anditomin: Nature's sophisticated synthetic route to a complex fungal meroterpenoid. *J Am Chem Soc* **136**,2014,15326–15336.
5. J.M. Lv, D. Hu, H. Gao, T. Kushiro, T. Awakawa, G.D. Chen, et al. Biosynthesis of helvolic acid and identification of an unusual C-4-demethylation process distinct from sterol biosynthesis. *Nat Commun* **8**,2017,1644.
6. Z.Q. Cao, S.Y. Li, J.M. Lv, H. Gao, G.D. Chen, T. Awakawa, et al. Biosynthesis of clinically used antibiotic fusidic acid and identification of two short-chain dehydrogenase/reductases with converse stereoselectivity. *Acta Pharm Sin B* **9**,2018,433–442.
7. Z.Q. Cao, J.M. Lv, Q. Liu, S.Y. Qin, G.D. Chen, P. Dai, et al. Biosynthetic study of cephalosporin P₁ reveals a multifunctional P450 enzyme and a site-selective acetyltransferase. *ACS Chem Biol* **15**,2020,44–51.
8. F.J. Jin, J. Maruyama, P.R. Juvvadi, M. Arioka, K. Kitamoto. Development of a novel quadruple auxotrophic host transformation system by *argB* gene disruption using *adeA* gene and exploiting adenine auxotrophy in *Aspergillus oryzae*. *FEMS Microbiol Lett* **239**,2004,79–85.